idarubicin profile

Idarubicin is an anthracycline antibiotic that is used as a chemotherapy agent to treat various cancers, including acute myeloid leukemia, breast cancer, and lymphoma. It works by interfering with DNA replication and cell division. Idarubicin is synthesized through a multi-step process starting from daunorubicin, another anthracycline antibiotic. It exerts its effects by binding to DNA, inhibiting topoisomerase II enzyme activity, and generating reactive oxygen species. Idarubicin's effectiveness in treating certain cancers, particularly acute myeloid leukemia, makes it a crucial therapeutic agent. Research focuses on understanding its mechanisms of action, optimizing its dosage and administration, and investigating its potential synergistic effects with other therapies. The study of idarubicin is crucial for developing novel anticancer strategies and improving patient outcomes.'
```

Idarubicin: An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	42890
CHEMBL ID	1117
CHEBI ID	42068
SCHEMBL ID	3750
MeSH ID	M0023493

Synonym
CHEMBL1117
AB00698511-09
AB00698511-08
BRD-K69650333-001-01-1
EU-0100600
idarubicin hydrochloride, solid
idarubicina [inn-spanish]
idarubicine [inn-french]
nsc 256439
idarubicina
daunomycin, 4-demethoxy-
idarubicinum [inn-latin]
5,12-naphthacenedione, 7,8,9,10-tetrahydro-9-acetyl-7-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-6,9,11-trihydroxy-, (7s-cis)-
idarubicin [inn:ban]
ccris 5083
4-desmethoxydaunorubicin
LOPAC0_000600
idarubicin
4-dmd
nsc256439
(7s,9s)-9-acetyl-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7h-tetracene-5,12-dione
5,12-naphthacenedione, 7,8,9,10-tetrahydro-9-acetyl-7-((3-amino-2,3,6-trideoxy-.alpha.-l-lyxo-hexopyranosyl)oxy)-6,9,11-trihydroxy-, (7s-cis)-
MLS001401448 ,
DM5 ,
4-demethoxydaunomycin
5,12-naphthacenedione, 9-acetyl-7-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7s-cis)-
smr000466355
CHEBI:42068 ,
(1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranoside
(1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranoside
58957-92-9
4-demethoxydaunorubicin
DB01177
KBIOSS_002388
NCGC00093976-01
NCGC00093976-03
NCGC00093976-02
4 desmethoxydaunorubicin
4 demethoxydaunorubicin
I 1656 ,
HMS2089D05
NCGC00093976-04
(7s,9s)-9-acetyl-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7h-tetracene-5,12-dione
idarubicin (inn)
D08062
zavedos (tn)
A832088
(7s,9s)-7-[(2r,4s,5s,6s)-4-azanyl-6-methyl-5-oxidanyl-oxan-2-yl]oxy-9-ethanoyl-6,9,11-tris(oxidanyl)-8,10-dihydro-7h-tetracene-5,12-dione
(7s,9s)-9-acetyl-7-[[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyl-2-oxanyl]oxy]-6,9,11-trihydroxy-8,10-dihydro-7h-tetracene-5,12-dione
NCGC00093976-05
sr-01000075934
HMS3261H22
CCG-204689
BCP9000773
idarubicine
unii-zrp63d75jw
idarubicinum
zrp63d75jw ,
BCPP000207
LP00600
5,12-naphthacenedione, 9-acetyl-7-((3-amino-2,3,6-trideoxy-.alpha.-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7s,9s)-
idarubicin [vandf]
(1s,3s)-3-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-6,11-dioxo-1-naphthacenyl 3-amino-2,3,6-trideoxy-.alpha.-l-lyxo-hexopyranoside
idarubicin [inn]
idarubicin [who-dd]
idarubicin [mi]
AKOS015895563
gtpl7083
(7s,9s)-9-acetyl-7-{[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,9,11-trihydroxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione
AB00698511-10
AB00698511-06
SCHEMBL3750
tox21_500600
NCGC00261285-01
idarubicinhydrochloride
4-dmdr
XDXDZDZNSLXDNA-TZNDIEGXSA-N
(7s,9s)-9-acetyl-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7h-tetracene-5,12-quinone;hydrochloride
(7s,9s)-7-[(2r,4s,5s,6s)-4-azanyl-6-methyl-5-oxidanyl-oxan-2-yl]oxy-9-ethanoyl-6,9,11-tris(oxidanyl)-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride
(7s,9s)-9-acetyl-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride
bdbm58490
cid_636362
(7s,9s)-9-acetyl-7-[[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyl-2-oxanyl]oxy]-6,9,11-trihydroxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride
AB00698511_11
DTXSID7023142 ,
AC-9384
SR-01000075934-1
idarubicin, united states pharmacopeia (usp) reference standard
(7s,9s)-9-acetyl-7-((2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyltetrahydro-2h-pyran-2-yloxy)-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione
4-demethoxy-daunorubicin
Q1063862
BRD-K69650333-003-14-0
BRD-K69650333-001-02-9
SDCCGSBI-0050582.P002
NCGC00093976-18
A935911
(7s,9s)-9-acetyl-7-(((2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione
HY-17381A
CS-0007534
5,12-naphthacenedione, 9-acetyl-7-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7s,9s)-
l01db06
idarubicinum (inn-latin)
(1s,3s)-3-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-6,11-dioxo-1-naphthacenyl 3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranoside
idarubicine (inn-french)
(1s,3s)-3-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-6,11-dioxo-1-naphthacenyl-3-amino-2,3,6-trideoxy-alpha-l-hexopyranoside
dtxcid503142
(7s-cis)-9-acetyl-7-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione
idarubicina (inn-spanish)
EN300-7479233

Excerpt	Reference	Relevance
"Idarubicin (IDA) is an anthracycline antibiotic, frequently used for the treatment of various human cancers. "	( Idarubicin-induced oxidative stress and apoptosis in cardiomyocytes: An Gu, Z; Huang, P; Li, Q; Li, T; Ren, L; Xu, D; Zhang, Y, 2021)	3.51
"Idarubicin (IDA) is an antineoplasic drug commonly used to treat hematologic diseases. "	( Stability of a high-concentrated aqueous solution of idarubicin stored in a polypropylene syringe for transarterial chemoembolization. Bourcier, B; Lagarce, F; Lebreton, V, 2022)	2.41
"Idarubicin (IDR) is a chemotherapy drug that is classified as an anthracycline antitumor."	( Apoferritin nanocages for targeted delivery of idarubicin against breast cancer cells. Mansouri, K; Mousavi, A; Rafipour, R, 2022)	1.7
"Idarubicin is an anthracycline antileukemic agent widely used in the treatment of hematological malignancies. "	( Dexrazoxane Averts Idarubicin-Evoked Genomic Damage by Regulating Gene Expression Profiling Associated With the DNA Damage-Signaling Pathway in BALB/c Mice. Ahmad, SF; Al-Hamamah, MA; Alshahrani, AY; Ansari, MA; Attia, MM; Attia, SM; Bakheet, SA; Nadeem, A; Saquib, Q, 2017)	2.23
"Idarubicin (IDR) is a potent chemotherapeutic agent used to treat variety of cancers."	( Structural investigation of idarubicin-DNA interaction: spectroscopic and molecular docking study. Charak, S; Mehrotra, R, 2013)	1.41
"Idarubicin (IDR) is an anthracycline compound that is used therapeutically for certain types of tumour."	( Idarubicin is a broad-spectrum enterovirus replication inhibitor that selectively targets the virus internal ribosomal entry site. Hou, HY; Kung, SH; Lin, CW; Lu, WW; Wu, KY, 2016)	2.6
"Idarubicin is a clinically effective synthetic anthracycline analog used in the treatment of several human neoplasms. "	( Bioreduction of idarubicin and formation of ROS responsible for DNA cleavage by NADPH-cytochrome P450 reductase and its potential role in the antitumor effect. Arinç, E; Celik, H, 2008)	2.13
"Idarubicin is a relatively hydrophobic member of the anthracycline family."	( The encapsulation of idarubicin within liposomes using the novel EDTA ion gradient method ensures improved drug retention in vitro and in vivo. Chwastek, G; Grynkiewicz, G; Gubernator, J; Korycińska, M; Kozubek, A; Lewrick, F; Stasiuk, M; Süss, R, 2010)	1.4
"Idarubicin is a synthetic anthracycline anticancer drug widely used in the treatment of some hematological malignancies. "	( Evaluation of the protective effects of quercetin, rutin, naringenin, resveratrol and trolox against idarubicin-induced DNA damage. Arinç, E; Celik, H, 2010)	2.02
"Idarubicin is an anthracycline antibiotic used in cancer therapy. "	( A comparison of the in vitro genotoxicity of anticancer drugs idarubicin and mitoxantrone. Błasiak, J; Gloc, E; Warszawski, M, 2002)	2
"Idarubicin is an anthracycline antibiotic extensively used in acute leukemia. "	( Protective role of antioxidant vitamin E and catechin on idarubicin-induced cardiotoxicity in rats. Ates, A; Candan, S; Kalender, S; Kalender, Y; Olcay, E; Yel, M, 2002)	2
"Idarubicin (IDA) is a member of an important class of anticancer agents, the anthracycline antibiotics. "	( Caffeine enhances myocardial uptake of idarubicin but reverses its negative inotropic effect. Kang, W; Weiss, M, 2003)	2.03
"Idarubicin is an active agent in breast cancer and is suitable for dose escalation."	( High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. Bengala, C; Biadi, O; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Favre, C; Fogli, S; Guarneri, V; Innocenti, F; Mariani, M; Pazzagli, I, 2003)	1.3
"Idarubicin (IDA) is a 4-demethoxy-anthracycline analogue of daunorubicin (DNR). "	( Activation of caspases-3/7 is dispensable for idarubicin-induced apoptotic DNA fragmentation in human leukemia cells. Qi, SN; Ueda, T; Yoshida, A, 2003)	2.02
"Idarubicin (IDA) is an anthracycline anticancer drug utilized in the treatment of acute leukemias. "	( Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrug-resistant cells. Duran, GE; Lacayo, NJ; Sikic, BI, )	1.87
"Idarubicin (IDA) is a structural analogue of daunorubicin with the same mechanism of action. "	( New oral drugs in older patients: a review of idarubicin in elderly patients. Crivellari, D; Lombardi, D; Spazzapan, S; Toffoli, G; Veronesi, A, 2004)	2.02
"Idarubicin is a substrate for CYP450 2D6 and 2C9. "	( In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Colburn, DE; Giles, FJ; Oladovich, D; Smith, JA, 2004)	1.99
"Idarubicin is a 4-demethoxy-anthracycline analogue of daunorubicin that has proven activity in non-Hodgkin lymphoma, and has been reported to cause less cardiotoxicity."	( Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma. Burton, C; Cunningham, D; Hancock, B; Hoskin, P; Linch, D; Qian, W; Smith, P; Vaughan-Hudson, G, 2005)	1.05
"Idarubicin (IDR) is a new analog of Daunorubicin (DNR) selected for clinical trials because of its outstanding activity in experimental leukemias of mice and in several experimental models when compared to DNR and Doxorubicin. "	( Phase I trial of Idarubicin (4-demethoxydaunorubicin) in adult acute leukemia. Carde, P; Chahine, G; Hayat, M; Hurteloup, P; Kamioner, D; Parmentier, C; Pico, JO; Schlumberger, M, 1984)	2.05
"Idarubicin is a new anthracycline, more potent in in vitro models than the common anthracyclines doxorubicin and daunorubicin. "	( Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells. Bogush, T; Robert, J, )	1.8
"Idarubicin (IDA) is a daunorubicin (DAU) analog that is being used to treat a variety of human malignancies. "	( Cellular pharmacology of idarubicinol in multidrug-resistant LoVo cell lines. Boiocchi, M; Corona, G; De Angeli, S; Gigante, M; Simone, F; Toffoli, G, 1996)	2.04
"Idarubicin is a highly lipophilic anthracycline and appears effective against tumours resistant to conventional anthracyclines. "	( Confocal microscopy of idarubicin localisation in sensitive and multidrug-resistant bladder cancer cell lines. Cooper, A; Duffy, PM; Hayes, MC; Smart, CJ, 1996)	2.05
"Idarubicin is an effective drug in acute leukemia but its use in non-Hodgkin lymphomas (NHLs) is not yet well established. "	( Idarubicin in patients with diffuse large cell lymphomas: a randomized trial comparing VACOP-B (A = doxorubicin) vs VICOP-B (I = idarubicin). Bertini, M; Botto, B; Calvi, R; Freilone, R; Gallamini, A; Gatti, AM; Liberati, AM; Meneghini, V; Orlandi, E; Orsucci, L; Pizzuti, M; Resegotti, L; Rota Scalabrini, D; Salvi, F; Todeschini, G; Vitolo, U, )	3.02
"Idarubicin is an anthracycline agent available as both oral and intravenous formulations. "	( Oral idarubicin. A review of its pharmacological properties and clinical efficacy in the treatment of haematological malignancies and advanced breast cancer. Buckley, MM; Lamb, HM, 1997)	2.25
"Idarubicin is a very effective drug for the early management of adult acute lymphoblastic leukaemia and may be presently considered (along with cyclosporin-A or other modulator) as the reference anthracycline for cases overexpressing the P-glycoprotein drug resistance mechanism."	( The role of idarubicin in adult acute lymphoblastic leukaemia: from drug resistance studies to clinical application. Barbui, T; Bassan, R; Borleri, G; Chiodini, B; Lerede, T; Rambaldi, A; Torri, V, 1997)	1.4
"Idarubicin is an effective agent in the treatment of acute myeloid leukaemia (AML), inducing complete remission in 39 to 80% of newly diagnosed patients. "	( Idarubicin: a pharmacoeconomic evaluation of its use in adult patients with acute myeloid leukaemia. Goa, KL; Whittington, R, 1993)	3.17
"Oral idarubicin (IDA) is an active drug in metastatic breast cancer, but its role in the management of this tumor is yet not established completely. "	( Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients. Aita, P; Bearz, A; Boiocchi, M; Colussi, AM; Corona, G; Crivellari, D; Robieux, I; Sorio, R; Stocco, F; Toffoli, G, 2000)	1.07
"Idarubicin (IDA) is an anthracycline used during treatment of acute myelogenous leukaemia (AML) and is clinically important because of its potency and lipophilicity (compared to the related compounds daunorubicin and doxorubicin). "	( Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells. Austin, CA; Errington, F; Tilby, MJ; Willmore, E, 2002)	2.05
"Idarubicin is an anthracycline anticancer drug used in haematological malignancies. "	( Genotoxicity of idarubicin and its modulation by vitamins C and E and amifostine. Błasiak, J; Gloc, E; Majsterek, I; Młynarski, W; Skórski, T; Stolarska, M; Woźniak, K, 2002)	2.1
"Idarubicin is an effective agent for the management of acute nonlymphocytic leukemia and is reportedly more potent and less cardiotoxic than daunorubicin or doxorubicin."	( Idarubicin: an anthracycline antineoplastic agent. Cersosimo, RJ, 1992)	2.45
"Idarubicin in i.v. form is an active drug in previously treated patients with unfavorable non-Hodgkin's lymphoma."	( Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma. Case, DC; Crawford, J; Gams, RA; Gerber, MC; Gould, J; Higano, CS; Pruitt, BT; Votaw, ML, 1992)	1.29
"Idarubicin is a 4-demethoxy-anthracycline analogue of daunorubicin which, when administered intravenously in combination with cytarabine, has therapeutic efficacy superior to that of standard induction and salvage treatment regimens in acute myelogenous leukaemia. "	( Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Faulds, D; Hollingshead, LM, 1991)	3.17
"Idarubicin is a new anthracycline derivative with therapeutic efficacy in metastatic breast cancer. "	( Oral administration of idarubicin as first line cytostatic therapy in patients with metastasized breast cancer and favourable prognosis. A trial of the phase II study group of the Association for Medical Oncology of the German Cancer Society. Bremer, K; Donhuijsen-Ant, R; Fritze, D; Klee, M; Possinger, K; Queisser, W; Rieche, K; Wagner, H; Westerhausen, M; Worst, P, 1991)	2.03
"Idarubicin is a new derivative of Daunorubicin which was found to be more potent and more active than Daunorubicin and Doxorubicin in several experimental leukemias. "	( Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies. Berman, E; Carella, AM; Ganzina, F; Maraone, MP, )	3.02
"Idarubicin in oral form is an active drug in previously treated patients with favorable histology non-Hodgkin's lymphoma."	( Phase II study of oral idarubicin in favorable histology non-Hodgkin's lymphoma. Case, DC; Dorsk, BM; Ervin, TJ; Gams, R; Gerber, M; Hayes, DM, 1990)	1.31
"Idarubicin (IDR) is a new anthracycline that can be administered orally. "	( Treatment of acute myeloid leukemia in elderly patients with oral idarubicin as a single agent. Guy, H; Harousseau, JL; Hurteloup, P; Milpied, N; Pris, J; Rigal-Huguet, F, 1989)	1.96
"Idarubicin (IDA) is an anthracycline analog which differs from the parent compound by the substitution of a C4 methoxyl group with an hydrogen atom in the aglycone moiety. "	( A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma. Capnist, G; Chisesi, T; de Dominicis, E; Dini, E, 1988)	2.04
"Idarubicin is a derivative of daunomycin and is characterized by the absence of the methoxyl group at the C-4 position. "	( Immunochemotherapy of a murine thymoma with the use of idarubicin monoclonal antibody conjugates. McKenzie, IF; Pietersz, GA; Smyth, MJ, 1988)	1.96

Excerpt	Reference	Relevance
"Idarubicin has a superior CR rate as well as long-term disease-free survival in comparison with daunorubicin, and it is becoming the first line treatment for acute myelogenous leukemia in adults."	( [Current situation and perspective for treatment of acute myelogenous leukemia in adults]. Fukushima, T; Ueda, T, 1998)	1.02
"Idarubicin has been successfully encapsulated in cholesterol-free liposomes, however, little is known about how the rate of drug release from circulating liposomes influences therapeutic activity. "	( Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity. Bally, MB; Dos Santos, N; Edwards, K; Karlsson, G; Masin, D; Tardi, PG; Waterhouse, D, 2005)	2.07
"Idarubicin has a superior CR rate as well as long-term disease-free survival in comparison with daunorubicin, and it is becoming the first line treatment for acute myelogenous leukemia in adults."	( [Current situation and perspective for treatment of acute myelogenous leukemia in adults]. Fukushima, T; Ueda, T, 1998)	1.02
"Idarubicin has been shown to have similar or superior antileukemic activity to daunorubicin with less cumulative cardiotoxicity. "	( Acute neurohumoral and cardiovascular effects of idarubicin in leukemia patients. Hartikainen, J; Jantunen, E; Nousiainen, T; Puustinen, J; Rantala, A; Remes, J; Vanninen, E; Vuolteenaho, O, 1998)	2
"Idarubicin has been added in 3 patients, with this addition occurring at 6 months in 2 patients and at 9 months in 1 patient."	( Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Cortes, J; Estey, EH; Freireich, EJ; Giles, FJ; Kantarjian, H; Keating, M; Lopez-Berestein, G; O'Brien, S, 1999)	1.02
"Idarubicin (IDR) has been used as the main drug in induction chemotherapy for acute myelogenous leukemia (AML) in the USA and Europe. "	( [Outcome of acute myelogenous leukemia in 41 patients treated with idarubicin: the prognosis of t(8;21) cases]. Hatake, K; Komatsu, N; Matsumoto, Y; Mori, M; Muroi, K; Ohtsuki, T; Ozawa, K, 2001)	1.99
"Idarubicinol has been reported to have greater cytotoxic activity than other anthracycline alcohol metabolites, which are regarded as much less active products of metabolism."	( Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture. Ames, MM; Kuffel, MJ; Reid, JM, 1992)	1
"Idarubicin has at least equivalent activity to daunorubicin and doxorubicin in leukemia."	( New anthracycline antitumor antibiotics. Green, MD; Muggia, FM, 1991)	1
"Idarubicin also has the advantage of oral administration, but the oral formulation of the drug remains investigational."	( Idarubicin: a second-generation anthracycline. Fields, SM; Koeller, JM, 1991)	2.45
"Idarubicin has prolonged retention in the plasma and has equal cytotoxic activity to the parent compound."	( Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds. Fuks, JZ; Wadler, S; Wiernik, PH, )	0.85
"Idarubicinol has been shown to be an active metabolite in experimental models, being as potent and as active as the parent compound."	( Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies. Di Pietro, N; Ganzina, F; Pacciarini, MA, 1986)	2.44
"Idarubicin has already been shown to be an important antileukaemic agent in Phase II-III studies."	( Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin. Ganzina, F; Hurteloup, P, 1986)	1.24

Excerpt	Reference	Relevance
"Idarubicin treatments altered the expression of 58 genes, and 16 of those were expressed at significantly different level."	( Dexrazoxane Averts Idarubicin-Evoked Genomic Damage by Regulating Gene Expression Profiling Associated With the DNA Damage-Signaling Pathway in BALB/c Mice. Ahmad, SF; Al-Hamamah, MA; Alshahrani, AY; Ansari, MA; Attia, MM; Attia, SM; Bakheet, SA; Nadeem, A; Saquib, Q, 2017)	1.5
"Idarubicin-treated animals exhibited a decrease in body and heart weight, a decrease in myocardial contractility, and changes in ECG parameters (P<0.01)."	( Protective role of antioxidant vitamin E and catechin on idarubicin-induced cardiotoxicity in rats. Ates, A; Candan, S; Kalender, S; Kalender, Y; Olcay, E; Yel, M, 2002)	1.28
"The idarubicin treated subline, K/IDA, was only resistant to taxol but was 12-fold sensitized to etoposide, suggesting that idarubicin had affected topoisomerase II in this subline."	( Development of drug resistance is reduced with idarubicin relative to other anthracyclines. Davey, MW; Davey, RA; Hargrave, RM; Kidman, AD, 1995)	1.03

Excerpt	Reference	Relevance
" Gastrointestinal morbidity was less in the cohort treated without Ara-C; however, infectious morbidity persisted at unacceptable levels and this program was terminated as too toxic to administer."	( Severe toxicity limits intensification of induction therapy for acute lymphoblastic leukemia. Berman, E; Gaynor, J; Gee, T; Kempin, S; Kritz, A; Little, C; Scheinberg, D; Sogoloff, H; Telford, P; Weiss, M, 1993)	0.29
" We illustrate a new statistical design strategy for monitoring both adverse and efficacy outcomes on a patient-by-patient basis in phase II and other single-arm clinical trials."	( New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. Estey, EH; Simon, RM; Thall, PF, 1996)	0.29
" We conclude that a combination of idarubicin and etoposide given orally as first-line treatment in elderly patients with AML is safe and effective."	( The use of an all oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukaemia in the elderly: a report of toxicity and efficacy. Galloway, MJ; Hamilton, PJ; Haynes, A; Iqbal, A; Jackson, GH; Proctor, SJ; Russell, N; Taylor, PR; Turner, G, 1997)	0.85
" Furthermore, CsA-treated patients had greater, and more severe, oral and intestinal mucosal toxicity, with more severe adverse events, including more cases of gram-negative bacteremia, and with a delayed hemopoietic recovery."	( Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia. Baccarani, M; Baraldo, M; Damiani, D; Ermacora, A; Fanin, R; Furlanut, M; Michieli, M; Pea, F; Russo, D; Zaja, F, 1998)	0.3
"Acute toxic effects of the antineoplastic anthraquinones carminomycin, epirubicin, idarubicin and mitoxantrone were studied in primary cultures of cardiomyocytes, which were isolated from adult rats."	( Anthraquinone-induced cell injury: acute toxicity of carminomycin, epirubicin, idarubicin and mitoxantrone in isolated cardiomyocytes. Andersson, BS; Carlberg, M; Eksborg, S; Sundberg, M; Vidal, RF, 1999)	0.76
"Idarubicin (IDR) is one of the most effective, but also toxic drugs in the treatment of AML."	( Toxicity and effectiveness of high-dose idarubicin during AML induction therapy: results of a pilot study in children. Behnisch, W; Bender-Götze, C; Creutzig, U; Graf, N; Hermann, J; Kabisch, H; Körholz, D; Mann, G; Niemeyer, CM; Reiter, A; Ritter, J; Scheel-Walter, H; Zimmermann, M, )	1.84
" In this study, we assessed the effect of a novel IH636 grape seed proanthocyanidin extract (GSPE) to ameliorate chemotherapy-induced toxic effects in cultured Chang epithelial cells, established from nonmalignant human tissue."	( Amelioration of the cytotoxic effects of chemotherapeutic agents by grape seed proanthocyanidin extract. Bagchi, D; Bagchi, M; Benner, EJ; Joshi, SS; Kuszynski, CA, 1999)	0.3
" Therefore, synergistic cytotoxicity of Idarubicin for lymphoma cells treated with an oligonucleotide targeting p53 message was demonstrated at oligonucleotide and Idarubicin concentrations which were minimally toxic to hematopoietic progenitor cells."	( Oligonucleotide enhanced cytotoxicity of Idarubicin for lymphoma cells. Benner, EJ; Bishop, MR; Copple, B; Greiner, TC; Iversen, PL; Jackson, JD; Joshi, SS; Mann, SL; Rao, AK; Sharp, JG; Vose, JM, 2001)	0.84
" The main side effect of idarubicin is free-radicals based cardiotoxicity."	( Genotoxicity of idarubicin and its modulation by vitamins C and E and amifostine. Błasiak, J; Gloc, E; Majsterek, I; Młynarski, W; Skórski, T; Stolarska, M; Woźniak, K, 2002)	0.96
" In the present study we investigated whether vitamin E and catechin can reduce the toxic effects of idarubicin."	( Protective role of antioxidant vitamin E and catechin on idarubicin-induced cardiotoxicity in rats. Ates, A; Candan, S; Kalender, S; Kalender, Y; Olcay, E; Yel, M, 2002)	0.78
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
" Safety was measured using the NCI classification system of common toxicity criteria for adverse events."	( [Effectiveness and safety of the FLAG-IDA regimen in acute refractory or recurrent leukaemia]. Domínguez Senín, L; Garrido Martínez, MT; Martín Chacón, E; Rodríguez Rodríguez, JN; Sánchez Argáiz, M, )	0.13
" Severe TACE-related toxicity was defined as the occurrence of any adverse event grade ≥ 4, or any adverse event that caused a prolongation of hospitalisation of >8 days, or any additional hospitalisation within 1 month after TACE."	( Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma. Adam, H; Aho, LS; Bedenne, L; Boulin, M; Cercueil, JP; Di Martino, C; Fagnoni, P; Guiu, B; Hillon, P; Jouve, JL; Lepage, C; Minello, A, 2014)	0.4
" There was a statistically significantly lower rate of grades 3 and 4 gastrointestinal adverse events in the palifermin arm (21% vs."	( A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia. Bradstock, KF; Collins, M; Cull, G; Di Iulio, J; Enno, A; Hahn, U; Lewis, ID; Link, E; Marlton, P; Schwarer, A; Seymour, JF; Szer, J, 2014)	0.4
" The efficacy, adverse effects and long- term prognosis among the three groups were compared."	( [Efficacy and safety analysis of different dose idarubicin plus cytarabine regimen as induction chemotherapy for young patients with de-novo acute myeloid leukemia]. Jin, J; Mai, WY; Mao, LP; Meng, HT; Qian, WB; Suo, SS; Tong, HY; Wei, JY; Yao, XM; Yu, WJ; Zhang, Y; Zhu, SL, 2016)	0.69
" The adverse effects were similar in the three group, other than the lowest count of WBC (P=0."	( [Efficacy and safety analysis of different dose idarubicin plus cytarabine regimen as induction chemotherapy for young patients with de-novo acute myeloid leukemia]. Jin, J; Mai, WY; Mao, LP; Meng, HT; Qian, WB; Suo, SS; Tong, HY; Wei, JY; Yao, XM; Yu, WJ; Zhang, Y; Zhu, SL, 2016)	0.69
" The adverse effects were similar in the three groups."	( [Efficacy and safety analysis of different dose idarubicin plus cytarabine regimen as induction chemotherapy for young patients with de-novo acute myeloid leukemia]. Jin, J; Mai, WY; Mao, LP; Meng, HT; Qian, WB; Suo, SS; Tong, HY; Wei, JY; Yao, XM; Yu, WJ; Zhang, Y; Zhu, SL, 2016)	0.69
" An important side effect of linezolid is linezolid-induced thrombocytopenia; so, the safety of linezolid for AML patients in myelosuppression is of concern."	( Linezolid is safe on platelet count for AML patients during myelosuppression after consolidation chemotherapy. Shi, T; Xie, W; Yang, X; Ye, X; Zhao, S; Zhu, J; Zhu, L, 2020)	0.56
"This retrospective clinical study suggests that it is safe to manage AML patients in complete remission during myelosuppression after standard consolidation chemotherapy with idarubicin and cytarabine, with about 7 days of linezolid therapy."	( Linezolid is safe on platelet count for AML patients during myelosuppression after consolidation chemotherapy. Shi, T; Xie, W; Yang, X; Ye, X; Zhao, S; Zhu, J; Zhu, L, 2020)	0.75
" The secondary outcomes included adverse events and cytogenetic risk in subgroup analyses."	( The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials. Lu, Y; Wang, H; Wu, Y; Xiao, Q; Xiao, X, 2020)	0.82
" When it comes to adverse drug reactions, it is not a significant difference."	( The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials. Lu, Y; Wang, H; Wu, Y; Xiao, Q; Xiao, X, 2020)	0.82
"L-DNR proved to be an effective drug within a multiagent approach, which shows a favorable overall profile, as well as similar adverse events when compared with IDA in HR-ALL."	( Efficacy and safety of induction chemotherapy with daunorubicin or idarubicin in the treatment of an adult with acute lymphoblastic leukemia. Wang, D; Wang, ZD; Zhang, CH; Zhang, Q, 2022)	0.96
"Cardiotoxicity is the major side effect of anthracyclines (doxorubicin, daunorubicin, epirubicin, and idarubicin), though being the most commonly used chemotherapy drugs and the mainstay of therapy in solid and hematological neoplasms."	( The Role of Mitochondrial Quality Control in Anthracycline-Induced Cardiotoxicity: From Bench to Bedside. Bai, R; Chang, X; Li, L; Li, Y; Lin, R; Liu, N; Liu, X; Peng, X; Ruan, Y; Tang, R; Wang, X; Wen, S, 2022)	0.94

Excerpt	Reference	Relevance
" The AUCs obtained for unchanged drugs were proportional to the dose, and the dose-independent pharmacokinetic parameters were very similar for the two drugs: total plasma clearance (39."	( Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients. Hurteloup, P; Rigal-Huguet, F; Robert, J, )	0.4
" The IDAol terminal half-life and mean residence time (MRT) were significantly increased in patients with impaired kidney function [MRT: group N, 63."	( Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. Camaggi, CM; Carisi, P; Efthymiopoulos, C; Guaraldi, M; Martoni, A; Pannuti, F; Strocchi, E; Strolin-Benedetti, M; Tononi, A, 1992)	1.73
" Due to its protracted half-life (64 hr in this study), this metabolite progressively accumulated and the ratio of the areas under the curve (0-24) idarubicinol/idarubicin increased from day to day."	( Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients. Huet, S; Hurteloup, P; Pris, J; Rigal-Huguet, F; Robert, J, 1990)	0.8
" There was substantial variability in idarubicin elimination among patients, but no indication of dose-dependent or of schedule-dependent changes in pharmacokinetic parameters."	( Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report. Ames, MM; Hammond, GD; Krailo, MD; Pendergrass, TW; Reid, JM, 1990)	0.79
" No pharmacokinetic modelling of Idarubicin was possible after oral administration."	( Plasma pharmacokinetics of Idarubicin and its 13-hydroxymetabolite after intravenous and oral administration under fasting and non-fasting conditions. Antila, K; Eksborg, S; Nilsson, B; Söderberg, M, 1990)	0.86
" No correlation was found between the pharmacokinetic parameters and the time to final progression."	( Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side effects. Bastholt, L; Dalmark, M; Ebbehøj, E; Elbaek, K; Jakobsen, A; Juul, P; Rasmussen, SN; Steiness, E, 1989)	0.58
" Each molecule is characterized by original metabolic and pharmacokinetic features, which can be compared to those of the reference anthracyclines, doxorubicin and daunorubicin."	( [Pharmacokinetics of new anthracyclines]. Robert, J, 1988)	0.27
" Pharmacokinetic parameters calculated for the intravenous plasma drug concentration, time data revealed a terminal half-life of 12."	( Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer. Gillies, HC; Harper, PG; Herriott, D; Liang, R; Ohashi, K; Rogers, HJ, 1987)	0.6
" For unchanged idarubicin, similar pharmacokinetic parameters were exhibited after the 1st and the 5th injection."	( Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients. Harousseau, JL; Huet, S; Hurteloup, P; Pris, J; Reiffers, J; Rigal-Huguet, F; Robert, J; Tamassia, V, 1987)	0.95
" The apparent terminal half-life of IDAol was significantly longer in the elderly than in the younger patients (mean half-life 59."	( Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results. Caporale, R; Cervi, L; Ciolli, S; Giuliani, G; Leoni, F; Pascarella, A; Rossi Ferrini, P; Salti, F, 1995)	0.64
" Although idarubicin was given in one-fifth of the dose, the intracellular peak concentration was 70% of that of daunorubicin."	( Comparison of the intracellular pharmacokinetics of daunorubicin and idarubicin in patients with acute leukemia. Paul, C; Sundman-Engberg, B; Tidefelt, U, 1994)	0.93
" The average terminal half-life was 30."	( Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. Braess, J; Hiddemann, W; Kaufmann, CC; Kern, W; Kühn, S; Rührs, H; Schleyer, E; Sträubel, G; Unterhalt, M, 1996)	0.81
" The plasma concentration time course of Ida was most properly described by the three-compartment pharmacokinetic model, independent of administration time."	( Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolite--a comparison of bolus versus 2 h infusion during a 3 day course. Björkholm, M; Eksborg, S; Fagerlund, E; Hast, R, 1997)	0.59
" The average terminal half-life was 30."	( Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. Braess, J; Hiddemann, W; Kaufmann, CC; Kern, W; Kühn, S; Rührs, H; Schleyer, E; Sträubel, G; Unterhalt, M, 1997)	0.81
" With respect to cellular resistance mechanisms, 2 different pharmacodynamic phases can be distinguished: intracellular distribution and cellular reaction."	( Intracellular pharmacokinetics of anthracyclines in human leukemia cells: correlation of DNA-binding with apoptotic cell death. Brieden, T; Gieseler, F; Kunze, J; Nüssler, V; Valsamas, S, 1998)	0.3
" Pharmacokinetic evaluations were performed by means of a two-compartment open model with zero-order absorption and first-order elimination using the WinNonlin pharmacokinetic software package."	( Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. Baccarani, M; Baraldo, M; Damiani, D; Ermacora, A; Fanin, R; Furlanut, M; Michieli, M; Pea, F; Russo, D, 1999)	0.52
" The main pharmacokinetic parameters of IDA, such as CL and volume of distribution at steady state (Vdss), were remarkably affected by the coadministration of CyA or CyA plus D-Ver, but no statistically significant difference was noted because of IDA pharmacokinetic interpatient variation."	( Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. Baccarani, M; Baraldo, M; Damiani, D; Ermacora, A; Fanin, R; Furlanut, M; Michieli, M; Pea, F; Russo, D, 1999)	0.52
"The results show that CyA alone at a dose of 10 mg x kg(-1) daily significantly increased systemic body exposure to both IDA and IDAOL in acute leukemia, and suggest that these pharmacokinetic effects were at least partially decreased when D-Ver was coadministered with CyA."	( Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. Baccarani, M; Baraldo, M; Damiani, D; Ermacora, A; Fanin, R; Furlanut, M; Michieli, M; Pea, F; Russo, D, 1999)	0.52
" Various pharmacokinetic profiles, with and without clinically relevant peak concentrations, were simulated in vitro."	( Induction of apoptosis by idarubicin: how important is the plasma peak? Clark, M; Gieseler, F; Puschmann, M; Stiebeling, K; Valsamas, S, 2000)	0.61
" We simulated a bolus application and a continuous infusion using two different pharmacokinetic profiles of idarubicin with comparable AUCs (area under the time curve)."	( Induction of apoptosis by idarubicin: how important is the plasma peak? Clark, M; Gieseler, F; Puschmann, M; Stiebeling, K; Valsamas, S, 2000)	0.82
"To clarify the pharmacokinetic properties of idarubicin (IDA) in Japanese patients and to clarify the relationship between the pharmacokinetic parameters of IDA or idarubicinol (IDAol), an active metabolite of IDA, and leukocytopenia or neutropenia, we examined the pharmacokinetics of IDA in patients with malignant lymphoma."	( A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma: relationship with leukocytopenia and neutropenia. Fukushima, T; Goto, N; Kuraishi, Y; Ogawa, M; Ohno, R; Okabe, KI; Ueda, T; Urabe, A; Yamashita, T, 2001)	0.87
" The plasma concentration-time data were analysed, assuming a biexponential disposition curve, both by the traditional (two-stage) method and by population pharmacokinetic modelling."	( Pharmacokinetics and toxicity of idarubicin in the rat. Hofmann, S; Kuhlmann, O; Weiss, M, )	0.41
" The pharmacokinetic parameters of idarubicin found after duodenal administration of the two formulations were different: area under the curve of concentration versus time (AUC) and elimination half-life were approximately 21 times and 30 times, respectively, higher after IDA-SLN administration than after the solution administration."	( Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. Bargoni, A; Cavalli, R; Fundarò, A; Gasco, MR; Vighetto, D; Zara, GP, 2002)	0.85
" Using a pharmacodynamic (PD) approach, the authors examined the validity of this model for patients with acute myeloid leukemia (AML) undergoing dose-intensive postinduction chemotherapy (HDT)."	( Pharmacodynamic modeling of thrombopoietin, platelet, and megakaryocyte dynamics in patients with acute myeloid leukemia undergoing dose intensive chemotherapy. Bernstein, SH; Jusko, WJ; Krzyzanski, W; Nichol, J; Wetzler, M, 2002)	0.31
"The peak plasma levels (C(max)), terminal elimination half-life (t(1/2)) and area under the concentration curve (AUC) both for IDA and for ETO did not differ from published data."	( Increased myelotoxicity of idarubicin: is there a pharmacological basis? Results of a pharmacokinetic and an in vitro cytotoxicity study. Bornhäuser, M; Ehninger, G; Illmer, T; Kroschinsky, F; Renner, U; Schaich, M; Schimmelpfennig, C; Schimming, C; Schleyer, E; Trümper, L, 2004)	0.62
" An open phase II pharmacokinetic and clinical study was performed to evaluate antileukemic efficacy, IDA pharmacokinetics and to investigate the presence of IDA and its reduced metabolite idarubicinol (IDAol) in cerebrospinal fluid (CSF) of patients treated with HD-IDA."	( High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Baratè, C; Cafro, AM; Camaggi, CM; Intropido, L; Marbello, L; Montillo, M; Morra, E; Nichelatti, M; Strocchi, E; Tedeschi, A; Tresoldi, E, 2007)	0.93
" The mean terminal half-life measured for IDA in this group of patients (14."	( High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Baratè, C; Cafro, AM; Camaggi, CM; Intropido, L; Marbello, L; Montillo, M; Morra, E; Nichelatti, M; Strocchi, E; Tedeschi, A; Tresoldi, E, 2007)	0.74
" Our data do not allow us to clearly attribute this behavior to a pharmacokinetic non-linearity since the baseline creatinine clearance, even within normal values, and patient age are significantly different in the two groups."	( High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Baratè, C; Cafro, AM; Camaggi, CM; Intropido, L; Marbello, L; Montillo, M; Morra, E; Nichelatti, M; Strocchi, E; Tedeschi, A; Tresoldi, E, 2007)	0.74
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
"To investigate the relationship between the improved stability of an anticancer drug-lipiodol emulsion and pharmacokinetic (PK) profile for transarterial chemoembolisation (TACE) of hepatocellular carcinoma (HCC)."	( Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin. Boulin, M; Cercueil, JP; Delhom, E; Denys, A; Fohlen, A; Guiu, B; Herrero, A; Imbs, DC; Panaro, F; Schmitt, A; Wendremaire, M, 2016)	0.63
" After TACE, mean idarubicin Cmax and AUC0-24h were 12."	( Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin. Boulin, M; Cercueil, JP; Delhom, E; Denys, A; Fohlen, A; Guiu, B; Herrero, A; Imbs, DC; Panaro, F; Schmitt, A; Wendremaire, M, 2016)	0.96
" • Improved emulsion stability for TACE resulted in a favourable pharmacokinetic profile."	( Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin. Boulin, M; Cercueil, JP; Delhom, E; Denys, A; Fohlen, A; Guiu, B; Herrero, A; Imbs, DC; Panaro, F; Schmitt, A; Wendremaire, M, 2016)	0.63

Excerpt	Reference	Relevance
"A randomized clinical trial was undertaken to compare the therapeutic effectiveness of idarubicin (IDR) to daunorubicin (DNR), and both were given in combination with cytarabine (CA) in acute myelogenous leukemic (AML) patients."	( A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. Banks, PL; Bartolucci, AA; Flaum, MA; Gerber, MC; Omura, GA; Velez-Garcia, E; Vogler, WR; Weiner, RS, 1992)	0.8
"We conducted a Phase I-II trial of 4-demethoxydaunorubicin (idarubicin, IDR) in combination with 1-beta-D-arabinofuranosylcytosine (ara-C) in 51 patients with relapsed or refractory acute nonlymphocytic leukemia, acute lymphocytic leukemia, or chronic myelogenous leukemia in blast crisis."	( 4-demethoxydaunorubicin (idarubicin) in combination with 1-beta-D-arabinofuranosylcytosine in the treatment of relapsed or refractory acute leukemia. Arlin, ZA; Berman, E; Clarkson, BD; Daghestani, A; Gee, TS; Hancock, C; Kempin, S; Raymond, V; Stevens, YW; Williams, L, 1989)	0.82
" When combined with Cytarabine, Idarubicin increased the incidence and severity of gastrointestinal symptoms."	( [Early phase II study of Idarubicin combined with cytarabine in acute myelogenous leukemia. Idarubicin Study Group]. Kimura, K; Masaoka, T; Ogawa, M; Yamada, K, 1993)	0.87
"The antitumor effects of Behenoyl-ara-C (BH-AC) in combination with Idarubicin (IDA) on leukemia were studied."	( [Antitumor effects of Behenoyl-ara-C (BH-AC) in combination with Idarubicin (IDA) in P 388 leukemic cell bearing mice]. Kiyota, T; Kuriyama, H; Watanabe, A, 1996)	0.77
" In this work we compared in vitro the effects of IDA and 2HIDA used alone and in combination with 2 microM cyclosporin A (CyA) in the MDR leukemic cell lines FLCR and K562R and in their sensitive parent cell lines FLC and K562."	( Comparative activity of idarubicin and idarubicinol in combination with cyclosporin A in multidrug-resistant leukemia cells. Abbadessa, V; Cajozzo, A; Gancitano, RA; Musso, M; Perricone, R; Porretto, F; Tolomeo, M, 1996)	0.6
" We conclude that idarubicin in combination with cytarabine and etoposide is a highly effective regimen for induction in children with AML."	( Results of treatment with an intensive induction regimen using idarubicin in combination with cytarabine and etoposide in children with acute myeloblastic leukemia. Chantada, G; Cygler, AM; Felice, MS; Gallego, M; Rossi, J; Sackmann-Muriel, F; Zubizarreta, P, )	0.7
"5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin has been applied in a treatment protocol for patients with a relapse of acute myeloid or lymphocytic leukemia."	( A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). Archimbaud, E; Berneman, Z; Dardenne, M; Dohner, H; Jaksic, B; Jehn, U; Labar, B; Louwagie, EA; Muus, P; Stryckmans, P; Suciu, S; Tjean, M; Wijermans, P; Willemze, R; Zittoun, R, 1997)	0.76
"The Children's Cancer Group (CCG) undertook a phase I study (CCG-0922) to determine a tolerable dose of idarubicin given with fludarabine and cytarabine in children with relapsed or refractory leukemia."	( Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group. Avramis, VI; Dinndorf, PA; Kelleher, JF; Krailo, MD; Liu-Mares, W; Mosher, RB; Reaman, GH; Sato, JK; Seibel, NL; Wiersma, S, 1997)	0.83
"A dose of idarubicin 12 mg/m2/d for 3 days given in combination with fludarabine and cytarabine was tolerated."	( Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group. Avramis, VI; Dinndorf, PA; Kelleher, JF; Krailo, MD; Liu-Mares, W; Mosher, RB; Reaman, GH; Sato, JK; Seibel, NL; Wiersma, S, 1997)	1.02
"The anthracycline analogue idarubicin, either alone or in combination with other antineoplastic drugs, has shown antileukemic activity in relapsed and refractory acute lymphoblastic leukemia (ALL)."	( A single high dose of idarubicin combined with high-dose ABA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University La Sapienza of Rome. Annino, L; Arcese, W; Chiaretti, S; D'Elia, G; Del Giudice, I; Ferrari, A; Giona, F; Mandelli, F; Moleti, ML; Testi, AM; Todisco, E, )	0.74
"The anthracycline analogue idarubicin, either alone or in combination with other antineoplastic drugs, has shown antileukemic activity in relapsed and refractory acute lymphoblastic leukemia (ALL)."	( A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University "La Sapienza" of Rome. Annino, L; Arcese, W; Chiaretti, S; D'Elia, G; Del Giudice, I; Ferrari, A; Giona, F; Mandelli, F; Moleti, ML; Testi, AM; Todisco, E, )	0.74
" Eighteen adult patients with relapsed/refractory ALL were treated on a phase I study of high-dose cytarabine combined with a single escalating dose of idarubicin."	( A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia. Drullinsky, P; Golde, DW; Maslak, P; Scheinberg, D; Weiss, MA, 1998)	0.76
"To determine the safety and efficacy of the combination of idarubicin, cytarabine and etoposide ("ICE") for induction and consolidation treatment of acute myeloid leukemia (AML), and of dose-intensification of cytarabine in this setting, 54 previously untreated patients in three cohorts were studied by sequential dose escalation of cytarabine, in combination with standard doses of idarubicin and etoposide."	( A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and consolidation treatment of adult acute myeloid leukemia. Australian Leukaemia Study Group (ALSG). Bishop, JF; Bradstock, KF; Cobcroft, R; Eliadis, P; Enno, A; Gill, D; Herrmann, RP; Juneja, S; Lowenthal, RM; Manoharan, A; Matthews, JP; Page, FJ; Rooney, KF; Rosenfeld, D; Seldon, M; Taylor, KM; Wolf, MM; Young, GA, 1999)	0.77
"We conclude that ATRA in combination with Ida and Ara-C can be administered safely to high-risk AML patients."	( All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial. Anglaret, B; Archimbaud, E; Belhabri, A; Chelghoum, Y; Dhedin, N; Dombret, H; Fière, D; Michallet, M; Reman, O; Thomas, X; Vekhoff, A; Wattel, E, 2002)	0.54
" 2-CdA in combination with DOX significantly increased the percentage of annexin V-positive cells, particularly after 48 h of incubation, as compared with DOX used in monotherapy (median AI for 2-CdA+DOX=37."	( Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia. Najder, M; Robak, T; Smolewski, P; Szmigielska-Kaplon, A, 2002)	0.31
" This study was conducted to define the dose-limiting toxicities (DLTs) of its combination with cytarabine (ara-C), idarubicin, or topotecan."	( Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. Cortes, JE; Douer, D; Estey, EH; Faderl, S; Garcia-Manero, G; Giles, FJ; Jeha, SS; Kantarjian, HM; Koller, CA; Levine, AM; O'Brien, SM; Thomas, DA, 2003)	0.76
" The anthracyclines doxorubicin, daunorubicin, and idarubicin were individually combined with DEX to study in vitro effects in leukemic myeloid cell lines."	( Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell lines. Freireich, EJ; Jendiroba, D; Keyhani, A; Liu, B; Pagliaro, L; Pearlman, M, 2003)	0.57
" Cytarabine metabolism was significantly decreased when combined with caspofungin or itraconazole."	( In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Colburn, DE; Giles, FJ; Oladovich, D; Smith, JA, 2004)	0.55
"High dose (HD) Ara-C combined with a single HD idarubicin dose (IDA) is an efficient and safe salvage regimen for patients with refractory or relapsed acute lymphoblastic leukemia as indicated by phase II studies."	( High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Baratè, C; Cafro, AM; Camaggi, CM; Intropido, L; Marbello, L; Montillo, M; Morra, E; Nichelatti, M; Strocchi, E; Tedeschi, A; Tresoldi, E, 2007)	1
" administration of 40 mg/m2 of IDA, combined with HD Ara-C, with a degree of myelosuppression equivalent to that reported with this agent administered in standard doses."	( High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Baratè, C; Cafro, AM; Camaggi, CM; Intropido, L; Marbello, L; Montillo, M; Morra, E; Nichelatti, M; Strocchi, E; Tedeschi, A; Tresoldi, E, 2007)	0.74
"The objective of this study was to investigate the efficacy and toxicity of standard-dose idarubicin in combination with continuous infusion of cytarabine as induction therapy in patients with acute myeloid leukemia (AML)."	( [Standard-dose of idarubicin in combination with continuous infusion of cytarabine as induction therapy in patients with acute myeloid leukaemia]. Chen, LJ; Li, JY; Lu, H; Lu, RN; Qian, SX; Qiu, HX; Sheng, RL; Wu, HX; Xu, W, 2009)	0.91
" We report on a phase I/II trial of the XIAP antisense oligonucleotide AEG35156 in combination with reinduction chemotherapy."	( Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. Altman, JK; Andreeff, M; Borthakur, G; Brandwein, J; Carter, BZ; Estey, EH; Hedley, DW; Jacob, C; Jolivet, J; Karp, JE; Kassis, J; LaCasse, E; Mak, DH; Morris, SJ; Schiller, GJ; Schimmer, AD; Tallman, MS; Xu, W, 2009)	0.57
"Twenty-four patients with rapidly relapsed or refractory AML were treated with escalating doses of AEG35156 (12 to 250 mg/m(2)) as an intravenous solution over 2 hours and 32 patients were treated with the highest planned dose of 350 mg/m(2) in combination with idarubicin and high-dose cytarabine reinduction chemotherapy."	( Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. Altman, JK; Andreeff, M; Borthakur, G; Brandwein, J; Carter, BZ; Estey, EH; Hedley, DW; Jacob, C; Jolivet, J; Karp, JE; Kassis, J; LaCasse, E; Mak, DH; Morris, SJ; Schiller, GJ; Schimmer, AD; Tallman, MS; Xu, W, 2009)	0.74
" Among the patients receiving 350 mg/m(2) of AEG35156 in combination with chemotherapy, 10 (91%) of 11 who were refractory to a single induction chemotherapy regimen achieved CR/CRp after reinduction with AEG35156 and chemotherapy."	( Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. Altman, JK; Andreeff, M; Borthakur, G; Brandwein, J; Carter, BZ; Estey, EH; Hedley, DW; Jacob, C; Jolivet, J; Karp, JE; Kassis, J; LaCasse, E; Mak, DH; Morris, SJ; Schiller, GJ; Schimmer, AD; Tallman, MS; Xu, W, 2009)	0.57
"At the highest dose tested, AEG35156 knocks down its target and appears very effective when combined with chemotherapy in patients with AML refractory to a single induction regimen."	( Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. Altman, JK; Andreeff, M; Borthakur, G; Brandwein, J; Carter, BZ; Estey, EH; Hedley, DW; Jacob, C; Jolivet, J; Karp, JE; Kassis, J; LaCasse, E; Mak, DH; Morris, SJ; Schiller, GJ; Schimmer, AD; Tallman, MS; Xu, W, 2009)	0.57
" The aim of this study was to investigate the cytotoxic effects of this agent in combination with conventional antileukemic agents."	( The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro. Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Mano, H; Miyawaki, S; Tanaka, M; Tsunoda, S; Yazawa, Y, 2009)	0.35
"The cytotoxic effects of GO in combination with antileukemic agents were studied against human CD33 antigen-positive leukemia HL-60, U937, TCC-S and NALM20 cells."	( The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro. Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Mano, H; Miyawaki, S; Tanaka, M; Tsunoda, S; Yazawa, Y, 2009)	0.35
" HDACi have single-agent clinical activity in haematological malignancies and have synergistic anti-leukaemia activity when combined with anthracyclines in vitro."	( A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Egorin, MJ; Espinoza-Delgado, I; Ferrajoli, A; Garcia-Manero, G; Holleran, JL; Kadia, TM; Kantarjian, HM; Madden, TL; Maddipotti, S; Newsome, W; Ravandi, F; Sanchez-Gonzalez, B; Schroeder, C; Thomas, DA; Yang, H; Zwiebel, JA, 2010)	0.61
"The authors conducted a phase 1/2 study of tipifarnib in combination with idarubicin and cytarabine (IA) in 95 patients with previously untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome."	( A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cortes, J; Estrov, Z; Faderl, S; Garcia-Manero, G; Jabbour, E; Kantarjian, H; O'Brien, S; Ravandi, F; Thomas, DA; Verstovsek, S; Wright, JJ, 2011)	0.83
"Although induction chemotherapy comprising high-dose cytarabine (HiDAC) in combination with idarubicin and etoposide or 'ICE' for adult acute myeloid leukaemia (AML) produces a complete remission rate of nearly 80%, gastrointestinal toxicity is significant."	( High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia. Avery, S; Coutsouvelis, J; Lee, D; Low, M; Opat, S; Patil, S; Salem, H; Schwarer, A; Spencer, A; Walker, P; Wei, A, 2013)	0.86
" We retrospectively evaluated the efficacy and toxicity of fractionated doses of gemtuzumab ozogamicin (GO) combined with a standard 3 + 7 induction regimen in young patients with AML in first relapse."	( Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse. de Revel, T; Eddou, H; Foissaud, V; Konopacki, J; Malfuson, JV; Thepenier, C, 2012)	0.38
" LY2181308 was administered with a loading dosage of three consecutive daily infusions of 750 mg followed by weekly intravenous (IV) maintenance doses of 750 mg."	( Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML). Andre, V; Andreeff, M; Brandt, JT; Callies, S; Erba, HP; Juckett, M; Kadam, S; Lahn, M; Sayar, H; Schmidt, S; Van Bockstaele, D, 2013)	0.6
"This study aims to determine the maximum tolerated dose (MTD) of clofarabine combined with the EORTC-GIMEMA 3 + 10 induction regimen (idarubicin + cytosine arabinoside) in adults with untreated acute myelogenous leukemia or high-risk myelodysplastic syndrome."	( Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): p Amadori, S; de Witte, T; Halkes, CJ; Karrasch, M; Marie, JP; Meert, L; Meloni, G; Muus, P; Rapion, J; Suciu, S; Vignetti, M; Willemze, R, 2014)	0.82
"This Phase 2 study tested the tolerability and efficacy of bortezomib combined with reinduction chemotherapy for pediatric patients with relapsed, refractory or secondary acute myeloid leukemia (AML)."	( A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group. Adlard, K; Alonzo, TA; Ballard, J; Gamis, AS; Gerbing, RB; Horton, TM; Howard, DS; Jenkins, G; Kelder, A; Moscow, JA; Perentesis, JP; Schuurhuis, GJ; Smith, FO, 2014)	0.65
"Patients with <400 mg/m(2) prior anthracycline received bortezomib combined with idarubicin (12 mg/m(2) days 1-3) and low-dose cytarabine (100 mg/m(2) days 1-7) (Arm A)."	( A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group. Adlard, K; Alonzo, TA; Ballard, J; Gamis, AS; Gerbing, RB; Horton, TM; Howard, DS; Jenkins, G; Kelder, A; Moscow, JA; Perentesis, JP; Schuurhuis, GJ; Smith, FO, 2014)	0.88
" A Phase 1 study demonstrated the safety of high dose pravastatin given with idarubicin and cytarabine in patients with AML and also demonstrated an encouraging response rate."	( SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia. Advani, AS; Appelbaum, FR; Copelan, E; List, AF; McDonough, S; Mulford, DA; Othus, M; Sekeres, MA; Willman, C, 2014)	0.92
" Our study suggests that the MTD of idarubicin in combination with HD-MTX, VDS, and PRED, should be 16 mg/m(2) ."	( A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial. Brion, A; Chabin, M; Clavert, A; Colombat, P; Cumin, I; Delwail, V; Escoffre-Barbe, M; Gardembas, M; Ingrand, P; Lacotte-Thierry, L; Legouffe, E; Olivier, G; Solal-Celigny, P, 2014)	0.95
"This study was aimed to investigate the clinical efficacy of idarubicin combined with methotrexate for treatment of patients with central nervous system diffuse large B-cell lymphoma."	( [Clinical efficacy of idarubicin combined with methotrexate for treatment of patients with central nervous system diffuse large B cell lymphoma]. Chen, BA; Xiao, YH; Yu, ZP; Yuan, P; Yue, TH, 2014)	0.96
"The primary objective of this trial was to assess the feasibility, toxicity profile, and antitumor activity of gemtuzumab ozogamicin (GO) combined with a chemotherapy remission-induction regimen in adults with untreated high-risk myelodysplastic syndrome (HR-MDS) or secondary acute myeloid leukemia (sAML)."	( Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013). Amadori, S; Baron, F; Bron, D; de Witte, T; Halkes, C; Meert, L; Muus, P; Selleslag, D; Suciu, S; Willemze, R, 2015)	1.86
" A Phase 2 study of high dose pravastatin given in combination with idarubicin and cytarabine demonstrated an impressive response rate [75% complete remission (CR), CR with incomplete count recovery (CRi)]."	( Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML). Advani, AS; Appelbaum, FR; Erba, HP; Li, H; Liedtke, M; List, AF; Medeiros, BC; Michaelis, LC; O'Dwyer, K; Othus, M, 2018)	0.95
"To ascertain the efficacy and safety of daunorubicin combined with cytarabine comparing with idarubicin combined with cytarabine as a standard induction therapy for acute Myeloid leukemia by a meta-analysis."	( The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials. Lu, Y; Wang, H; Wu, Y; Xiao, Q; Xiao, X, 2020)	1.03
" We evaluated and cross-checked the randomized clinical trials (RCTs) comparing daunorubicin combined with cytarabine (DA) and idarubicin combined with cytarabine (IA) by two reviewers independently according to Cochrane Handbook for Systematic Reviewers of Interventions."	( The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials. Lu, Y; Wang, H; Wu, Y; Xiao, Q; Xiao, X, 2020)	1.02
" This phase Ib/II study evaluated the safety and efficacy of fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin combined with the B-cell lymphoma-2 inhibitor venetoclax in ND-AML and R/R-AML."	( Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. Adeoti, M; Alvarado, Y; Andreeff, M; Borthakur, G; Daver, N; DiNardo, CD; Garcia-Manero, G; Issa, G; Jabbour, E; Jain, N; Kadia, T; Kantarjian, HM; Konopleva, MY; Kornblau, S; Lachowiez, CA; Loghavi, S; Maiti, A; Masarova, L; Montalban Bravo, G; Pemmaraju, N; Ravandi, F; Sasaki, K; Short, NJ; Takahashi, K; Wang, S; Xiao, L; Yilmaz, M, 2021)	0.83
"The present study aimed to investigate the efficacy and safety for alternate application of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) combined with idarubicin (IDA)/daunorubicin (DNR) in treatment of acute promyelocytic leukemia (APL)."	( Alternate application of all-trans-retinoic acid and arsenic trioxide combined with idarubicin/daunorubicin in treatment of acute promyelocytic leukemia. Mao, Y; Tang, F; Xu, X; Zhu, X, 2022)	1.14
" A prospective single-center phase Ib/II study evaluating fludarabine, cytarabine, G-CSF, and idarubicin combined with venetoclax (FLAG-IDA + VEN) in patients with newly diagnosed (ND) or relapsed/refractory AML."	( Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Adeoti, M; Alvarado, Y; Andreeff, M; Borthakur, G; Bravo, GM; Daver, N; DiNardo, CD; Garcia-Manero, G; Issa, G; Jabbour, E; Jain, N; Kadia, T; Kantarjian, HM; Konopleva, MY; Kornblau, S; Lachowiez, CA; Loghavi, S; Maiti, A; Masarova, L; Pemmaraju, N; Ravandi, F; Sasaki, K; Short, NJ; Takahashi, K; Wang, SA; Xiao, L; Yilmaz, M, 2022)	0.94
" We treated 174 consecutive patients with newly diagnosed CBF-AML in a prospective clinical trial of FLAG-based induction/consolidation in combination with gemtuzumab ozogamicin (FLAG-GO; N = 65) or in combination with idarubicin (FLAG-IDA; N = 109)."	( Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderso Alvarado, Y; Borthakur, G; Brandt, M; Daver, N; DiNardo, C; Garcia-Manero, G; Jabbour, EJ; Kadia, T; Kantarjian, H; Ohanian, M; Patel, K; Pemmaraju, N; Pierce, S; Ravandi, F; Takahashi, K; Wang, X, 2022)	1.11
"Venetoclax (VEN) in combination with intensive chemotherapy (IC) is increasingly used to treat patients with high-risk acute myeloid leukemia (AML)."	( Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed/refractory patients with AML - A systematic review. Fredman, D; Gafter-Gvili, A; Raanani, P; Sherban, A; Shimony, S; Stahl, M; Wolach, O; Yeshurun, M, 2023)	0.91

Excerpt	Reference	Relevance
" Unlike the other currently available anthracyclines, idarubicin has significant oral bioavailability (average 28%), and an oral dosage form is currently under investigation."	( Idarubicin: an anthracycline antineoplastic agent. Cersosimo, RJ, 1992)	1.97
" administration of the drug in another study, the bioavailability of idarubicin alone can be estimated to about 21%, whereas the bioavailability of the sum idarubicin + idarubicinol is about 41%."	( Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients. Huet, S; Hurteloup, P; Pris, J; Rigal-Huguet, F; Robert, J, 1990)	0.84
" dose, and the bioavailability of the oral dose ranged between 9% and 39%."	( Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients. D'Incalci, M; Erranti, D; Freshi, A; Tirelli, U; Zanette, L; Zucchetti, M, 1990)	0.28
" The bioavailability of DMDR given PO was about 39% according to comparison of the areas under the plasma DMDR concentration versus time curves for the two routes, but 45% according to comparison of the 24-h cumulative urinary excretion rates."	( Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). Bodey, GP; Burgess, M; Feun, LG; Kavanagh, J; Loo, TL; Lu, K; Savaraj, N, 1986)	0.27
" routes suggests an oral bioavailability of approximately 24%."	( Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin. Howell, A; Lucas, SB; Margison, JM; Smith, DB; Wilkinson, PM, 1987)	0.27
" The present study was undertaken to investigate the pharmacokinetics and bioavailability of idarubicin in man."	( Pharmacokinetic study of intravenous and oral idarubicin in cancer patients. Libretti, A; Moro, E; Pacciarini, MA; Piazza, E; Tamassia, V; Vago, G, 1987)	0.75
"Two anthracycline analogues, idarubicin and menogaril, have acceptable bioavailability via the oral route of administration."	( Potential role of oral anthracyclines in older patients with cancer. de Valeriola, DL; Lasota, WS; Piccart, MJ, 1994)	0.58
" Unlike the other currently available anthracyclines, IDA has significant oral bioavailability (about 30%)."	( [Clinical pharmacology of idarubicin]. Robak, T, 1993)	0.59
" The bioavailability of oral idarubicin and of oral doxifluridine allows for their use in an oral 3 drug regimen."	( Phase II study of an oral combination of doxifluridine, prednimustine and idarubicin (FUPRIDA) for first line treatment of advanced breast cancer. Alberto, P, 1993)	0.81
" The bioavailability of idarubicin is 20 to 25%, but if the activity of idarubicinol is taken into account, it is effectively about 40%."	( Clinical pharmacokinetics of idarubicin. Robert, J, 1993)	0.88
" These perspectives are somewhat hampered by the large variation in bioavailability between individual patients and the obvious requirement to monitor plasma concentration and area-under the curve values (AUC) for an appropriate adjustment of idarubicin dose."	( Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. Braess, J; Hiddemann, W; Kaufmann, CC; Kern, W; Kühn, S; Rührs, H; Schleyer, E; Sträubel, G; Unterhalt, M, 1996)	0.99
" The joint bioavailability of the parent compound and its active metabolite Idarubicinol is around 40%."	( [Oral idarubicin in treatment of advanced breast carcinoma]. Heinisch, H; Kerpel-Fronius, S, 1996)	1
" These perspectives are somewhat hampered by the large variation in bioavailability between individual patients and the obvious requirement to monitor plasma concentration and area-under-the-curve values (AUC) for an appropriate adjustment of idarubicin dose."	( Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. Braess, J; Hiddemann, W; Kaufmann, CC; Kern, W; Kühn, S; Rührs, H; Schleyer, E; Sträubel, G; Unterhalt, M, 1997)	0.99
" The aim of this research was to study whether the bioavailability of idarubicin can be improved by administering IDA-SLN duodenally to rats."	( Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. Bargoni, A; Cavalli, R; Fundarò, A; Gasco, MR; Vighetto, D; Zara, GP, 2002)	0.81
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."	( Hologram QSAR model for the prediction of human oral bioavailability. Andricopulo, AD; Moda, TL; Montanari, CA, 2007)	0.34

Excerpt	Relevance	Reference
" Unlike the other currently available anthracyclines, idarubicin has significant oral bioavailability (average 28%), and an oral dosage form is currently under investigation."	( Idarubicin: an anthracycline antineoplastic agent. Cersosimo, RJ, 1992)	1.97
" Median hematological values during the first cycle for this dosage included WBC, 1,300/mm3; platelets, 129,000/mm3; and hemoglobin, 10."	( Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma. Case, DC; Crawford, J; Gams, RA; Gerber, MC; Gould, J; Higano, CS; Pruitt, BT; Votaw, ML, 1992)	0.57
"Eighteen untreated elderly patients (median age 75 years) with non-Hodgkin's lymphoma (NHL) entered a phase II study with oral Idarubicin (4-demethoxidaunorubicin) at a dosage of 30-35 mg/m2 on day 1 and every 3 weeks thereafter."	( A phase II study of oral idarubicin (4-demethoxidaunorubicin) in previously untreated elderly patients with non-Hodgkin's lymphoma. Carbone, A; Errante, D; Monfardini, S; Sorio, R; Tirelli, U; Zagonel, V, 1991)	0.79
"44 at a cumulative IDA dosage of 322 mg/m2."	( Phase II study of oral idarubicin in elderly patients with advanced breast cancer. Bastit, P; Chevallier, B; Hurteloup, P; Marty, M; Metz, R; Monnier, A; Namer, M; Roche, H, 1990)	0.59
"Fourteen patients with extensive-disease non-small-cell lung cancer (E-NSCLC) were treated with oral 4-demethoxydaunorubicin (idarubicin, 4DMDR) at a dosage of 10 mg/m2/day x 5 days every 3 weeks."	( Phase II study of idarubicin in extensive-disease non-small-cell lung cancer. Carr, DT; Holoye, PY; Jeffries, D; Umsawasdi, T, 1989)	0.82
" In order to reduce the incidence of severe complications noted with HDARA-C-containing regimens, we used a combination of intravenous (IV) idarubicin (IDARUB) at optimal dosage and cytarabine (ARA-C) at intermediate dosage."	( Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine. Dufour, P; Facon, T; Guy, H; Harousseau, JL; Hurteloup, P; Ifrah, N; Milpied, N; Reiffers, J; Rigal-Huguet, F, 1989)	0.73
" at a dosage of 600 mg/m2 on the same day as fluorouracil (600 mg/m2/i."	( Intravenous administration of cyclophosphamide, methotrexate and 5-fluorouracil in metastatic breast cancer. A pilot study. Brandi, M; De Lena, M; Logroscino, A; Lorusso, V; Maiello, E; Paradiso, A, 1988)	0.27
"25 mg/kg body weight or PO at 1 mg/kg body weight, whereas [14C]DNR was dosed IV at 1 mg/kg body weight."	( Disposition and metabolism of [14-14C] 4-demethoxydaunorubicin HCl (idarubicin) and [14-14C]daunorubicin HCl in the rat. A comparative study. Arcamone, F; Lazzati, M; Vicario, GP; Zini, G, 1986)	0.51
" The drug was given in divided doses over 5 days and dosage was repeated every 3 weeks."	( A phase II trial of 4-demethoxydaunorubicin in refractory epithelial ovarian cancer. Copeland, LJ; Edwards, CL; Gershenson, DM; Kavanagh, JJ; Saul, PB, 1986)	0.27
"Twelve patients affected by different types of acute leukemia received idarubicin (4-demethoxy-daunorubicin) by oral route at the total dosage of 45, 60 or 90 mg/m2 distributed over three consecutive days."	( Oral idarubicin in adult acute leukemia: a preliminary experience. Annaloro, C; Lambertenghi-Deliliers, G; Pacciarini, MA; Pogliani, E; Polli, EE, 1986)	1.02
" Cellular D-DNM concentrations were maximal at the end of intravenous dosing and at 2 to 4 hours after D-DNM ingestion."	( Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunomycin. Haanen, C; Linssen, PC; Speth, PA; van de Loo, FA; Wessels, HM, 1986)	0.27
" Since there was no severe toxicity, after 2 cycles the dosage was increased to 60 mg/m2 per cycle."	( Phase II study of oral 4-demethoxydaunorubicin in previously treated (except anthracyclines) metastatic breast cancer patients. Kolarić, K; Mechl, Z; Potrebica, V; Sopkova, B, 1987)	0.27
" A group of 16 patients in relapse received idarubicin at a dosage of 5-6 mg/m2/day for 3 consecutive days; a second group of 6 relapsing and 4 previously untreated cases was treated with a sequential combination of idarubicin and arabinosyl cytosine."	( Therapeutic activity of 4-demethoxydauno-rubicin (idarubicin) in adult acute leukemia. Lambertenghi-Deliliers, G; Maiolo, AT; Pacciarini, MA; Pogliani, E; Polli, EE, 1983)	0.78
" Dose-response curves for AML blast cells were characterized by an initial shoulder and then an exponential decrease in survival."	( Sensitivities of AML blast stem cells to idarubicin and daunorubicin: a comparison with normal hematopoietic progenitors. Curtis, JE; McCulloch, EA; Minden, MD; Minkin, S, 1995)	0.56
" The maximum tolerated dosage was determined to be 2 mg/cat/d given for 3 consecutive days every 3 weeks."	( Efficacy of, and toxicoses associated with, oral idarubicin administration in cats with neoplasia. Cotter, SM; L'Heureux, DA; Moore, AS; Rand, WM; Ruslander, D, 1995)	0.55
" These studies should address specific issues such as optimal dosage regimens as a function of 'physiological age', and quality of life."	( Potential role of oral anthracyclines in older patients with cancer. de Valeriola, DL; Lasota, WS; Piccart, MJ, 1994)	0.29
"Seventeen patients with APL were salvaged with ATRA at a dosage of 50 mg/m2/day for 3 months or until complete remission (CR) was achieved; idarubicin (12 mg/m2/day for 4 days) was added if blast plus promyelocyte count either was or reached > or = 10 x 10(3)/microliters."	( All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. Cortes, JE; Estey, E; Hirsh-Ginsberg, C; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Robertson, LE; Stass, S, 1994)	0.49
" For consolidation with NOVE, rhGM-CSF was given according to the same dosage schedule."	( Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia. Del Valle, F; Döhner, H; Ehrhardt, R; Fischer, JT; Haas, R; Ho, AD; Huberts, H; Hunstein, W; Kaplan, E; Witt, B, 1993)	1.73
"The influence of three different dosage schedules of anthracycline (idarubicin or daunorubicin)-intensified preparative therapy prior to T-cell-depleted allogeneic bone marrow transplantation (BMT) on (1) the severity and duration of oral toxicity (mucositis), (2) the duration of bone marrow aplasia, and (3) overall survival, relapse, and disease-free survival was studied in 99 BMT patients with standard- or high-risk hematologic malignancies."	( Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent. de Witte, T; Dompeling, E; Donnelly, P; Linssen, P; Minderman, H; Muus, P; Schattenberg, A, 1993)	1.96
" Median hematologic values during the first cycle for this dosage included WBC 1300/mm3, platelets 129,000/mm3, and hemoglobin 10."	( Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma. Case, DC; Crawford, J; Gams, RA; Gerber, MC; Gould, J; Higano, CS; Pruitt, BT; Votaw, ML, 1993)	0.57
" The result indicated that Idarubicin is a useful drug for the treatment of acute leukemia, and the clinical optimal dosage estimated was either 10 mg/m2 or 12 mg/m2 once daily for 3 consecutive days."	( [Early phase II study of Idarubicin, a new anthracycline anticancer drug, in acute leukemia. Idarubicin Study Group]. Kimura, K; Masaoka, T; Ogawa, M; Yamada, K, 1993)	0.89
" Considering effectiveness and safety, the clinical optimal dosage of Idarubicin when used concomitantly with Cytarabine was judged to be 12 mg/m2 once daily for 3 consecutive days."	( [Early phase II study of Idarubicin combined with cytarabine in acute myelogenous leukemia. Idarubicin Study Group]. Kimura, K; Masaoka, T; Ogawa, M; Yamada, K, 1993)	0.82
" In acute lymphoblastic leukemia (ALL), the role of agreement regarding ANT dosage and schedule, preferable compound, and indications for remission induction and consolidation treatment phases."	( Role of anthracyclines in the treatment of adult acute lymphoblastic leukemia. Barbui, T; Bassan, R; Lerede, T; Rambaldi, A, 1996)	0.29
" ATRA was administered orally beginning on the first day of induction at the dosage of 45 mg/m2/d until complete remission (CR), whereas IDA was administered intravenously at the dosage of 12 mg/m2/d on days 2, 4, 6, and 8 of the induction."	( AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Avvisati, G; Diverio, D; Falda, M; Ferrara, F; Lazzarino, M; Lo Coco, F; Mandelli, F; Petti, MC; Russo, D, 1996)	0.58
" When IDA was administered at this dosage or higher, there were three CRs and four partial responses, with an overall response rate of 26."	( A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan. Tamura, K, 1996)	0.62
") over 30 minutes daily on days 1 to 3, in combination with BH-AC 300 mg/m2 over 4 hours daily on days 1 to 7 (in patients aged 41 to 65 years, BH-AC dosage was decreased to 200 mg/m2/d)."	( Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study. Ahn, HS; Cho, KS; Choi, YM; Chung, TJ; Hwang, TJ; Kim, CC; Kim, DW; Kim, HJ; Kim, HK; Kim, HS; Kim, JS; Lee, KS; Park, HS; Park, JW; Song, HS, 1996)	0.59
" IDA is bioavailable in an oral dosage form."	( Pharmacology of chronic oral daily administration of idarubicin. Aita, P; Bearz, A; Boiocchi, M; Corona, G; Crivellari, D; Rimondi, G; Robieux, I; Sorio, R; Stocco, F; Toffoli, G, )	0.38
" The data suggest a dose-response relationship for increasing doses of idarubicin with 0/3 complete responses (CR) at 20 mg/m2, 1/3 CR at 30 mg/m2, and 7/12 (58%) CR at idarubicin doses > or = 40 mg/m2."	( A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia. Drullinsky, P; Golde, DW; Maslak, P; Scheinberg, D; Weiss, MA, 1998)	0.8
" These adverse effects might be overcome by increasing the intensity of postremission therapy and modifying the dosing schedule."	( Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin. Bow, EJ; Gallant, G; Rubinger, M; Schacter, BA; Shore, TB; Williams, GJ; Woloschuk, D, 1998)	0.51
" In older patients (> 60 years) the dosage of idarubicin and ifosfamide was reduced to 75% in the initial cycle."	( DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma. Borchmann, P; Diehl, V; Engert, A; Münch, R; Reiser, M; Schnell, R; Straub, G; Ubelacker, R; Wilhelm, M; Wörmann, B, 1998)	0.88
" Our findings raise important questions concerning the need for a dosage adjustment of IDA when MDR modulators are coadministered."	( Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. Baccarani, M; Baraldo, M; Damiani, D; Ermacora, A; Fanin, R; Furlanut, M; Michieli, M; Pea, F; Russo, D, 1999)	0.52
" bolus, and this dosage regimen was repeated every 3 weeks."	( [Clinical effect of idarubicin on malignant lymphoma]. Kuraishi, Y; Masaoka, T; Ogawa, M; Ohashi, Y; Ohno, R; Urabe, A, 1999)	0.63
" Cytarabine was given to Cohort 1 at the conventional dosage of 100 mg/m2 per day by continuous infusion for 7 days in induction and 5 days in consolidation; to Cohort 2 at high-dose (HiDAC) (3 g/m2 intravenously twice daily on days 1, 3, 5 and 7) during induction with conventional dosage during consolidation; to Cohort 3 HiDAC was given for both induction and consolidation."	( A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and consolidation treatment of adult acute myeloid leukemia. Australian Leukaemia Study Group (ALSG). Bishop, JF; Bradstock, KF; Cobcroft, R; Eliadis, P; Enno, A; Gill, D; Herrmann, RP; Juneja, S; Lowenthal, RM; Manoharan, A; Matthews, JP; Page, FJ; Rooney, KF; Rosenfeld, D; Seldon, M; Taylor, KM; Wolf, MM; Young, GA, 1999)	0.53
" We conclude that CBP at a cumulative dosage of 1 g/m2 together with intercalating agents (IDA/MIT) has antileukemic efficacy in elderly patients."	( Continuous-infusion carboplatin in combination with idarubicin or mitoxantrone for high-risk acute myeloid leukemia: a randomised phase II study. Archimbaud, E; Assouline, D; Belhabri, A; Blanc, M; Fière, D; Michallet, M; Thomas, X; Tigaud, JD; Troncy, J; Wattel, E, 1999)	0.55
"These data confirm the existence of a saturable myocardial uptake mechanism for idarubicin and might provide useful information for optimizing anthracycline dosage regiments."	( Kinetic analysis of saturable myocardial uptake of idarubicin in rat heart: effect of doxorubicin and hypothermia. Kang, W; Weiss, M, 2003)	0.8
" The dosage of the immune suppressive reagents that were administered to prevent the rejection of the transplanted kidney were reduced during chemotherapy to minimize the adverse effect of immune suppression, and G-CSF was administrated to shorten the neutropenic period."	( [Intensive multi-drug chemotherapy for acute myeloid leukemia in a renal allograft recipient]. Fuchigami, K; Fukushima, T; Hata, T; Honda, M; Jinnai, I; Kuriyama, K; Miyazaki, Y; Togami, K; Tomonaga, M; Yamasaki, J, 2003)	0.32
"Six-month intravenous chemotherapy included carboplatin plus etoposide alternating with cyclophosphamide plus vincristine (Regimen 1) and the same drugs at higher dosage plus idarubicin (Regimen 2)."	( Results of a prospective study for the treatment of retinoblastoma. Casak, S; Chantada, G; Dávila, MT; Fandiño, A; Manzitti, J; Raslawski, E; Schvartzman, E, 2004)	0.52
" Following complete staging after course 2, radiotherapy was applied at a dosage of 3600-4140 cGy in conventional schedule (180 or 200 cGy per day) to whole brain (with 3600 cGy to eyes in one case because of eye involvement) and then 2 additional courses of R-IDARAM (totally four courses) chemotherapy regimen were applied."	( Modified IDARAM chemotherapy regimen for primary central nervous system lymphoma: experience of three cases. Alptekin, M; Erkutlu, I; Kilciksiz, S; Okan, V; Pehlivan, M; Sari, I; Yilmaz, M, 2008)	0.35
" Clofarabine dosed at 52 mg/m2 was used in adult patients with refractory ALL to maximize response before allo-HSCT."	( The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia. Brown, AW; McGregor, BA; Osswald, MB; Savona, MR, 2009)	0.35
" LY2181308 was administered with a loading dosage of three consecutive daily infusions of 750 mg followed by weekly intravenous (IV) maintenance doses of 750 mg."	( Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML). Andre, V; Andreeff, M; Brandt, JT; Callies, S; Erba, HP; Juckett, M; Kadam, S; Lahn, M; Sayar, H; Schmidt, S; Van Bockstaele, D, 2013)	0.6
"This systematic review and meta-analysis compared the efficacy of different anthracyclines and anthracycline dosing schedules for induction therapy in acute myeloid leukaemia in children and adults younger than 60 years of age."	( Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis. Alonzo, TA; Beyene, J; Lehrnbecher, T; Leibundgut, K; Sung, L; Teuffel, O, 2013)	0.39
" To further intensify anthracycline dosage without increasing cardiotoxicity, we compared potentially less cardiotoxic liposomal daunorubicin (L-DNR) to idarubicin at a higher-than-equivalent dose (80 vs 12 mg/m(2) per day for 3 days) during induction."	( Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Bourquin, JP; Creutzig, U; Dworzak, MN; Fleischhack, G; Graf, N; Klingebiel, T; Kremens, B; Lehrnbecher, T; Reinhardt, D; Ritter, J; Sander, A; Schrauder, A; Starý, J; von Neuhoff, C; von Stackelberg, A; Zimmermann, M, 2013)	0.84
" Using TR-FRET, we screened the Sigma LOPAC library for MBD2-MBD inhibitors and identified four compounds that also validated in a dose-response series."	( Time-Resolved Fluorescence Resonance Energy Transfer Assay for Discovery of Small-Molecule Inhibitors of Methyl-CpG Binding Domain Protein 2. Giovinazzo, H; Nelson, WG; Walker, D; Wyhs, N; Yegnasubramanian, S, 2014)	0.4
" After six cycles of R-IDARAM at 3-weekly intervals, radiotherapy was applied at a dosage of 2000-4000 cGy in conventional schedule (180 or 200 cGy/day) to whole brain or spinal cord in all patients."	( Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma. Cen, J; Li, C; Liu, X; Ma, Y; Mei, K; Qian, L; Shen, J; Wang, Y; Zhao, D, 2014)	0.68
" Therefore, in study AML-BFM 2004 we aimed to improve outcome of HR-patients by adding moderately dosed 2-Chloro-2-Deoxyadenosine (2-CDA) to the respective consolidation treatment backbone without increasing toxicity."	( Randomised Introduction of 2-CDA as Intensification during Consolidation for Children with High-risk AML--results from Study AML-BFM 2004. Bourquin, JP; Creutzig, U; Dworzak, M; Fleischhack, G; Graf, N; Gruhn, B; Klingebiel, T; Kremens, B; Lehrnbecher, T; Reinhardt, D; Stray, J; von Neuhoff, C; von Stackelberg, A; Zimmermann, M, 2015)	0.42
" Fourteen patients were included, and selinexor dosage was 60 mg (3 patients), 80 mg (3 patients), and 100 mg (7 patients) weekly."	( A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients. Acuña-Cruz, E; Barragán, E; Bergua, JM; Boluda, B; Cano-Ferri, I; Martín-Herreros, B; Martínez Sánchez, MP; Martínez-Cuadrón, D; Martínez-López, J; Megías-Vericat, JE; Montesinos, P; Rodríguez-Veiga, R; Sanz, M; Sargas, C; Sempere, A; Serrano, A; Suárez-Varela, S; Torrent, A; Torres-Miñana, L; Vives, S, 2021)	0.62
" Compared with RATIFY, this study extended midostaurin treatment from 14 days to 21 days, substituted anthracyclines (idarubicin or daunorubicin), and introduced variation in standard combination chemotherapy dosing ("7+3" or "5+2" in more fragile patients)."	( Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial. Bengoudifa, BR; Caillot, D; Cluzeau, T; Farkas, F; Gilotti, G; Griskevicius, L; Hodzic, S; Legrand, O; Luppi, M; Minotti, C; Montesinos, P; Rambaldi, A; Sierra, J; Thomas, X; Venditti, A, 2023)	1.4

Class	Description
anthracycline antibiotic	An organic compound that has a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine and which exhibits antibiotic activity.
deoxy hexoside
monosaccharide derivative	A carbohydrate derivative that is formally obtained from a monosaccharide.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	13.1863	0.0032	45.4673	12,589.2998	AID1705; AID2517; AID2572; AID2573
Chain A, 2-oxoglutarate Oxygenase	Homo sapiens (human)	Potency	14.1254	0.1778	14.3909	39.8107	AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1	Homo sapiens (human)	Potency	24.9618	0.1259	19.1169	125.8920	AID2353; AID2549; AID2708
Chain A, Ferritin light chain	Equus caballus (horse)	Potency	39.8107	5.6234	17.2929	31.6228	AID2323
endonuclease IV	Escherichia coli	Potency	25.1189	0.7079	12.4324	31.6228	AID1708
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	26.6795	0.1000	20.8793	79.4328	AID488773; AID588453
ATAD5 protein, partial	Homo sapiens (human)	Potency	3.1913	0.0041	10.8903	31.5287	AID493106; AID493107
USP1 protein, partial	Homo sapiens (human)	Potency	44.9647	0.0316	37.5844	354.8130	AID504865
PPM1D protein	Homo sapiens (human)	Potency	2.0821	0.0052	9.4661	32.9993	AID1347411
Microtubule-associated protein tau	Homo sapiens (human)	Potency	8.0687	0.1800	13.5574	39.8107	AID1460; AID1468
DNA polymerase III, partial	Bacillus subtilis	Potency	1.0621	1.0621	14.1528	26.6795	AID485295
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	28.1838	0.0112	12.4002	100.0000	AID1030
regulator of G-protein signaling 4	Homo sapiens (human)	Potency	37.6858	0.5318	15.4358	37.6858	AID504845
nonstructural protein 1	Influenza A virus (A/WSN/1933(H1N1))	Potency	39.8107	0.2818	9.7212	35.4813	AID2326
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	0.8768	0.0015	30.6073	15,848.9004	AID1224819; AID1224820; AID1224821; AID1224823
Parkin	Homo sapiens (human)	Potency	5.8048	0.8199	14.8306	44.6684	AID720573
arylsulfatase A	Homo sapiens (human)	Potency	11.9955	1.0691	13.9551	37.9330	AID720538
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	9.7077	0.0355	20.9770	89.1251	AID504332
Bloom syndrome protein isoform 1	Homo sapiens (human)	Potency	10.5468	0.5406	17.6392	96.1227	AID2364; AID2528; AID2585
hexokinase-4 isoform 1	Homo sapiens (human)	Potency	0.7079	2.5119	13.8003	28.1838	AID743205
NPC intracellular cholesterol transporter 1 precursor	Homo sapiens (human)	Potency	115.8210	0.0126	2.4518	25.0177	AID485313
peripheral myelin protein 22 isoform 1	Homo sapiens (human)	Potency	0.4256	23.9341	23.9341	23.9341	AID1967
D(1A) dopamine receptor	Homo sapiens (human)	Potency	8.4498	0.0224	5.9449	22.3872	AID488981; AID488982; AID488983
vitamin D3 receptor isoform VDRA	Homo sapiens (human)	Potency	7.6111	0.3548	28.0659	89.1251	AID504847
chromobox protein homolog 1	Homo sapiens (human)	Potency	39.8107	0.0060	26.1688	89.1251	AID488953
thyroid hormone receptor beta isoform a	Homo sapiens (human)	Potency	36.4261	0.0100	39.5371	1,122.0200	AID1469; AID1479
potassium voltage-gated channel subfamily H member 2 isoform d	Homo sapiens (human)	Potency	10.0000	0.0178	9.6374	44.6684	AID588834
glucokinase regulatory protein	Homo sapiens (human)	Potency	0.7079	2.5119	13.8003	28.1838	AID743205
huntingtin isoform 2	Homo sapiens (human)	Potency	0.6310	0.0006	18.4198	1,122.0200	AID1688
DNA polymerase beta	Homo sapiens (human)	Potency	14.1254	0.0224	21.0102	89.1251	AID485314
mitogen-activated protein kinase 1	Homo sapiens (human)	Potency	22.3872	0.0398	16.7842	39.8107	AID1454
flap endonuclease 1	Homo sapiens (human)	Potency	26.6795	0.1337	25.4129	89.1251	AID488816; AID588795
ubiquitin carboxyl-terminal hydrolase 2 isoform a	Homo sapiens (human)	Potency	16.4816	0.6561	9.4520	25.1189	AID463106
ras-related protein Rab-9A	Homo sapiens (human)	Potency	58.0479	0.0002	2.6215	31.4954	AID485297
serine/threonine-protein kinase mTOR isoform 1	Homo sapiens (human)	Potency	6.2024	0.0037	8.6189	23.2809	AID2660; AID2666; AID2667; AID2668
eyes absent homolog 2 isoform a	Homo sapiens (human)	Potency	125.8920	1.1998	14.6419	50.1187	AID488837
histone-lysine N-methyltransferase 2A isoform 2 precursor	Homo sapiens (human)	Potency	29.8816	0.0103	23.8567	63.0957	AID2662
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)	Potency	26.8545	0.4256	12.0591	28.1838	AID504536
tumor susceptibility gene 101 protein	Homo sapiens (human)	Potency	7.9433	0.1298	10.8331	32.6090	AID485342
DNA polymerase eta isoform 1	Homo sapiens (human)	Potency	14.1254	0.1000	28.9256	213.3130	AID588591
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	7.9433	0.0501	27.0736	89.1251	AID588590
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	17.7828	0.0079	8.2332	1,122.0200	AID2551
geminin	Homo sapiens (human)	Potency	15.5441	0.0046	11.3741	33.4983	AID463097; AID504364
DNA polymerase kappa isoform 1	Homo sapiens (human)	Potency	17.3114	0.0316	22.3146	100.0000	AID588579
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	1.6598	0.0056	12.3677	36.1254	AID624032; AID624044
survival motor neuron protein isoform d	Homo sapiens (human)	Potency	0.6310	0.1259	12.2344	35.4813	AID1458
M-phase phosphoprotein 8	Homo sapiens (human)	Potency	29.0594	0.1778	24.7352	79.4328	AID488949
muscleblind-like protein 1 isoform 1	Homo sapiens (human)	Potency	7.9433	0.0041	9.9625	28.1838	AID2675
histone acetyltransferase KAT2A isoform 1	Homo sapiens (human)	Potency	22.3872	0.2512	15.8432	39.8107	AID504327
lamin isoform A-delta10	Homo sapiens (human)	Potency	0.2837	0.8913	12.0676	28.1838	AID1459; AID1487
Interferon beta	Homo sapiens (human)	Potency	2.0821	0.0033	9.1582	39.8107	AID1347411
Glutamate receptor 1	Rattus norvegicus (Norway rat)	Potency	15.8489	0.0141	8.6024	39.8107	AID2572
Glutamate receptor 2	Rattus norvegicus (Norway rat)	Potency	15.8489	0.0015	51.7393	15,848.9004	AID2572
Glutamate receptor 3	Rattus norvegicus (Norway rat)	Potency	15.8489	0.0141	8.6024	39.8107	AID2572
Glutamate receptor 4	Rattus norvegicus (Norway rat)	Potency	15.8489	0.0141	8.6024	39.8107	AID2572
D(1A) dopamine receptor	Sus scrofa (pig)	Potency	0.4140	0.0037	8.1081	23.2809	AID2667
Inositol monophosphatase 1	Rattus norvegicus (Norway rat)	Potency	1.9953	1.0000	10.4756	28.1838	AID1457
Ataxin-2	Homo sapiens (human)	Potency	0.1000	0.0119	12.2221	68.7989	AID588378
Single-stranded DNA cytosine deaminase	Homo sapiens (human)	Potency	67.1545	28.1838	60.1453	89.1251	AID1347430; AID1347431
ATP-dependent phosphofructokinase	Trypanosoma brucei brucei TREU927	Potency	30.1313	0.0601	10.7453	37.9330	AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
NPYLR7B	Aedes aegypti (yellow fever mosquito)	EC50 (µMol)	4.2900	0.0390	2.2899	18.3000	AID1259426
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
regulation of gene expression	Amyloid-beta precursor protein	Homo sapiens (human)
cognition	Amyloid-beta precursor protein	Homo sapiens (human)
G2/M transition of mitotic cell cycle	Amyloid-beta precursor protein	Homo sapiens (human)
microglial cell activation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of protein phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
suckling behavior	Amyloid-beta precursor protein	Homo sapiens (human)
astrocyte activation involved in immune response	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of translation	Amyloid-beta precursor protein	Homo sapiens (human)
protein phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
intracellular copper ion homeostasis	Amyloid-beta precursor protein	Homo sapiens (human)
endocytosis	Amyloid-beta precursor protein	Homo sapiens (human)
response to oxidative stress	Amyloid-beta precursor protein	Homo sapiens (human)
cell adhesion	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of epidermal growth factor-activated receptor activity	Amyloid-beta precursor protein	Homo sapiens (human)
Notch signaling pathway	Amyloid-beta precursor protein	Homo sapiens (human)
axonogenesis	Amyloid-beta precursor protein	Homo sapiens (human)
learning or memory	Amyloid-beta precursor protein	Homo sapiens (human)
learning	Amyloid-beta precursor protein	Homo sapiens (human)
mating behavior	Amyloid-beta precursor protein	Homo sapiens (human)
locomotory behavior	Amyloid-beta precursor protein	Homo sapiens (human)
axo-dendritic transport	Amyloid-beta precursor protein	Homo sapiens (human)
cholesterol metabolic process	Amyloid-beta precursor protein	Homo sapiens (human)
negative regulation of cell population proliferation	Amyloid-beta precursor protein	Homo sapiens (human)
adult locomotory behavior	Amyloid-beta precursor protein	Homo sapiens (human)
visual learning	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of gene expression	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of gene expression	Amyloid-beta precursor protein	Homo sapiens (human)
negative regulation of gene expression	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycle	Amyloid-beta precursor protein	Homo sapiens (human)
microglia development	Amyloid-beta precursor protein	Homo sapiens (human)
axon midline choice point recognition	Amyloid-beta precursor protein	Homo sapiens (human)
neuron remodeling	Amyloid-beta precursor protein	Homo sapiens (human)
dendrite development	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of Wnt signaling pathway	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular matrix organization	Amyloid-beta precursor protein	Homo sapiens (human)
forebrain development	Amyloid-beta precursor protein	Homo sapiens (human)
neuron projection development	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of chemokine production	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of interleukin-1 beta production	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of interleukin-6 production	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
ionotropic glutamate receptor signaling pathway	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of multicellular organism growth	Amyloid-beta precursor protein	Homo sapiens (human)
negative regulation of neuron differentiation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of glycolytic process	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of mitotic cell cycle	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of JNK cascade	Amyloid-beta precursor protein	Homo sapiens (human)
astrocyte activation	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of long-term neuronal synaptic plasticity	Amyloid-beta precursor protein	Homo sapiens (human)
collateral sprouting in absence of injury	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of inflammatory response	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of peptidyl-tyrosine phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of synapse structure or activity	Amyloid-beta precursor protein	Homo sapiens (human)
synapse organization	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of calcium-mediated signaling	Amyloid-beta precursor protein	Homo sapiens (human)
neuromuscular process controlling balance	Amyloid-beta precursor protein	Homo sapiens (human)
synaptic assembly at neuromuscular junction	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of protein metabolic process	Amyloid-beta precursor protein	Homo sapiens (human)
neuron apoptotic process	Amyloid-beta precursor protein	Homo sapiens (human)
smooth endoplasmic reticulum calcium ion homeostasis	Amyloid-beta precursor protein	Homo sapiens (human)
neuron cellular homeostasis	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Amyloid-beta precursor protein	Homo sapiens (human)
response to interleukin-1	Amyloid-beta precursor protein	Homo sapiens (human)
modulation of excitatory postsynaptic potential	Amyloid-beta precursor protein	Homo sapiens (human)
NMDA selective glutamate receptor signaling pathway	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of spontaneous synaptic transmission	Amyloid-beta precursor protein	Homo sapiens (human)
cytosolic mRNA polyadenylation	Amyloid-beta precursor protein	Homo sapiens (human)
negative regulation of long-term synaptic potentiation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of long-term synaptic potentiation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transduction	Amyloid-beta precursor protein	Homo sapiens (human)
cellular response to amyloid-beta	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of presynapse assembly	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of amyloid fibril formation	Amyloid-beta precursor protein	Homo sapiens (human)
amyloid fibril formation	Amyloid-beta precursor protein	Homo sapiens (human)
neuron projection maintenance	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of T cell migration	Amyloid-beta precursor protein	Homo sapiens (human)
central nervous system development	Amyloid-beta precursor protein	Homo sapiens (human)
negative regulation of receptor internalization	Ataxin-2	Homo sapiens (human)
regulation of translation	Ataxin-2	Homo sapiens (human)
RNA metabolic process	Ataxin-2	Homo sapiens (human)
P-body assembly	Ataxin-2	Homo sapiens (human)
stress granule assembly	Ataxin-2	Homo sapiens (human)
RNA transport	Ataxin-2	Homo sapiens (human)
mRNA processing	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
cytidine deamination	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
somatic diversification of immunoglobulins	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
somatic hypermutation of immunoglobulin genes	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
B cell differentiation	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
regulation of nuclear cell cycle DNA replication	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
defense response to bacterium	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
positive regulation of gene expression via chromosomal CpG island demethylation	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
isotype switching	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
cellular response to lipopolysaccharide	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
DNA cytosine deamination	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
DNA demethylation	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
cytidine to uridine editing	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
negative regulation of single stranded viral RNA replication via double stranded DNA intermediate	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
defense response to virus	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Amyloid-beta precursor protein	Homo sapiens (human)
DNA binding	Amyloid-beta precursor protein	Homo sapiens (human)
serine-type endopeptidase inhibitor activity	Amyloid-beta precursor protein	Homo sapiens (human)
signaling receptor binding	Amyloid-beta precursor protein	Homo sapiens (human)
protein binding	Amyloid-beta precursor protein	Homo sapiens (human)
heparin binding	Amyloid-beta precursor protein	Homo sapiens (human)
enzyme binding	Amyloid-beta precursor protein	Homo sapiens (human)
identical protein binding	Amyloid-beta precursor protein	Homo sapiens (human)
transition metal ion binding	Amyloid-beta precursor protein	Homo sapiens (human)
receptor ligand activity	Amyloid-beta precursor protein	Homo sapiens (human)
PTB domain binding	Amyloid-beta precursor protein	Homo sapiens (human)
protein serine/threonine kinase binding	Amyloid-beta precursor protein	Homo sapiens (human)
signaling receptor activator activity	Amyloid-beta precursor protein	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
cytidine deaminase activity	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
protein binding	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
zinc ion binding	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
ubiquitin protein ligase binding	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
identical protein binding	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
RNA binding	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
extracellular space	Amyloid-beta precursor protein	Homo sapiens (human)
dendrite	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular region	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular space	Amyloid-beta precursor protein	Homo sapiens (human)
nuclear envelope lumen	Amyloid-beta precursor protein	Homo sapiens (human)
cytoplasm	Amyloid-beta precursor protein	Homo sapiens (human)
mitochondrial inner membrane	Amyloid-beta precursor protein	Homo sapiens (human)
endosome	Amyloid-beta precursor protein	Homo sapiens (human)
early endosome	Amyloid-beta precursor protein	Homo sapiens (human)
endoplasmic reticulum	Amyloid-beta precursor protein	Homo sapiens (human)
endoplasmic reticulum lumen	Amyloid-beta precursor protein	Homo sapiens (human)
smooth endoplasmic reticulum	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi apparatus	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi lumen	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi-associated vesicle	Amyloid-beta precursor protein	Homo sapiens (human)
cytosol	Amyloid-beta precursor protein	Homo sapiens (human)
plasma membrane	Amyloid-beta precursor protein	Homo sapiens (human)
clathrin-coated pit	Amyloid-beta precursor protein	Homo sapiens (human)
cell-cell junction	Amyloid-beta precursor protein	Homo sapiens (human)
synaptic vesicle	Amyloid-beta precursor protein	Homo sapiens (human)
cell surface	Amyloid-beta precursor protein	Homo sapiens (human)
membrane	Amyloid-beta precursor protein	Homo sapiens (human)
COPII-coated ER to Golgi transport vesicle	Amyloid-beta precursor protein	Homo sapiens (human)
axon	Amyloid-beta precursor protein	Homo sapiens (human)
growth cone	Amyloid-beta precursor protein	Homo sapiens (human)
platelet alpha granule lumen	Amyloid-beta precursor protein	Homo sapiens (human)
neuromuscular junction	Amyloid-beta precursor protein	Homo sapiens (human)
endosome lumen	Amyloid-beta precursor protein	Homo sapiens (human)
trans-Golgi network membrane	Amyloid-beta precursor protein	Homo sapiens (human)
ciliary rootlet	Amyloid-beta precursor protein	Homo sapiens (human)
dendritic spine	Amyloid-beta precursor protein	Homo sapiens (human)
dendritic shaft	Amyloid-beta precursor protein	Homo sapiens (human)
perikaryon	Amyloid-beta precursor protein	Homo sapiens (human)
membrane raft	Amyloid-beta precursor protein	Homo sapiens (human)
apical part of cell	Amyloid-beta precursor protein	Homo sapiens (human)
synapse	Amyloid-beta precursor protein	Homo sapiens (human)
perinuclear region of cytoplasm	Amyloid-beta precursor protein	Homo sapiens (human)
presynaptic active zone	Amyloid-beta precursor protein	Homo sapiens (human)
spindle midzone	Amyloid-beta precursor protein	Homo sapiens (human)
recycling endosome	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular exosome	Amyloid-beta precursor protein	Homo sapiens (human)
receptor complex	Amyloid-beta precursor protein	Homo sapiens (human)
early endosome	Amyloid-beta precursor protein	Homo sapiens (human)
membrane raft	Amyloid-beta precursor protein	Homo sapiens (human)
cell surface	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi apparatus	Amyloid-beta precursor protein	Homo sapiens (human)
plasma membrane	Amyloid-beta precursor protein	Homo sapiens (human)
plasma membrane	Glutamate receptor 1	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor 2	Rattus norvegicus (Norway rat)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
nucleus	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
cytoplasm	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
cytosol	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
protein-containing complex	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
nucleus	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
cytoplasm	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
P-body	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID521220	Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay	2007	Nature chemical biology, May, Volume: 3, Issue:5	Chemical genetics reveals a complex functional ground state of neural stem cells.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID95000	Cytotoxic activity against K562 erythroleukemic cells	1999	Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15	Solution structure of iron(III)-anthracycline complexes.
AID731882	Cytotoxicity against human ES2 cells after 24 hrs by XTT assay	2013	ACS medicinal chemistry letters, Mar-14, Volume: 4, Issue:3	The structure of anthracycline derivatives determines their subcellular localization and cytotoxic activity.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID524791	Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID562245	Antimycobacterial activity against Mycobacterium smegmatis grown in nitrogen -limited broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID524796	Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID731877	Displacement of YOYO1 from phage lambda DNA by FID assay	2013	ACS medicinal chemistry letters, Mar-14, Volume: 4, Issue:3	The structure of anthracycline derivatives determines their subcellular localization and cytotoxic activity.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1678479	Inhibition of recombinant His6-tagged SARS-CoV-2 main protease using Dabcyl-KTSAVLQ-SGFRKM-E(Edans-NH2) as substrate preincubated for 15 mins followed by substrate addition by FRET based assay	2020	ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12	Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.
AID524795	Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID562241	Antimycobacterial activity against Mycobacterium smegmatis grown in carbon-limited broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID562243	Antimycobacterial activity against Mycobacterium smegmatis grown in Luria-Bertani broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID524793	Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID409956	Inhibition of mouse brain MAOB	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID681288	TP_TRANSPORTER: inhibition of DNP-SG uptake (DNP-SG: 0.01 uM, Idarbicin: 10 uM) in membrane vesicles from GLC4/ADR cells	1997	Biochimica et biophysica acta, May-22, Volume: 1326, Issue:1	Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1678478	Inhibition of recombinant His6-tagged SARS-CoV-2 main protease assessed as residual enzyme activity at 100 uM using Dabcyl-KTSAVLQ-SGFRKM-E(Edans-NH2) as substrate preincubated for 15 mins followed by substrate addition by FRET based assay relative to con	2020	ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12	Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.
AID685503	HARVARD: Inhibition of blood stage Plasmodium falciparum Dd2 infection	2012	Proceedings of the National Academy of Sciences of the United States of America, May-29, Volume: 109, Issue:22	Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
AID562244	Antimycobacterial activity against Mycobacterium smegmatis grown in carbon-limited broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID731885	Cytotoxicity against human MCF7 cells after 24 hrs by XTT assay	2013	ACS medicinal chemistry letters, Mar-14, Volume: 4, Issue:3	The structure of anthracycline derivatives determines their subcellular localization and cytotoxic activity.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID731878	Cytotoxicity against mouse DA-3 cells assessed as reduction in cell viability at 20 uM by XTT assay	2013	ACS medicinal chemistry letters, Mar-14, Volume: 4, Issue:3	The structure of anthracycline derivatives determines their subcellular localization and cytotoxic activity.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID731874	Ratio of idarubicin IC50 to compound IC50 for displacement of SYBR from phage lambda DNA	2013	ACS medicinal chemistry letters, Mar-14, Volume: 4, Issue:3	The structure of anthracycline derivatives determines their subcellular localization and cytotoxic activity.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID685501	HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells	2012	Proceedings of the National Academy of Sciences of the United States of America, May-29, Volume: 109, Issue:22	Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
AID748999	Inhibition of NDM-1 (unknown origin) using nitrocefin as substrate preincubated 10 mins followed by substrate addition measured after 20 mins relative to control	2013	Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11	An altered zinc-binding site confers resistance to a covalent inactivator of New Delhi metallo-beta-lactamase-1 (NDM-1) discovered by high-throughput screening.
AID731872	Cellular uptake in mouse DA-3 cell nucleus at 10 uM after 30 mins by DRAQ5 deep red staining-based confocal microscopic analysis relative to control	2013	ACS medicinal chemistry letters, Mar-14, Volume: 4, Issue:3	The structure of anthracycline derivatives determines their subcellular localization and cytotoxic activity.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID524794	Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID562242	Antimycobacterial activity against Mycobacterium smegmatis grown in nitrogen -limited broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID685502	HARVARD: Inhibition of blood stage Plasmodium falciparum 3D7 infection	2012	Proceedings of the National Academy of Sciences of the United States of America, May-29, Volume: 109, Issue:22	Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID749000	Inhibition of NDM-1 (unknown origin) using nitrocefin as substrate preincubated 10 mins followed by substrate addition measured after 20 mins	2013	Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11	An altered zinc-binding site confers resistance to a covalent inactivator of New Delhi metallo-beta-lactamase-1 (NDM-1) discovered by high-throughput screening.
AID731873	Ratio of idarubicin IC50 to compound IC50 for displacement of YOYO1 from phage lambda DNA	2013	ACS medicinal chemistry letters, Mar-14, Volume: 4, Issue:3	The structure of anthracycline derivatives determines their subcellular localization and cytotoxic activity.
AID477295	Octanol-water partition coefficient, log P of the compound	2010	European journal of medicinal chemistry, Apr, Volume: 45, Issue:4	QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID524790	Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID409954	Inhibition of mouse brain MAOA	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID588220	Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset	2008	Toxicology mechanisms and methods, , Volume: 18, Issue:2-3	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID731883	Cytotoxicity against mouse DA-3 cells after 24 hrs by XTT assay	2013	ACS medicinal chemistry letters, Mar-14, Volume: 4, Issue:3	The structure of anthracycline derivatives determines their subcellular localization and cytotoxic activity.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID731870	Cellular uptake in mouse DA-3 cell lysosome at 10 uM after 30 mins by LysoTracker green staining-based confocal microscopic analysis relative to control	2013	ACS medicinal chemistry letters, Mar-14, Volume: 4, Issue:3	The structure of anthracycline derivatives determines their subcellular localization and cytotoxic activity.
AID748997	Inhibition of TEM-1 (unknown origin) using nitrocefin as substrate preincubated 10 mins followed by substrate addition measured after 20 mins relative to control	2013	Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11	An altered zinc-binding site confers resistance to a covalent inactivator of New Delhi metallo-beta-lactamase-1 (NDM-1) discovered by high-throughput screening.
AID524792	Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID685500	HARVARD: Cytotoxicity in HepG2 cell line	2012	Proceedings of the National Academy of Sciences of the United States of America, May-29, Volume: 109, Issue:22	Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
AID748998	Inhibition of TEM-1 (unknown origin) using nitrocefin as substrate preincubated 10 mins followed by substrate addition measured after 20 mins	2013	Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11	An altered zinc-binding site confers resistance to a covalent inactivator of New Delhi metallo-beta-lactamase-1 (NDM-1) discovered by high-throughput screening.
AID731871	Cellular uptake in mouse DA-3 cell mitochondria at 10 uM after 30 mins by mitotracker red staining-based confocal microscopic analysis	2013	ACS medicinal chemistry letters, Mar-14, Volume: 4, Issue:3	The structure of anthracycline derivatives determines their subcellular localization and cytotoxic activity.
AID1755099	Cytotoxicity against human BJ cells assessed as reduction in cell viability at 58 uM	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Antimalarial activity of 2,6-dibenzylidenecyclohexanone derivatives.
AID731875	Ratio of doxorubicin IC50 to compound IC50 for displacement of SYBR from phage lambda DNA	2013	ACS medicinal chemistry letters, Mar-14, Volume: 4, Issue:3	The structure of anthracycline derivatives determines their subcellular localization and cytotoxic activity.
AID562240	Antimycobacterial activity against Mycobacterium smegmatis grown in Luria-Bertani broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID731884	Cytotoxicity against human SKOV3 cells after 24 hrs by XTT assay	2013	ACS medicinal chemistry letters, Mar-14, Volume: 4, Issue:3	The structure of anthracycline derivatives determines their subcellular localization and cytotoxic activity.
AID1676758	Antiplasmodial activity against Plasmodium falciparum 3D7 infected in human erythrocytes assessed as growth inhibition at 58 uM after 72 hrs by SYBR Gren-I fluorescent dye based method	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Synthesis and Structure-Activity Relationship of Dual-Stage Antimalarial Pyrazolo[3,4-
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID731876	Displacement of SYBR from phage lambda DNA by FID assay	2013	ACS medicinal chemistry letters, Mar-14, Volume: 4, Issue:3	The structure of anthracycline derivatives determines their subcellular localization and cytotoxic activity.
AID311524	Oral bioavailability in human	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Hologram QSAR model for the prediction of human oral bioavailability.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1719374	Cytotoxicity against human BJ cells assessed as reduction in cell viability at 58 uM by relative to control	2021	Bioorganic & medicinal chemistry letters, 03-01, Volume: 35	Identification of Plasmodium falciparum heat shock 90 inhibitors via molecular docking.
AID1171738	Antiproliferative activity against human K562 cells after 72 hrs	2014	Journal of natural products, Dec-26, Volume: 77, Issue:12	Injury-induced biosynthesis of methyl-branched polyene pigments in a white-rotting basidiomycete.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID312292	Cytotoxicity against human K562 cells after 5 days by XTT assay	2007	Journal of natural products, Dec, Volume: 70, Issue:12	Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1347414	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347412	qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	155 (9.19)	18.7374
1990's	437 (25.92)	18.2507
2000's	546 (32.38)	29.6817
2010's	438 (25.98)	24.3611
2020's	110 (6.52)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	454 (25.29%)	5.53%
Reviews	139 (7.74%)	6.00%
Case Studies	321 (17.88%)	4.05%
Observational	3 (0.17%)	0.25%
Other	878 (48.91%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (221)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Traitement Des Carcinomes hépatocellulaires Sur Cirrhose Child A/B7 Par Injection Intra-artérielle hépatique d'Une émulsion de Lipiodol et Idarubicine : Etude de Phase II, Monobras, Multicentrique. [NCT03727633]	Phase 2	53 participants (Anticipated)	Interventional	2018-07-19	Recruiting
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Poor-Risk Acute Myelogenous Leukemia [NCT00840177]	Phase 2	115 participants (Actual)	Interventional	2009-12-10	Completed
Phase I Study of Lenalidomide and Conventional Chemotherapy in Acute Myeloid Leukemia [NCT01132586]	Phase 1	61 participants (Actual)	Interventional	2010-05-31	Completed
A Prospective Randomized Comparison of Idarubicin and High-dose Daunorubicin in Combination With Cytarabine in the Induction Chemotherapy for Acute Myeloid Leukemia [NCT01145846]	Phase 3	316 participants (Anticipated)	Interventional	2010-05-31	Recruiting
Randomized Phase-II Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine [NCT01180322]	Phase 2	277 participants (Actual)	Interventional	2010-11-30	Completed
A Phase 1b Study of JNJ-75276617 in Combination With AML-Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations [NCT05453903]	Phase 1	150 participants (Anticipated)	Interventional	2022-10-04	Recruiting
CLAG-M or FLAG-Ida Chemotherapy Followed Immediately by Related/Unrelated Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1 Study [NCT04375631]	Phase 1	120 participants (Anticipated)	Interventional	2020-12-03	Recruiting
A Multicenter, Prospective, Non-randomized, Phase I-II Trial to Assess the Efficacy and Safety of the Combination of Oral Quizartinib and the FLAG-IDA Chemotherapy Regimen in First Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Patients [NCT04112589]	Phase 1/Phase 2	63 participants (Actual)	Interventional	2019-12-26	Active, not recruiting
A Phase I and Expansion Cohort Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia [NCT03194932]	Phase 1	62 participants (Actual)	Interventional	2017-07-11	Completed
A Phase II Randomized Study to Assess the Efficacy on Outcome of Venetoclax Combined With Cytarabine Versus Idarubicin Combined With Cytarabine Administered as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission [NCT04968015]	Phase 2	134 participants (Anticipated)	Interventional	2022-05-25	Recruiting
A Phase I-II Study of the Efficacy and Safety of Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes [NCT01305135]	Phase 1/Phase 2	41 participants (Actual)	Interventional	2010-12-30	Completed
Phase 1 Study of FLAG-Ida With Pivekimab Sunirine (PVEK [IMGN632]) for Adults With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms [NCT06034470]	Phase 1	30 participants (Anticipated)	Interventional	2024-01-13	Recruiting
An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Total Therapy for Adult T-lymphoblastic Lymphoma/Leukemia [NCT03564704]	Phase 2/Phase 3	80 participants (Anticipated)	Interventional	2016-02-14	Recruiting
Phase 1b, Open-label, Dose Escalation Study of Quizartinib in Combination With Induction and Consolidation Chemotherapy in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) [NCT02834390]	Phase 1	7 participants (Actual)	Interventional	2016-08-12	Completed
An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Target Total Therapy for Adult Early T-cell Progenitor Acute Lymphoblastic Leukemia/Lymphoma [NCT03553238]	Phase 2/Phase 3	70 participants (Anticipated)	Interventional	2016-02-14	Recruiting
A Phase I Study of Volasertib Combined With Standard Induction Chemotherapy for Previously Untreated Patients With Acute Myeloid Leukemia (VIAC) [NCT02527174]	Phase 1	0 participants (Actual)	Interventional	2016-11-30	Withdrawn(stopped due to Volasertib no longer available)
Multicenter Randomised Clinical Trial in Acute Myeloid Leukemia Treatment Based on Three Anthracyclines, Comparing Two Types of Consolidation With Different ARA-C Doses Followed by One Year Maintenance [NCT01587430]	Phase 4	245 participants (Anticipated)	Interventional	2010-01-31	Active, not recruiting
PROTOCOL FOR First Line TREATMENT ADAPTED TO RISK of Acute Myeloblastic Leukemia in Patients LESS THAN OR EQUAL TO 65 YEARS [NCT01296178]		200 participants (Anticipated)	Interventional	2010-12-31	Recruiting
HEC73543 Versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukemia: a Multicenter, Open-label, Randomized Phase 3 Trial [NCT05586074]	Phase 3	324 participants (Anticipated)	Interventional	2023-03-03	Recruiting
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid [NCT02339740]	Phase 3	158 participants (Actual)	Interventional	2015-07-21	Active, not recruiting
A Safety and Tolerability Trial of Crenolanib and Chemotherapy With Cytarabine and Anthracyclines in Patients With Newly Diagnosed Acute Myeloid Leukemia With FLT3 Activating Mutations [NCT02283177]	Phase 2	44 participants (Actual)	Interventional	2015-01-31	Completed
Phase II/III Randomized Study to Improve Overall Survival in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus Mycop [NCT02416388]	Phase 2/Phase 3	3,100 participants (Anticipated)	Interventional	2015-01-31	Recruiting
Moscow-Berlin 2015 Multicenter Randomized Study for Treatment of Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults [NCT03390387]		4,000 participants (Anticipated)	Interventional	2015-11-30	Recruiting
A 2:1 Randomized Phase II Trial to Compare the Efficacy and Safety of Standard Chemotherapy Plus Quizartinib Versus Standard Chemotherapy Plus Placebo in Adult Patients With Newly Diagnosed FLT3 Wild-type AML [NCT04107727]	Phase 2	273 participants (Actual)	Interventional	2019-09-05	Active, not recruiting
A Phase II, Open-label, Single Arm Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Twice Daily Midostaurin (PKC412) Combined With Standard Chemotherapy and as a Single Agent Post-consolidation Therapy in Children With Untreated FLT3-mutate [NCT03591510]	Phase 2	23 participants (Anticipated)	Interventional	2019-03-13	Recruiting
An Investigator Sponsored Phase I Trial of Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML [NCT03661515]	Phase 1	16 participants (Actual)	Interventional	2018-07-17	Completed
Prospective Evaluation of Sorafenib Combined With Standard Therapy in Newly Diagnosed Adult Core-binding Factor Acute Myeloid Leukemia: an Open-label , Randomised Controlled, Multicenter Phase II Trial [NCT05404516]	Phase 2	88 participants (Anticipated)	Interventional	2020-01-01	Recruiting
"Comparing the Efficacy and Safety of Venetoclax Combined With Decitabine Versus Conventional 7+3 Induction Chemotherapy of Acute Myeloid Leukemia in Young Adults" [NCT05177731]	Phase 3	188 participants (Anticipated)	Interventional	2022-03-01	Recruiting
A Phase I Study of MEK Inhibitor MEK162 Combined With Idarubicin and Cytarabine Induction in Patients With Relapsed/Refractory RAS-Mutated Acute Myeloid Leukemia [NCT02049801]	Phase 1	1 participants (Actual)	Interventional	2014-12-31	Terminated(stopped due to logistics)
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) [NCT02013648]	Phase 3	203 participants (Anticipated)	Interventional	2014-07-31	Active, not recruiting
Prospective Evaluation of Standard Chemotherapy Regimen of Idarubicin and Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) [NCT00422591]	Phase 2	175 participants (Actual)	Interventional	2006-12-31	Completed
Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE II [NCT02185768]	Phase 2	46 participants (Actual)	Interventional	2015-01-31	Completed
A Phase II Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia [NCT01035502]	Phase 2	51 participants (Actual)	Interventional	2009-12-31	Completed
A Randomised Phase-III Trial of the Cooperative Weichteilsarkom Study Group (CWS) for Localised High-risk Rhabdomyosarcoma and Localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in Children, Adolescents, and Young Adults [NCT00876031]	Phase 3	195 participants (Actual)	Interventional	2009-07-01	Completed
PROTOCOL FOR THE TREATMENT Acute Lymphoblastic Leukemia With Ph 'NEGATIVE IN ELDERLY PATIENTS (> 55 Years) [NCT01366898]	Phase 4	100 participants (Anticipated)	Interventional	2007-06-30	Recruiting
Transarterial Chemoembolization With Lipiodol-Idarubicin Emulsion in the Treatment of Hepatocellular Carcinoma: a Prospective, Multicenter, Real-world Study [NCT05280444]	Phase 2/Phase 3	216 participants (Anticipated)	Interventional	2022-05-28	Recruiting
A Phase I/II Multi-center Study of HDM201 Added to Chemotherapy in Adult Subjects With Relapsed/Refractory (R/R) or Newly Diagnosed Acute Myeloid Leukemia (AML) [NCT03760445]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2019-11-15	Withdrawn(stopped due to It was determined that the study design may not be optimal given the changing AML treatment landscape.)
Randomized Phase II Trial Seeking the Most Promising Drug Association With Azacitidine- in Higher Risk Myelodysplastic Syndromes [NCT01342692]	Phase 2	320 participants (Anticipated)	Interventional	2011-06-30	Active, not recruiting
Phase II Study of Idarubicin, Cytarabine, and Vorinostat in Patients With High-Risk MDS and AML [NCT00656617]	Phase 2	106 participants (Actual)	Interventional	2008-04-30	Completed
A Phase IV, Randomized Study to Evaluate the Safety and Efficacy of Idarubicin at Different Dosages Combined With Cytarabine as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia [NCT02277847]	Phase 4	400 participants (Anticipated)	Interventional	2010-03-31	Enrolling by invitation
A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old [NCT03257241]	Phase 3	582 participants (Anticipated)	Interventional	2017-07-03	Recruiting
A Randomised Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA Versus Standard ATRA and Anthracycline-Based Chemotherapy (AIDA Regimen) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia [NCT00482833]	Phase 3	276 participants (Actual)	Interventional	2007-08-31	Completed
Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloid Blast Phase of CML [NCT02115295]	Phase 2	458 participants (Anticipated)	Interventional	2014-05-19	Recruiting
A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Patients Wit [NCT04778397]	Phase 3	346 participants (Anticipated)	Interventional	2021-07-01	Active, not recruiting
A Collaboration Phase 2 Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia [NCT05955261]	Phase 2	70 participants (Anticipated)	Interventional	2023-07-25	Recruiting
A Randomized, Phase II Study of CX-01 Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia [NCT02873338]	Phase 2	75 participants (Actual)	Interventional	2016-08-31	Completed
Aezea (Cenersen) in Combination With Chemotherapy for Treatment of Acute Myelogenous Leukemia Subjects ≥55 Years of Age With No Response to Single Frontline Induction Course in a Randomized Double-Blind Placebo-Controlled Multi-Center Study [NCT00967512]	Phase 2	0 participants (Actual)	Interventional	2012-01-31	Withdrawn(stopped due to Study Was Terminated due to lack of Funding.)
A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma [NCT02703272]	Phase 3	72 participants (Actual)	Interventional	2016-07-01	Terminated(stopped due to IDMC recommended that enrolment be stoped, as the EFS hazard ratio and associated p-value crossed the futility boundary specified in protocol (July 2020).)
A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over [NCT00005823]	Phase 3	2,000 participants (Anticipated)	Interventional	1998-12-31	Completed
A Phase I Dose Escalation Study of Ibrutinib With Idarubicin/Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia [NCT02635074]	Phase 1	2 participants (Actual)	Interventional	2016-11-30	Terminated(stopped due to safety)
ALLR3: An International Collaborative Trial for Relapsed and Refractory Acute Lymphoblastic Leukaemia (ALL) [NCT00967057]	Phase 3	470 participants (Anticipated)	Interventional	2002-10-31	Completed
A Phase Ib Feasibility Study of Personalized Kinase Inhibitor Therapy Combined With Induction in Acute Leukemias Who Exhibit In Vitro Kinase Inhibitor Sensitivity [NCT02779283]	Phase 1	7 participants (Actual)	Interventional	2016-01-13	Completed
A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia [NCT01822015]	Early Phase 1	55 participants (Actual)	Interventional	2013-03-15	Completed
An Open-Label Phase 2 Trial of LY2181308 Sodium Administered in Combination With Idarubicin and Cytarabine to Patients With Refractory or Relapsed Acute Myeloid Leukemia [NCT00620321]	Phase 2	24 participants (Actual)	Interventional	2008-03-31	Completed
A Multi-center Prospective Single Arm Clinical Study of Reduced Intensive 3 + 5 Idarubicin and Cytarabine Chemotherapy Plus Venetoclax as First-line Treatment for Adults With Acute Myeloid Leukaemia and High-risk Myelodysplastic Syndrome [NCT06050941]	Phase 2	60 participants (Anticipated)	Interventional	2023-10-20	Not yet recruiting
A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation [NCT02421939]	Phase 3	371 participants (Actual)	Interventional	2015-10-20	Active, not recruiting
Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas Combining DC Bead Microspheres Loaded With Idarubicin (Zavedos®): Phase I Trial [NCT01040559]	Phase 1	18 participants (Anticipated)	Interventional	2009-12-31	Completed
Clofarabine in Combination With a Standard Remission Induction Regimen (AraC and Idarubicin) in Patients 18-60 Years Old With Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS) : a Phase I-II [NCT00838240]	Phase 1/Phase 2	114 participants (Anticipated)	Interventional	2008-11-30	Recruiting
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® ) During Consolidation [NCT00866918]	Phase 3	106 participants (Actual)	Interventional	2009-03-09	Completed
Randomized Comparison of Consolidation Treatment in Elderly Patients With Acute Myeloid Leukemia: Idarubicin (IDA) Combined With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone [NCT04216771]	Phase 2/Phase 3	320 participants (Anticipated)	Interventional	2020-01-31	Recruiting
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia: A Phase I Study (AflacLL1401) [NCT02680951]	Phase 1	0 participants (Actual)	Interventional	2015-12-31	Withdrawn(stopped due to Withdrawn due to lack of participants.)
A Phase 1b, Open-label Study of LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia [NCT02652871]	Phase 1	36 participants (Anticipated)	Interventional	2016-05-09	Completed
Dose-intense Idarubicin Induction in Young Patients With Acute Myeloid Leukemia [NCT04069208]	Phase 2	42 participants (Anticipated)	Interventional	2019-09-03	Recruiting
A Phase II Study of the Impact of Clinicogenetic Risk-Stratified Management on Outcomes of Acute Myeloid Leukemia in Older Patients [NCT03226418]	Phase 2	75 participants (Actual)	Interventional	2017-07-07	Active, not recruiting
Phase II Clinical Evaluation of Vorinostat Combined With Salvage Reinduction Chemotherapy Including Gemtuzumab Ozogamicin, Idarubicin and Cytarabine and Vorinostat Maintenance in Relapse or Refractory Acute Myeloid Leukemia Patients With 50 Years or Older [NCT01039363]	Phase 2	27 participants (Anticipated)	Interventional		Not yet recruiting
Clofarabine, Idarubicin, and Cytarabine Combination as Induction Therapy for Younger Patients With Acute Myeloid Leukemia (AML) [NCT01025154]	Phase 2	63 participants (Actual)	Interventional	2010-01-31	Completed
Idarubicin+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for Intermediate-risk Acute Myeloid Leukemia Undergoing Autologous Hematopoietic Stem Cell Transplantation [NCT02671708]	Phase 2/Phase 3	153 participants (Actual)	Interventional	2016-01-31	Completed
"A Phase I Trial of Volasertib (BI 6727), an Intravenous Polo-Like Kinase Inhibitor, in Combination With 7+3 Induction Chemotherapy for Patients With Acute Myeloid Leukemia" [NCT02905994]	Phase 1	0 participants (Actual)	Interventional	2016-09-30	Withdrawn(stopped due to Funding Withdrawn)
A Phase II Pilot Study of Bortezomib (PS-341, Velcade) Combined With Reinduction Chemotherapy in Children and Young Adults With Recurrent, Refractory or Secondary Acute Myeloid Leukemia [NCT00666588]	Phase 2	52 participants (Actual)	Interventional	2008-04-30	Completed
A Phase 1 Trial of Indoximod in Combination With Idarubicin and Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) [NCT02835729]	Phase 1	54 participants (Actual)	Interventional	2016-07-31	Completed
An Open-label,Multi-center,Prospective Study of Idarubicin and Etoposide Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia [NCT01873807]	Phase 4	100 participants (Anticipated)	Interventional	2013-05-31	Recruiting
Idarubicin, Cytarabine and Pravastatin (IAP) for Induction of Newly Diagnosed Acute Myeloid Leukemia (AML) [NCT01831232]		24 participants (Actual)	Interventional	2013-05-31	Completed
Autologous Peripheral Blood Stem Cell Mobilization and Transplantation for Myelofibrosis [NCT00006367]	Phase 2	0 participants	Interventional	2000-05-31	Completed
Phase II Study Of Combined Modality Postremission Therapy As Determined By Molecular Response (Adaptive Regulation) In The Treatment Of Acute Promyelocytic Leukemia (APL) [NCT00016159]	Phase 2	35 participants (Anticipated)	Interventional	2000-11-30	Completed
Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result [NCT00146120]	Phase 3	400 participants	Interventional	1998-05-31	Completed
A Phase 3, Randomized, Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Decitabine Combined With HAAG Regimen in Newly Diagnosed Acute Myeloid Leukemia Patients Younger Than 60 Years [NCT04087967]	Phase 3	162 participants (Anticipated)	Interventional	2019-04-01	Recruiting
Phase 1B/II Study of Escalating Doses of Pevonedistat (TAK-924, Formerly MLN4924) Administered in Combination With Standard Induction Chemotherapy (Cytarabine and Idarubicin) in Newly Diagnosed High Risk Acute Myelogenous Leukemia (AML) [NCT03330821]	Phase 1/Phase 2	53 participants (Anticipated)	Interventional	2018-04-18	Active, not recruiting
A Pilot Study of Lestaurtinib (CEP-701) in Combination With Chemotherapy in Young Patients With Relapsed or Refractory FLT3-mutant Acute Myeloid Leukemia [NCT00469859]	Phase 1/Phase 2	14 participants (Actual)	Interventional	2007-06-30	Completed
A Phase 2 Study of Idarubicin Based Combined Modality Therapy in Primary Central Nervous System Lymphoma [NCT00193973]	Phase 2	20 participants (Actual)	Interventional	2001-07-31	Completed
Idarubicin Overcomes Multidrug Resistant-1(MDR1) Induced Chemoresistance With Higher Induction Remission Rate and Remission Quality Than Daunorubicin in de Novo Acute Myeloid Leukemia Patients [NCT01889407]		94 participants (Anticipated)	Observational [Patient Registry]	2013-08-31	Recruiting
[NCT01958996]	Phase 1/Phase 2	27 participants (Anticipated)	Interventional	2009-01-31	Completed
Pilot Study of Crenolanib Combined With Standard Salvage Chmetherapy in Subjects With Relapsed/Refractory Acute Myeloid Leukemia [NCT02626338]	Phase 1/Phase 2	16 participants (Actual)	Interventional	2016-02-29	Completed
Combined Retinoic Acid,Arsenic Trioxide and Chemotherapy for Newly-diagnosed Acute Promyelocytic Leukemia: Chinese National Multi-center Randomized Study [NCT01987297]	Phase 4	738 participants (Anticipated)	Interventional	2012-06-30	Active, not recruiting
Philadelphia -Negative High-risk Children Acute Lymphoblastic Leukemia(ALL) Treatment:Induction Therapy:Vincristine(V),Idarubicin(I),L-asparaginase(L),Dexamethasone(D);Consolidation:V+Daunorubicin(D)+L+D, Methotrexate,Cytarabine [NCT01990807]	Phase 4	20 participants (Anticipated)	Interventional	2012-10-31	Recruiting
[NCT02020161]	Phase 4	200 participants (Anticipated)	Interventional	2012-06-30	Recruiting
LIDA-B: Treatment of Cirrhosis-related Hepatocellular Carcinoma With the Intrahepatic Arterial Injection of an Emulsion of Lipiodol and Idarubicin (Zavedos®): Phase I Study [NCT02028949]	Phase 1	15 participants (Actual)	Interventional	2012-11-22	Completed
A Phase I Study of Pomalidomide Given at the Time of Lymphocyte Recovery Following Induction Timed Sequential Chemotherapy With Cytarabine, Daunorubicin and Etoposide (AcDVP16) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk MD [NCT02029950]	Phase 1	50 participants (Actual)	Interventional	2013-12-16	Completed
An ALFA 2101 Multicenter Randomized Phase II Study: CPX-351 Versus Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics [NCT05260528]	Phase 2	210 participants (Anticipated)	Interventional	2023-05-03	Recruiting
A Randomized Trial Comparing Z-Dex With VAD as Induction Therapy for Patients With Multiple Myeloma [NCT00006232]	Phase 3	200 participants (Anticipated)	Interventional	1996-10-31	Completed
A Phase II, Single Arm Study of Tislelizumab Combined With DNA Demethylation Agent +/- CAG Regimen in the Treatment of Patients With High-risk AML or AML Patients Older Than 60 Years of Age Who Are Unfit for Intensive Chemotherapy [NCT04541277]	Phase 2	55 participants (Anticipated)	Interventional	2020-09-01	Recruiting
A Phase II Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia [NCT03164057]	Phase 2	206 participants (Actual)	Interventional	2017-06-15	Active, not recruiting
Four-Arm Randomized Phase II Study of SGI-110: 5 Days, Versus 10 Days, Versus 5 Days + Idarubicin, Versus 5 Days + Cladribine, in Previously Untreated Patients >/= 70 Years With Acute Myeloid Leukemia [NCT02096055]	Phase 2	44 participants (Actual)	Interventional	2014-04-04	Completed
A Phase I/II Clinical Trial of PXD101 in Combination With Idarubicin in Patients With AML Not Suitable for Standard Intensive Therapy [NCT00878722]	Phase 1/Phase 2	41 participants (Actual)	Interventional	2007-08-31	Completed
Optimal Treatment Strategy Based on Prognostic Groups for Pediatric de Novo Acute Myeloid Leukemia [NCT02848183]	Phase 2	350 participants	Interventional	2016-01-31	Recruiting
Gemtuzumab Ozogamicin (CMA-676) Followed or Not by Intensive Chemotherapy as Initial Treatment for Elderly Patients With Acute Myeloid Leukemia: An EORTC-LG Pilot Phase II Study [NCT00006122]	Phase 2	106 participants (Actual)	Interventional	2000-06-30	Completed
Randomized Phase II Trial of Idarubicin + Ara-C +/- Bevacizumab in Patients Age < 60 With Untreated Acute Myeloid Leukemia [NCT00096148]	Phase 2	120 participants (Actual)	Interventional	2004-10-31	Terminated(stopped due to Administratively complete.)
AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia(APL) [NCT00180128]	Phase 4	80 participants (Anticipated)	Interventional	2000-01-31	Recruiting
Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia [NCT00187005]	Phase 3	53 participants (Actual)	Interventional	1998-07-31	Terminated(stopped due to Toxicity)
A Study of Children With Refractory or Relapsed Acute Lymphoblastic Leukemia (ALLR16) [NCT00187083]	Phase 3	40 participants (Actual)	Interventional	1997-02-28	Completed
Salvage Therapy With Idarubicin in Immunocompetent Patients With Relapsed or Refractory Primary Central Nervous System Lymphomas [NCT00210366]	Phase 2	25 participants (Anticipated)	Interventional	2004-11-30	Terminated(stopped due to due to slow accrual)
Randomized Phase II/III-Study on All-Trans Retinoic Acid in Combination With Induction and Consolidation Therapy as Well as Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia [NCT00151242]	Phase 2/Phase 3	920 participants (Actual)	Interventional	2004-07-31	Completed
[NCT02937662]	Phase 2	60 participants (Anticipated)	Interventional	2016-10-31	Recruiting
Phase I/II Clinical Study of Idarubicin Dose Intensification for Remission Induction Therapy in Acute Myeloid Leukemia Patients Age of 65 Years or Less [NCT01518556]	Phase 1/Phase 2	49 participants (Actual)	Interventional	2011-07-31	Active, not recruiting
A Randomized Controlled, Multi-center Clinical Study of Anbijian (Idarubicin Hydrochloride for Injection) vs. Epirubicin Lipiodol Emulsion Transhepatic Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma [NCT05053386]		186 participants (Anticipated)	Interventional	2021-10-31	Not yet recruiting
A Study to Determine the Safety and Efficacy of Using CD8-High Density Microparticles (CD8-HDM) to Deplete CD8+ Cells From Donor Lymphocyte Infusion in Order to Reduce Graft-versus-Host Disease (GvHD) Without Compromising an Anti-Leukemia Effect in Patien [NCT00004878]	Phase 2	0 participants (Actual)	Interventional		Withdrawn(stopped due to study never opened)
PETHEMA-LAM99:Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years [NCT00464217]	Phase 4	100 participants	Interventional	1998-10-31	Completed
Multicenter, Phase 2 Clinical Trial Evaluating the Efficacy and Tolerability of Induction and Consolidation Chemotherapy Comprising Fludarabine, Cytarabine, and Attenuated-dose Idarubicin in Elderly Patients With AML(Acute Myeloid Leukemia) [NCT01247493]	Phase 2	108 participants (Actual)	Interventional	2007-06-30	Completed
FLAG-IDA Chemotherapy Induction Follow by Intensive Chemotherapy Postremission +/- Autologous Hemopoietic Stem Cell Transplantation or Bone Marrow Transplantation in Patients With High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemi [NCT00487448]	Phase 4	200 participants (Anticipated)	Interventional	1998-07-31	Completed
A Phase 1/2 Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia [NCT02310321]	Phase 1/Phase 2	84 participants (Actual)	Interventional	2015-02-26	Active, not recruiting
Phase I Dose Escalating Trial of VELCADE (PS-341) in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous Leukemia [NCT00505700]	Phase 1	36 participants (Anticipated)	Interventional	2003-07-31	Completed
A Phase 1 Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia [NCT02236013]	Phase 1	80 participants (Actual)	Interventional	2015-01-07	Completed
A Phase I/II, Open-label Multicenter Trial to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia [NCT02306291]	Phase 1/Phase 2	91 participants (Actual)	Interventional	2015-03-31	Completed
A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Induction Chemotherapy for Newly Diagnosed Fit Adults With Acute Myeloid Leukemia [NCT04801797]	Phase 2	172 participants (Anticipated)	Interventional	2021-05-20	Recruiting
TREATMENT OF ADULT PATIENTS WITH RELAPSING ACUTE LYMPHOCYTIC LEUKEMIA, A MULTICENTER TRIAL [NCT00002532]	Phase 2	0 participants	Interventional	1993-01-31	Active, not recruiting
ACUTE MYELOID LEUKAEMIA TRIAL 12 [NCT00002658]	Phase 3	2,000 participants (Anticipated)	Interventional	1994-01-31	Active, not recruiting
A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction Therapy and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation [NCT02632708]	Phase 1	153 participants (Actual)	Interventional	2015-12-31	Active, not recruiting
HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia [NCT01484171]	Phase 3	50 participants (Anticipated)	Interventional	2011-08-31	Recruiting
A Phase I Trial Evaluating the Effect of the Addition of HMGCoA-Reductase Inhibition With Pravastatin to Salvage Chemotherapy Idarubicin-HDAC in Patients With Relapsed or Refractory Acute Myelogenous Leukemia [NCT00107523]	Phase 1	0 participants	Interventional	2005-01-31	Completed
Multicenter Therapy-Optimization Trial AML-BFM 2004 for the Treatment of Acute Myeloid Leukemias in Children and Adolescents [NCT00111345]	Phase 2/Phase 3	550 participants (Actual)	Interventional	2004-03-31	Active, not recruiting
Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia [NCT06001788]	Phase 1	171 participants (Anticipated)	Interventional	2023-12-31	Recruiting
Arsenic Trioxide, High-Dose Cytarabine and Idarubicin Induction Therapy in Previously Untreated de Novo and Secondary Adult Acute Myeloid Leukemia Patients < 60 Years Old - A Phase I Study [NCT00093483]	Phase 1	61 participants (Actual)	Interventional	2002-04-30	Completed
A Phase 1 Study of Suberoylanilide Hydroxamic Acid (Vorinostat, SAHA) in Combination With Idarubicin in Relapsed or Refractory Leukemia [NCT00331513]	Phase 1	40 participants (Actual)	Interventional	2006-03-31	Completed
IDA VS MTZ IN INDUCTION AND INTENSIFICATION TREATMENT OF AML OR MDS IN CHILDREN, A PHASE III RANDOMIZED STUDY [NCT00002517]	Phase 3	0 participants	Interventional	1993-03-31	Completed
A Phase I Study Investigating the Combination of RAD001 With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) [NCT01154439]	Phase 1	11 participants (Actual)	Interventional	2010-10-31	Completed
A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia [NCT00801489]	Phase 2	270 participants (Anticipated)	Interventional	2007-04-04	Recruiting
Treatment of Acute Promyelocytic Leukemia (APL) With All-Trans Retinoic Acid, and Arsenic +/- Idarubicin [NCT00413166]	Phase 2	78 participants (Actual)	Interventional	2006-12-31	Completed
Phase II Study of Combined All-Trans Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy [NCT00528450]	Phase 2	1 participants (Actual)	Interventional	2007-09-30	Terminated(stopped due to Lack of accrual)
A Phase 2 Study of Clofarabine, Idarubicin, Cytarabine, Vincristine, and Corticosteroids for Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia [NCT02135874]	Phase 2	18 participants (Actual)	Interventional	2014-10-27	Completed
A Phase 1b Study With Expansion Cohort of Escalating Doses of KRT-232 (AMG 232) Administered in Combination With Standard Induction Chemotherapy (Cytarabine and Idarubicin) in Newly Diagnosed Acute Myelogenous Leukemia (AML) [NCT04190550]	Phase 1	24 participants (Anticipated)	Interventional	2021-02-04	Active, not recruiting
Transarterial Chemoembolization Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients With Hepatocellular Carcinoma (IDADOX) [NCT06114082]	Phase 2	128 participants (Anticipated)	Interventional	2023-04-28	Recruiting
German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003) [NCT00198991]	Phase 4	1,883 participants (Actual)	Interventional	2003-04-30	Completed
Phase I/II Study on Cytarabine and Idarubicin Combined With Escalating Doses of Clofarabine as Induction Therapy in Patients With Acute Myeloid Leukemia and High Risk for Induction Failure (AMLSG 17-10) [NCT01534702]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	2012-01-31	Recruiting
[NCT01540812]		418 participants (Actual)	Observational	2012-02-29	Completed
A Phase II Study of Bevacizumab (rhuMab VEGF, NSC 704865), Idarubicin and Cytarabine in Patients With Chronic Myeloid Leukemia in Blast Phase [NCT00023920]	Phase 2	60 participants (Actual)	Interventional	2001-07-31	Terminated(stopped due to Administratively complete.)
Randomized Multicenter Treatment Optimization Study In Chronic Myeloid Leukemia (CML) Interferon-a Vs. Allogeneic Stem Cell Transplantation Vs. High-Dose Chemotherapy Followed By Autografting And Interferon-a Maintainance In Early Chronic Phase [NCT00025402]	Phase 3	1,000 participants (Anticipated)	Interventional	1997-07-31	Active, not recruiting
Open Label, Phase II Dosing Study of Ara-C Chemotherapy in Combination With EL625 and Idarubicin in Refractory and Relapsed Acute Myelogenous Leukemia (AML) [NCT00074737]	Phase 2	53 participants (Actual)	Interventional	2004-04-30	Completed
Idarubicin and Ara-C in Combination With Gemtuzumab-Ozogamicin (IAGO) for Young Untreated Patients, Without an HLA Identical Sibling, With High Risk MDS or AML Developing After a Preceding Period With MDS During 6 Months Duration: A Phase II Study [NCT00077116]	Phase 2	31 participants (Actual)	Interventional	2003-11-30	Completed
Cardioprotection With Dexrazoxane in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS), Myeloid Blast Phase of Chronic Myeloid Leukemia (CML), Ph+ AML, and Myeloid Blast Phase of Myeloproliferative Neoplasms [NCT03589729]	Phase 2	100 participants (Anticipated)	Interventional	2018-09-19	Recruiting
Gemtuzumab Ozogamicin (GO) Combined With Standard Intensive Chemotherapy Versus Standard Intensive Chemotherapy Alone For Induction/Consolidation In Patients 61-75 Years Old With Previously Untreated AML: A Randomized Phase III Trial (AML-17) Of The EORTC [NCT00052299]	Phase 3	472 participants (Actual)	Interventional	2002-09-30	Completed
Protocol for the Treatment of Adults Aged NCT00209833]	Phase 2/Phase 3	200 participants	Interventional	1999-01-31	Active, not recruiting
Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) as Induction Therapy and a Randomized Trial of Thalidomide vs Thalidomide Plus Oral Idarubicin as Maintenance Therapy in Patients With Multiple Myeloma [NCT00124813]	Phase 2	80 participants (Anticipated)	Interventional	2002-08-31	Recruiting
Phase III - Study on All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia [NCT00151255]	Phase 3	500 participants (Anticipated)	Interventional	2004-06-30	Completed
Treatment of Elderly Patients (>60 Years) With Acute Myeloblastic Leukemia or Advanced MDS (RAEB-T): An Open Randomized Study to Test the Efficacy of G-CSF-Priming and a Feasibility Trial of Dose-Reduced Allogeneic Transplantation and of Autologous Stem C [NCT00199147]	Phase 4	250 participants	Interventional	2000-01-31	Recruiting
A Randomized, Multicenter Open Label Phase II Study to Determine the Safety and Efficacy of Induction Therapy With Imatinib in Comparison With Standard Induction Chemotherapy in Elderly (> 55 Years) Patients With Ph Positive Acute Lymphoblastic Leukemia ( [NCT00199186]	Phase 2	0 participants	Interventional	2002-03-31	Recruiting
Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006), an Oral Vascular Endothelial Growth Factor (VEGF), Rapidly Accelerated Fibrosarcoma (RAF) and FMS-like Tyrosine Kinase 3 (FLT3), in Patients With High-risk MDS and AML [NCT00542971]	Phase 1/Phase 2	78 participants (Actual)	Interventional	2007-10-31	Completed
The Efficiency of CAMS-2016 Trial for the Newly Diagnosed Pediatric Acute Myeloid Leukemia: A Prospective Single Centre Trial From China [NCT03173612]		132 participants (Anticipated)	Interventional	2016-08-31	Recruiting
A Combination of Cladribine, Idarubicin, Cytarabine (CLIA) and Quizartinib for the Treatment of Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)) [NCT04047641]	Phase 1/Phase 2	80 participants (Anticipated)	Interventional	2019-10-22	Recruiting
A Randomized Phase II Study of Nuclear Factor-kappa B (NF-κB) Inhibition During Induction Chemotherapy for Patients With Acute Myelogenous Leukemia [NCT02144675]	Phase 2	27 participants (Actual)	Interventional	2009-01-31	Completed
Phase I/II Study of Decitabine (DAC) Followed by Clofarabine, Idarubicin, and Cytarabine (CIA) in Acute Leukemia [NCT01794702]	Phase 1/Phase 2	65 participants (Actual)	Interventional	2013-02-20	Completed
A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Continuation Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Mye [NCT02668653]	Phase 3	539 participants (Actual)	Interventional	2016-09-01	Completed
Phase II Trial Examining Epigenetic Priming With Decitabine Followed by Idarubicin and Cytarabine for Patients With Relapsed or Refractory AML. [NCT01607645]	Phase 2	7 participants (Actual)	Interventional	2012-07-31	Terminated(stopped due to The study was terminated early because there were other competing protocols.)
Treatment of di Novo Acute Myeloid Leukemia With the Combination of Increasing Doses of Idarubicin, Cytarabine and Sensitization (Priming) With G-CSF. A Phase II Prospective Study of Toxicity and Efficacy. [NCT01700413]	Phase 2	48 participants (Actual)	Interventional	2012-10-31	Completed
A Multi-Center, Open-Label, Phase 1/1b Study of Escalating Doses of RO5503781 Administered Orally as 1) a Single Agent, 2) In Combination With Cytarabine, or 3) With Cytarabine and Anthracycline and 4) Assessing PK and Safety of New Optimized Formulation [NCT01773408]	Phase 1	122 participants (Actual)	Interventional	2013-02-28	Completed
A Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With 7+3 Induction Chemotherapy in Patients With Acute Myeloid Leukemia [NCT01779843]	Phase 1	22 participants (Actual)	Interventional	2013-04-30	Completed
"RANDOMIZED COMPARISON OF ALTERNATING TRIPLE THERAPY (ATT) VERUS CHOP IN PATIENTS WITH INTERMEDIATE GRADE LYMPHOMAS AND IMMUNOBLASTIC LYMPHOMAS WITH INTERNATIONAL INDEX 2-5" [NCT00002565]	Phase 3	61 participants (Actual)	Interventional	1994-05-25	Completed
Risk-adapted Therapy for Primary Acute Myeloid Leukemia (AML) in Adult Patients up to 70 Years Old [NCT04687098]	Phase 2	1,034 participants (Actual)	Interventional	2012-02-01	Completed
Multicenter, Prospective, Open-label, Single-arm, Phase I-II Clinical Trial to Analyze Induction Therapy With a Combination of Fludarabine, Idarubicin, Cytarabine, G-CSF and Plerixafor for the Treatment of Young Patients With Relapsed or Refractory AML [NCT01435343]	Phase 1/Phase 2	55 participants (Actual)	Interventional	2012-07-31	Completed
Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children： A Prospective Multicenter Study in South China [NCT05313958]	Phase 2/Phase 3	43 participants (Anticipated)	Interventional	2021-12-01	Recruiting
Clinical Study of Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated Acute Myeloid Leukemia [NCT05053425]		30 participants (Anticipated)	Interventional	2021-10-20	Recruiting
A Randomized Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA and Idarubicin Versus Standard ATRA and Anthracyclines-based Chemotherapy (AIDA Regimen) for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia [NCT02688140]	Phase 3	280 participants (Anticipated)	Interventional	2016-06-30	Active, not recruiting
A Phase I Study Using Bortezomib (Velcade, Formerly Known as PS-341) With Weekly Idarubicin for the Treatment of Elderly (>/= 60 Years) and Relapsed Patients With Acute Myelogenous Leukemia [NCT00382954]	Phase 1	55 participants (Anticipated)	Interventional	2004-02-29	Completed
Autologous Peripheral Blood Stem Cell Transplantation (PSCT) Versus a Second Intensive Consolidation Course After a Common Induction and Consolidation Course in Patients With Bad Prognosis Myelodysplastic Syndromes (MDS) and Acute Myelogenous Leukemia Sec [NCT00002926]	Phase 3	80 participants (Anticipated)	Interventional	1996-12-31	Active, not recruiting
A Prospective Randomized Phase I/II Study of Clofarabine (Clo) and Ara-C vs Clo and Ida vs Clo Plus Ida and Ara-C in Patients With First Relapse or First Salvage of Primary Refractory AML; and High-Grade MDS(>/= 10% Blasts); or CML in Myeloid Blasts Phase [NCT00067028]	Phase 2	116 participants (Actual)	Interventional	2003-12-31	Completed
PHASE II STUDY OF HIGH DOSE CYTARABINE COMBINED WITH A SINGLE HIGH DOSE OF IDARUBICIN FOR NEWLY DIAGNOSED PATIENTS WITH AML: THE AML-3 PROTOCOL [NCT00002800]	Phase 2	60 participants (Anticipated)	Interventional	1996-07-31	Completed
Treatment of Patients With Acute Lymphoblastic Leukemia With Unfavorable Features: A Phase III Group-wide Study [NCT00002812]	Phase 3	2,078 participants (Actual)	Interventional	1996-09-30	Completed
Idarubicin and Cladribine in Recurrent and Refractory Acute Myeloid Leukemia: A POG Phase II Study [NCT00003178]	Phase 2	120 participants (Actual)	Interventional	1998-03-31	Completed
A Phase I Study of Cytosine Arabinoside, Idarubicin, and Amifostine as Induction Therapy for Patients With Newly Diagnosed Acute Myeloid Leukemia [NCT00003268]	Phase 1	0 participants	Interventional	1998-01-31	Completed
PHASE I-II STUDY OF IDARUBICIN, CYTARABINE AND R115777 (TIPIFARNIB, ZARNESTRA; 702818; IND 58359), A FARNESYLTRANSFERASE INHIBITOR, IN PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIAS [NCT00096122]	Phase 1/Phase 2	95 participants (Actual)	Interventional	2004-09-30	Completed
Pilot Study for Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia [NCT00199095]	Phase 4	40 participants	Interventional	1997-02-28	Completed
Multicenter Trial for Treatment of Acute Lymphocytic Leukemia in Adults (Pilot Study 06/99) [NCT00199056]	Phase 4	225 participants	Interventional	1999-10-31	Completed
Multicenter Study To Optimize Treatment in Elderly Patients (> 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2) [NCT00198978]	Phase 4	377 participants (Actual)	Interventional	2003-01-31	Completed
Safety and Clinical Activity of Treanda® (Bendamustine HCL) and Idarubicin in Combination Therapy for Patients Age >= 50 With Previously Untreated Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome [NCT01141725]	Phase 1/Phase 2	39 participants (Actual)	Interventional	2010-09-30	Completed
Phase I/II Randomized Study of Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome [NCT01289457]	Phase 1/Phase 2	282 participants (Actual)	Interventional	2011-02-02	Completed
A Phase 2 Study of E7070, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-risk Myelodysplastic Syndromes [NCT01692197]	Phase 2	43 participants (Actual)	Interventional	2013-02-01	Completed
A Phase II Study of the Aurora A Kinase Inhibitor Alisertib in Combination With 7+3 Induction Chemotherapy in Patients With High-risk Acute Myeloid Leukemia [NCT02560025]	Phase 2	42 participants (Actual)	Interventional	2015-12-31	Completed
Phase II Study of Fludarabine + Idarubicin + Aracytine in Refractory or Relapsed ALL in Children [NCT00003729]	Phase 2	13 participants (Actual)	Interventional	1998-12-31	Terminated(stopped due to low accrual)
Treatment Protocol for Relapsed Anaplastic Large Cell Lymphoma of Childhood and Adolescence [NCT00317408]		96 participants (Anticipated)	Interventional	2004-04-30	Active, not recruiting
A PHASE III STUDY IN CHILDREN WITH UNTREATED ACUTE MYELOGENOUS LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) [NCT00002798]	Phase 3	880 participants (Actual)	Interventional	1996-08-31	Completed
EXTRAMEDULLARY RELAPSE AND OCCULT BONE MARROW INVOLVEMENT IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE III GROUP-WIDE STUDY [NCT00002816]	Phase 3	120 participants (Anticipated)	Interventional	1996-12-31	Completed
INDUCTION WITH ALL-TRANS RETINOIC ACID IN COMBINATION WITH IDARUBICIN AND INTENSIVE CONSOLIDATION FOLLOWED BY BONE MARROW TRANSPLANTATION OR A RANDOMIZED MAINTENANCE TREATMENT DEPENDING UPON THE AMOUNT OF MINIMAL RESIDUAL DISEASE IN ACUTE PROMYELOCYTIC LE [NCT00002701]	Phase 3	750 participants (Anticipated)	Interventional	1995-10-31	Active, not recruiting
RANDOMIZED PHASE III STUDY TO EVALUATE THE VALUE OF rHuG-CSF IN INDUCTION AND OF AN ORAL SCHEDULE AS CONSOLIDATION TREATMENT IN ELDERLY PATIENTS WITH ACUTE MYELOGENOUS LEUMEKIA (AML-13 PROTOCOL) [NCT00002719]	Phase 3	500 participants (Anticipated)	Interventional	1995-12-31	Completed
A Randomised Study Comparing an Oral Regimen (Idarubicin and Etoposide) With an Intravenous Regimen (MAE) for Consolidation in Patients Over 55 Years With Acute Myeloid Leukaemia in First Complete Remission [NCT00003602]	Phase 3	400 participants (Anticipated)	Interventional	1998-03-31	Active, not recruiting
CAMP-010: PHASE I/II STUDY OF IN VIVO PURGING FOLLOWED BY HIGH DOSE CHEMOTHERAPY, AUTOLOGOUS HEMATOPOIETIC STEM CELL INFUSION AND IMMUNOTHERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA [NCT00002761]	Phase 1/Phase 2	0 participants (Actual)	Interventional	1996-02-29	Withdrawn(stopped due to PI left institution)
Treatment of Relapsed Acute Myelogenous Leukemia Consisting of Intermediate Dose Cytosine Arabinoside (ARA-C) Plus Interspaced Continuous Infusion Idarubicin, Followed by Continuous Infusion of Low-Dose ARA-C, A Phase II Study by the EORTC-LCG [NCT00003758]	Phase 2	60 participants (Anticipated)	Interventional	1998-12-31	Active, not recruiting
A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse [NCT00002989]	Phase 3	207 participants (Anticipated)	Interventional	1997-03-31	Active, not recruiting
Use of G-CSF Stimulated HLA-Identical Allogeneic Peripheral Blood Stem Cells for Patients With High Risk Acute Myelogenous Leukemia or CML in Blast Crisis [NCT00002833]	Phase 2	53 participants (Actual)	Interventional	1994-10-31	Completed
RANDOMIZED PHASE III STUDY OF INDUCTION (ICE VS MICE VS DCE) AND INTENSIVE CONSOLIDATION (IDIA VS NOVIA VS DIA) FOLLOWED BY BONE MARROW TRANSPLANTATION IN ACUTE MYELOGENOUS LEUKEMIA: AML 10 PROTOCOL [NCT00002549]	Phase 3	1,520 participants (Anticipated)	Interventional	1993-11-30	Active, not recruiting
PHASE II TRIAL OF POST-REMISSION THERAPY WITH HuM195 AND CYTOTOXIC CHEMOTHERAPY FOR ACUTE PROMYELOCYTIC LEUKEMIA [NCT00002609]	Phase 2	40 participants (Actual)	Interventional	1994-08-31	Completed
PROSPECTIVE CONTROLLED STUDY FOR THE OPTIMIZATION OF THERAPY IN CHRONIC MYELOID LEUKEMIA (CML): MULTICENTRIC STUDY FOR THE EVALUATION OF INTERFERON ALPHA VS ALLOGENIC BM TRANSPLANTATION WITH CHEMOTHERAPY IN CML [NCT00002771]	Phase 3	750 participants (Anticipated)	Interventional	1995-01-31	Active, not recruiting
High-Dose Cytarabine and Idarubicin Induction, High Dose Etoposide and Cyclophosphamide Intensification, Autologous Stem Cell Transplantation and Interleukin-2 Immune Modulation in Previously Untreated De Novo and Secondary Adult Myeloid Leukemia [NCT00002945]	Phase 3	61 participants (Actual)	Interventional	1996-12-31	Completed
Treatment Protocol for Patients With Standard Risk Acute Myelogenous Leukemia and Its Variants: Induction Using High-Dose Cytarabine, Mitoxantrone and Ethyol; Consolidation With Cytarabine and Idarubicin and Maintenance With 13 Cis Retinoic Acid and Alpha [NCT00003405]	Phase 2	0 participants (Actual)	Interventional	1998-04-30	Withdrawn(stopped due to No enrollment)
A Randomized Prospective Study of Early Intensification Versus Alternating Triple Therapy for Patients With Poor Prognosis Lymphoma [NCT00002835]	Phase 3	116 participants (Actual)	Interventional	1995-10-30	Completed
A Randomised Study Comparing CIDEX (CCNU, Oral Idarubicin and Dexamethasone) With Melphalan and Prednisolone in Relapsed Multiple Myeloma [NCT00003603]	Phase 3	660 participants (Anticipated)	Interventional	1998-03-31	Active, not recruiting
Pilot Study of Intensive Chemotherapy Followed by Peripheral Blood Stem Cell Harvesting for Autotransplantation of Adults With Chronic Myelogenous Leukemia and High Risk Acute Leukemia [NCT00004905]	Phase 2	0 participants	Interventional	1999-10-31	Completed
Randomised Controlled Trial of CID (Chlorambucil, Idarubicin, Dexamethasone) Versus CD (Chlorambucil, Dexamethasone) for Induction of Remission in Low Grade Non-Hodgkin's Lymphoma (Kiel Classification) Followed by Randomised Controlled Assessment of Stand [NCT00003639]	Phase 3	200 participants (Anticipated)	Interventional	1993-11-30	Active, not recruiting
ALinC 17: Continuous Intensification for Very High Risk Acute Lymphocytic Leukemia (A.L.L.): A Pediatric Oncology Group Pilot Study [NCT00003783]	Phase 2	36 participants (Actual)	Interventional	1999-03-31	Completed
A Randomized Multicenter Study of More Intensive Versus Less Intensive Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia (AML) or Transformed Refractory Anemia With Excess Blasts (RAEB-t). [NCT00363025]	Phase 3	465 participants	Interventional	1999-11-30	Terminated
Phase I/II Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) [NCT02464657]	Phase 1/Phase 2	44 participants (Actual)	Interventional	2015-07-31	Completed
Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, [NCT03926624]	Phase 3	450 participants (Anticipated)	Interventional	2019-11-22	Recruiting
Autologous Bone Marrow Transplantation for Non-M3 Acute Myeloid Leukemia (AML) in First Remission in Patients NCT00534469]	Phase 2	60 participants (Actual)	Interventional	2000-02-08	Active, not recruiting
Treatment Optimization in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment - a Phase IV-trial With a Phase III-part to Evaluate Safety and Efficacy of Ne [NCT02881086]	Phase 3	1,000 participants (Actual)	Interventional	2016-08-31	Active, not recruiting
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 (B-NHL-M-2021) [NCT05518383]	Phase 4	300 participants (Anticipated)	Interventional	2022-05-25	Recruiting
Phase I-II Study of Crenolanib Combined With Standard Salvage Chemotherapy, and Crenolanib Combined With 5-Azacitidine in Acute Myeloid Leukemia Patients With FLT3 Activating Mutations [NCT02400281]	Phase 1/Phase 2	28 participants (Actual)	Interventional	2015-09-30	Completed
Allogeneic Hematopoietic Stem Cell Transplantation as Initial Salvage Therapy for Patients With Primary Induction Failure Acute Myeloid Leukemia Refractory to High-Dose Cytarabine-Based Induction Chemotherapy [NCT02441803]	Phase 2	11 participants (Actual)	Interventional	2015-09-14	Active, not recruiting
PROSPECTIVE RANDOMISED STUDY TO COMPARE INTERFERON-ALPHA-n1 (WELLFERON) VS 'IDAC' CHEMOTHERAPY AND AUTOGRAFTING FOLLOWED BY INTERFERON ALPHA-n1 (WELLFERON) IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA [NCT00002868]	Phase 3	744 participants (Anticipated)	Interventional	1997-11-20	Completed
Phase II Trial Utilizing Idarubicin in Combination With High Dose Ara-C for Induction Therapy for Adult Acute Myelogenous Leukemia (AML) [NCT00528398]	Phase 2	111 participants (Actual)	Interventional	1994-09-30	Completed
An Investigator-Initiated Study To Evaluate Ara-C and Idarubicin in Combination With the Selective Inhibitor Of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Relapsed Or Refractory AML [NCT02249091]	Phase 2	42 participants (Actual)	Interventional	2014-09-30	Completed
Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination With Chemotherapy in Pediatric Patients From 28 Days to Less Than 18 Years of Age With Relapsed/Refractory B or T Acute Lymphoblast [NCT03860844]	Phase 2	67 participants (Actual)	Interventional	2019-08-06	Terminated(stopped due to Study was prematurely stopped due to sponsor decision (stage 2 efficacy criteria not met); not due to safety concerns.)
Phase II Study of Adult Acute Lymphoblastic Leukaemia (ALL): Imatinib in Combination With Chemotherapy in Ph+ Patients, and Post-remissional Treatment Intensification in High-risk Ph- Patients, With Minimal Residual Disease Monitoring. [NCT00458848]	Phase 2	470 participants (Actual)	Interventional	2004-10-31	Completed
BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1 (BLAST MRD AML-1): A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination With Conventional Intensive Chemotherapy as F [NCT04214249]	Phase 2	124 participants (Anticipated)	Interventional	2021-02-17	Recruiting
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma [NCT03117751]	Phase 2/Phase 3	790 participants (Actual)	Interventional	2017-03-29	Active, not recruiting
A Phase 1/2 Study of Sequential Idarubicin + Cytarabine, Followed by Lenalidomide, in Patients With Myelodysplastic Syndrome (RAEB-2) or With Previously Untreated Acute Myeloid Leukemia [NCT00831766]	Phase 1/Phase 2	51 participants (Actual)	Interventional	2009-06-25	Completed
A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin With High Dose Cytarabine (IA) Versus IA With Vorinostat (NSC-701852) (IA + V) in Younger Patients With Previously Untreated Acute Myeloid Leukemia (AML) [NCT01802333]	Phase 3	754 participants (Actual)	Interventional	2013-02-12	Completed
Phase III Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crenolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects ≤ 75 Years of Age With Relapsed/Refractory FLT3 Mutated Acute Myelo [NCT03250338]	Phase 3	322 participants (Anticipated)	Interventional	2018-06-05	Recruiting
AML-02: Study of the Activity and Safety of the Addition of Omacetaxine to the Standard-of-Care Induction Therapy Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML Patients [NCT02440568]	Phase 1/Phase 2	22 participants (Actual)	Interventional	2015-06-05	Terminated
Epacadostat With Idarubicin and Cytarabine (EIC) for First-line Treatment of AML Patients Fit for Intensive Chemotherapy; a Phase I Study [NCT03444649]	Phase 1	0 participants (Actual)	Interventional	2018-09-30	Withdrawn(stopped due to IMP will not be further developed)
Retrospective Study on TACE for HCC by TANDEM and Idarubicin [NCT03349957]		98 participants (Actual)	Observational	2017-12-01	Completed
Safety and Efficacy of Chemotherapy Combined With Adoptive Transfer of Human Leukocyte Antigen (HLA)-Haploidentical Donor Lymphocyte Infusion (DLI) in Older Patients With Righ-Risk Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) [NCT02046122]	Phase 1/Phase 2	19 participants (Actual)	Interventional	2014-07-31	Completed
A Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive AML Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory AML [NCT03214562]	Phase 1/Phase 2	116 participants (Anticipated)	Interventional	2017-09-26	Recruiting
Phase I/II Study of the Combination of Dasatinib With Chemotherapy for High Risk Acute Myeloid Leukemia (AML) Patients [NCT01876953]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2013-09-13	Terminated(stopped due to Due to the budget issues, the study discontinued at Phase II.)
Hepatocellular Carcinoma Under 3 cm Treated by Percutaneous Tumor Destruction: Multicentric Phase 2 Test Evaluating the Impact of Adjuvant Chemotherapy by Intra-arterial Infusion of Idarubicin-lipiodol on the Hepatic Recurrence [NCT04178642]	Phase 2	0 participants (Actual)	Interventional	2020-09-22	Withdrawn(stopped due to no participants enrolled)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00067028 (2) [back to overview]	Overall Response Rate (ORR)
NCT00067028 (2) [back to overview]	Participants With a Response
NCT00096122 (1) [back to overview]	Number of Participants With Complete Response
NCT00413166 (1) [back to overview]	Complete Response (CR) Rate
NCT00422591 (2) [back to overview]	Overall Survival (OS)
NCT00422591 (2) [back to overview]	Event-Free Survival (EFS)
NCT00458848 (3) [back to overview]	Number of Patients Reaching Complete Hematological Response After Induction Therapy
NCT00458848 (3) [back to overview]	Percentage of Participants Reaching Disease Free Survival
NCT00458848 (3) [back to overview]	Percentage of Participants Reaching Overall Survival
NCT00469859 (2) [back to overview]	>80% Inhibition of FLT3 Phosphorylation in a Majority of Post-treatment Trough Time Points
NCT00469859 (2) [back to overview]	Dose-limiting Toxicity
NCT00528450 (1) [back to overview]	Molecular Remission Rate
NCT00534469 (2) [back to overview]	Disease-Free Survival at 2-Year Post-Transplant
NCT00534469 (2) [back to overview]	Disease-Free Survival at 2-Year Post-Transplant by Cytogenetic Risk
NCT00542971 (2) [back to overview]	Maximum Tolerated Dose (MTD)
NCT00542971 (2) [back to overview]	Number of Participants With Complete Response
NCT00620321 (6) [back to overview]	Percentage of Participants With Response to LY2181308 Sodium in Combination With Idarubicin and Cytarabine (Remission Rates)
NCT00620321 (6) [back to overview]	Change From Baseline in Survivin Index at Day 2
NCT00620321 (6) [back to overview]	Area Under the Curve of LY2181308 Over the Dosing Interval
NCT00620321 (6) [back to overview]	Number of Participants With Adverse Events (Safety Profile)
NCT00620321 (6) [back to overview]	Number of Participants Who Died Due to Progressive Disease or Unknown Cause During the 21 Days Post Study Treatment Follow-Up
NCT00620321 (6) [back to overview]	Pharmacodynamics: Number of Participants With Survivin Protein Expression
NCT00656617 (2) [back to overview]	Progression Free Survival (PFS) at 7 Months
NCT00656617 (2) [back to overview]	Participant Response
NCT00666588 (5) [back to overview]	Proteasome Inhibition Activity
NCT00666588 (5) [back to overview]	Dose Limiting Toxicity
NCT00666588 (5) [back to overview]	Overall Response (Complete Remission [CR] and CR With Partial Recovery [CRp]) During Course 1
NCT00666588 (5) [back to overview]	Feasibility of Stem Cell Quantitation: Percentage of Leukemia Initiation Cells (LIC) Depletion
NCT00666588 (5) [back to overview]	NF-kB Activity by Enzyme-linked Immunosorbent Assay (ELISA)
NCT00831766 (5) [back to overview]	Median Overall Survival (OS)
NCT00831766 (5) [back to overview]	Rate of Lenalidomide Related Toxicity During Maintenance Therapy
NCT00831766 (5) [back to overview]	Phase II: Complete Response Rate of Participants Treated at Maximum Tolerated Dose (MTD)
NCT00831766 (5) [back to overview]	Median Progression-Free Survival (PFS)
NCT00831766 (5) [back to overview]	Phase I: Recommended Phase II Dose
NCT00840177 (4) [back to overview]	Overall Survival (OS)
NCT00840177 (4) [back to overview]	Relapse-free Survival (RFS)
NCT00840177 (4) [back to overview]	Frequency and Severity of Toxicity as Assessed by NCI CTCAE Version 3.0
NCT00840177 (4) [back to overview]	Complete Remission (CR) Rate (Including CR With Incomplete Recovery)
NCT00866918 (4) [back to overview]	Event-free Survival (EFS)
NCT00866918 (4) [back to overview]	Hematologic Remission Rate
NCT00866918 (4) [back to overview]	Overall Survival (OS)
NCT00866918 (4) [back to overview]	Hematologic, Molecular, and Cytogenetic Remission Rate
NCT00878722 (11) [back to overview]	Overall Survival
NCT00878722 (11) [back to overview]	Relapse-Free Survival
NCT00878722 (11) [back to overview]	Remission Duration
NCT00878722 (11) [back to overview]	Time to Response (CR and PR)
NCT00878722 (11) [back to overview]	Event-Free Survival
NCT00878722 (11) [back to overview]	Elimination t½
NCT00878722 (11) [back to overview]	Duration of Response (CR and PR)
NCT00878722 (11) [back to overview]	Belinostat Cmax
NCT00878722 (11) [back to overview]	Belinostat AUC (Area Under Curve)
NCT00878722 (11) [back to overview]	Maximum Tolerated Dose, Dose Limiting Toxicity
NCT00878722 (11) [back to overview]	Overall Response
NCT01025154 (2) [back to overview]	Median Event-Free Survival (EFS)
NCT01025154 (2) [back to overview]	Overall Response: Number of Participants With Complete Remission or Complete Remission Without Platelet Recovery
NCT01141725 (4) [back to overview]	Disease-free Survival (DFS)
NCT01141725 (4) [back to overview]	Maximum Tolerated Dose
NCT01141725 (4) [back to overview]	Median Survival
NCT01141725 (4) [back to overview]	Incidence of Greater Than or Equal to Grade 3 Toxicity
NCT01289457 (4) [back to overview]	Response Rates of Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI)
NCT01289457 (4) [back to overview]	Overall Survival
NCT01289457 (4) [back to overview]	Maximum Tolerated Dose (MTD) of Clofarabine, Idarubicin, and Cytarabine
NCT01289457 (4) [back to overview]	Event-Free Survival (EFS) at 2 Years
NCT01607645 (13) [back to overview]	Duration of Thrombocytopenia Defined as Platelet Count Less Than 100,000
NCT01607645 (13) [back to overview]	Duration of Severe Neutropenia Defined as an ANC Less Than 500
NCT01607645 (13) [back to overview]	Duration of Moderate Neutropenia Defined as an ANC Less Than 1000
NCT01607645 (13) [back to overview]	Cytogenetic Response Defined as no Detectable Cytogenetic Abnormality in a Subsequent BM Specimen After Induction or Re-induction
NCT01607645 (13) [back to overview]	CRMRD+ Defined as a Morphologic CR But With Minimal Residual Disease by Flow Cytometry, Cytogenetics, or Other Known Molecular Biomarkers
NCT01607645 (13) [back to overview]	CRMRD- Defined as Morphologic CR Without Evidence of Minimal Residual Disease by Flow Cytometry, Cytogenetics, or Other Known Molecular Biomarkers
NCT01607645 (13) [back to overview]	CRi Defined as Meeting All Criteria for a Morphologic CR But ANC Remains Less Than 1,000/μL and/or Platelet Count Less Than 100,000/μL
NCT01607645 (13) [back to overview]	CRiMRD+ Defined as Meeting All Criteria for a CRi But With Evidence of Minimal Residual Disease by Flow Cytometry, Cytogenetics, or Other Known Molecular Biomarkers
NCT01607645 (13) [back to overview]	Number of Participants Who Achieved Morphologic CR
NCT01607645 (13) [back to overview]	Frequency and Severity of Grade 3, 4, and 5 Toxicities With Each Course of Decitabine-priming, Idarubicin, and Cytarabine According to NCI Common Terminology Criteria for Adverse Events Version (CTCAE) 4.0
NCT01607645 (13) [back to overview]	TRM With Each Course of Decitabine-priming, Idarubicin, and Cytarabine
NCT01607645 (13) [back to overview]	Severe Prolonged Aplasia
NCT01607645 (13) [back to overview]	Resistant Disease Defined as Patient Survives at Least 14 Days After Completion of the Last Dose of Induction or Re-induction But Has Persistent Leukemia in Peripheral Blood (PB) or BM
NCT01692197 (4) [back to overview]	Disease-free Survival
NCT01692197 (4) [back to overview]	Duration of Response
NCT01692197 (4) [back to overview]	Overall Response
NCT01692197 (4) [back to overview]	Overall Survival
NCT01794702 (4) [back to overview]	To Determine the Disease-free Survival (DFS).
NCT01794702 (4) [back to overview]	Overall Survival
NCT01794702 (4) [back to overview]	Number of Participants With a Response
NCT01794702 (4) [back to overview]	Maximum Tolerated Dose (MTD) of Clofarabine
NCT01802333 (10) [back to overview]	EFS of Arm I Compared to Arm II
NCT01802333 (10) [back to overview]	Event-free Survival (EFS)
NCT01802333 (10) [back to overview]	Overall Survival (OS)
NCT01802333 (10) [back to overview]	Prevalence of the Mutation NPM1 in Patients on This Study.
NCT01802333 (10) [back to overview]	Rate of Allogeneic HCT
NCT01802333 (10) [back to overview]	Cytogenetic Risk Distribution of Patients on This Study
NCT01802333 (10) [back to overview]	Frequency and Severity of Toxicities
NCT01802333 (10) [back to overview]	Complete Response (CR) Rate
NCT01802333 (10) [back to overview]	Disease-free Survival (DFS)
NCT01802333 (10) [back to overview]	Disease-free Survival (DFS) Among High Risk Patients
NCT01831232 (6) [back to overview]	Progression Free Survival (PFS)
NCT01831232 (6) [back to overview]	Rate of Complete Remission (CR), Remission With Incomplete Blood Count Recovery (CRi) and Partial Remission (PR)
NCT01831232 (6) [back to overview]	Number of Biomarker-positive Participants With Clinical Responses
NCT01831232 (6) [back to overview]	Number of Participants With Good Complete Remission (CR)
NCT01831232 (6) [back to overview]	Number of Participants With TRM.
NCT01831232 (6) [back to overview]	Overall Survival
NCT01876953 (1) [back to overview]	Maximum Tolerated Dose of Dasatinib (Phase I)
NCT02046122 (8) [back to overview]	Percentage of Subjects With Unacceptable Toxicity
NCT02046122 (8) [back to overview]	Number of Participants With Immune Recovery
NCT02046122 (8) [back to overview]	Number of Days to Hematopoietic Recovery
NCT02046122 (8) [back to overview]	Rate of Efficacy
NCT02046122 (8) [back to overview]	Overall Survival
NCT02046122 (8) [back to overview]	Number of Subjects With Unacceptable Toxicity
NCT02046122 (8) [back to overview]	Disease Free Survival
NCT02046122 (8) [back to overview]	Percentage of Subjects With Acute GVHD
NCT02096055 (5) [back to overview]	Number of Participants With the Most Frequently Reports Grade 3 or 4 Adverse Event.
NCT02096055 (5) [back to overview]	Survival
NCT02096055 (5) [back to overview]	Number of Participants With a Complete Response
NCT02096055 (5) [back to overview]	Leukemia-free Survival
NCT02096055 (5) [back to overview]	Remission Duration
NCT02144675 (1) [back to overview]	Inhibition of NF-kB Target Transcripts and/or Inhibition of Drug Efflux in at Least 50% of Patients
NCT02249091 (8) [back to overview]	Number of Participants With CR/CRi = Overall Reponse Rate
NCT02249091 (8) [back to overview]	Event-Free Survival
NCT02249091 (8) [back to overview]	Early Death Rate
NCT02249091 (8) [back to overview]	Progression-Free Survival
NCT02249091 (8) [back to overview]	Relapse-Free Survival
NCT02249091 (8) [back to overview]	Percentage of Patients Transplanted After Induction Therapy (Stem Cell Transplantation)
NCT02249091 (8) [back to overview]	Overall Survival
NCT02249091 (8) [back to overview]	Number of Participants With Partial Remission (PR) = Rate of PR
NCT02339740 (2) [back to overview]	EFS in High Risk APL Patients
NCT02339740 (2) [back to overview]	Event-free Survival (EFS) in Standard Risk Acute Promyelocytic Leukemia (APL) Patients
NCT02421939 (12) [back to overview]	Percentage of Participants Who Achieved Transfusion Conversion and Maintenance
NCT02421939 (12) [back to overview]	Percentage of Participants With Complete Remission (CR) With Partial Hematological Recovery (CRh)
NCT02421939 (12) [back to overview]	Duration of Remission
NCT02421939 (12) [back to overview]	Duration of Overall Survival (OS)
NCT02421939 (12) [back to overview]	Duration of Leukemia-Free Survival (LFS)
NCT02421939 (12) [back to overview]	Duration of Event-Free Survival (EFS)
NCT02421939 (12) [back to overview]	Percentage of Participants With Composite Complete Remission (CRc Rate)
NCT02421939 (12) [back to overview]	Change From Baseline in Brief Fatigue Inventory (BFI)
NCT02421939 (12) [back to overview]	Number of Participants With Adverse Events
NCT02421939 (12) [back to overview]	Percentage of Participants With Complete Remission and Complete Remission With Partial Hematological Recovery (CR/CRh) in the Gilteritinib Arm
NCT02421939 (12) [back to overview]	Percentage of Participants With Complete Remission (CR) Rate
NCT02421939 (12) [back to overview]	Percentage of Participants Who Underwent Hematopoietic Stem Cell Transplant
NCT02440568 (6) [back to overview]	Toxicity: Describe by the Adverse Events as Assessed by the CTCAE Grading
NCT02440568 (6) [back to overview]	Time to Hematologic Recovery
NCT02440568 (6) [back to overview]	Progression Free Survival
NCT02440568 (6) [back to overview]	Overall Participant Survival
NCT02440568 (6) [back to overview]	Optimally Tolerated Dose
NCT02440568 (6) [back to overview]	Event Free Survival
NCT02464657 (4) [back to overview]	Overall Survival
NCT02464657 (4) [back to overview]	Maximum Tolerated Dose (MTD) of Nivolumab
NCT02464657 (4) [back to overview]	Event-Free Survival (EFS)
NCT02464657 (4) [back to overview]	Relapse Free Survival
NCT02560025 (6) [back to overview]	Number of Participants With Serious Adverse Events
NCT02560025 (6) [back to overview]	Median Relapse Free Survival
NCT02560025 (6) [back to overview]	1 Year Overall Survival Rate
NCT02560025 (6) [back to overview]	Median Duration of Remission
NCT02560025 (6) [back to overview]	Number of Participants That Achieved Complete Remission With Incomplete Blood Count Recovery (CRi)
NCT02560025 (6) [back to overview]	Number of Participants That Achieved Complete Remission
NCT02626338 (1) [back to overview]	Clinical Response to Crenolanib With Standard Salvage Chemotherapy
NCT02668653 (5) [back to overview]	Number of Participants With Treatment-emergent Adverse Events Occurring in ≥10% Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
NCT02668653 (5) [back to overview]	Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
NCT02668653 (5) [back to overview]	Complete Remission (CR) Rate at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
NCT02668653 (5) [back to overview]	Composite CR Rate at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
NCT02668653 (5) [back to overview]	Event-free Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
NCT02703272 (37) [back to overview]	Part 1 and Part 2: Gene Expression Evaluated by Disease-specific Biomarkers at Baseline
NCT02703272 (37) [back to overview]	Part 2: Percentage of Participants Who Achieved Complete Response (CR)
NCT02703272 (37) [back to overview]	Part 2: Overall Survival
NCT02703272 (37) [back to overview]	Part 2: Number of Participants With c-MYC Gene Rearrangement
NCT02703272 (37) [back to overview]	Part 2: Apparent (Oral) Plasma Clearance (CL/F) of Ibrutinib
NCT02703272 (37) [back to overview]	Part 2: Number of Participants Who Proceeded to Stem Cell Transplantation
NCT02703272 (37) [back to overview]	Part 2: Duration of Response
NCT02703272 (37) [back to overview]	Part 2: Tumor Volume Reduction Rate at Day 14
NCT02703272 (37) [back to overview]	Part 1: Apparent (Oral) Volume of Distribution (Vd/F) of Ibrutinib
NCT02703272 (37) [back to overview]	Part 1 and Part 2: Visual Analog Scale (VAS) Score for Palatability
NCT02703272 (37) [back to overview]	Part 1: Apparent (Oral) Plasma Clearance (CL/F) of Ibrutinib
NCT02703272 (37) [back to overview]	Part 1: Apparent (Oral) Plasma Clearance (CL/F) of Ibrutinib
NCT02703272 (37) [back to overview]	Part 1: Apparent (Oral) Volume of Distribution (Vd/F) of Ibrutinib
NCT02703272 (37) [back to overview]	Part 2: Time to Response
NCT02703272 (37) [back to overview]	Part 2: Percentage of Participants With EFS at 3 Years
NCT02703272 (37) [back to overview]	Part 2: Percentage of Participants With EFS at 2 Years
NCT02703272 (37) [back to overview]	Part 1 and Part 2: Overall Response Rate (ORR)
NCT02703272 (37) [back to overview]	Part 1: Area Under the Plasma Concentration-time Curve (AUC) of Ibrutinib
NCT02703272 (37) [back to overview]	Part 1: Area Under the Plasma Concentration-time Curve (AUC) of Ibrutinib
NCT02703272 (37) [back to overview]	Part 1: Maximum Observed Plasma Concentration (Cmax) of Ibrutinib
NCT02703272 (37) [back to overview]	Part 1: Maximum Observed Plasma Concentration (Cmax) of Ibrutinib
NCT02703272 (37) [back to overview]	Part 2: Apparent (Oral) Plasma Clearance (CL/F) of Ibrutinib
NCT02703272 (37) [back to overview]	Part 1 and Part 2: Number of Participants With Greater Than (>) 90% Bruton's Tyrosine Kinase (BTK) Occupancy
NCT02703272 (37) [back to overview]	Part 2: Apparent (Oral) Plasma Clearance (CL/F) of Ibrutinib
NCT02703272 (37) [back to overview]	Part 1 and Part 2: Number of Participants With Adverse Events as Measure of Safety and Tolerability
NCT02703272 (37) [back to overview]	Part 2: Percentage of Participants Who Achieved Partial Response (PR)
NCT02703272 (37) [back to overview]	Part 2: Apparent (Oral) Volume of Distribution (Vd/F) of Ibrutinib
NCT02703272 (37) [back to overview]	Part 2: Event Free Survival (EFS) Between the 2 Treatment Groups
NCT02703272 (37) [back to overview]	Part 2: Apparent (Oral) Volume of Distribution (Vd/F) of Ibrutinib
NCT02703272 (37) [back to overview]	Part 2: Area Under the Plasma Concentration-time Curve (AUC) of Ibrutinib
NCT02703272 (37) [back to overview]	Part 2: Area Under the Plasma Concentration-time Curve (AUC) of Ibrutinib
NCT02703272 (37) [back to overview]	Part 2: Area Under the Plasma Concentration-time Curve (AUC) of Ibrutinib
NCT02703272 (37) [back to overview]	Part 2: Maximum Observed Plasma Concentration (Cmax) of Ibrutinib
NCT02703272 (37) [back to overview]	Part 2: Maximum Observed Plasma Concentration (Cmax) of Ibrutinib
NCT02703272 (37) [back to overview]	Part 2: Number of Participants With CD79B, CARD11, and MYD Mutations
NCT02703272 (37) [back to overview]	Part 2: Maximum Observed Plasma Concentration (Cmax) of Ibrutinib
NCT02703272 (37) [back to overview]	Part 2: Apparent (Oral) Volume of Distribution (Vd/F) of Ibrutinib
NCT02834390 (10) [back to overview]	Pharmacokinetic Parameter Accumulation Ratio (AR) of Quizartinib and Active Metabolite (AC886) After a Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT02834390 (10) [back to overview]	Pharmacokinetic Parameter Area Under the Concentration-Time Curve During Dosing Interval of Quizartinib and Metabolite (AC886) After Daily Dose of 20 mg or 40 mg With Chemotherapy to Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia
NCT02834390 (10) [back to overview]	Pharmacokinetic Parameter Maximum Serum Concentration (Cmax) of Geometric Means of Quizartinib and Active Metabolite (AC886) After Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia
NCT02834390 (10) [back to overview]	Pharmacokinetic Parameter Metabolite to Parent Ratio (MR) of Active Metabolite (AC886) After a Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT02834390 (10) [back to overview]	Pharmacokinetic Parameter Time of Maximum Plasma Concentration (Tmax) of Quizartinib and the Active Metabolite (AC886) After a Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT02834390 (10) [back to overview]	Pharmacokinetic Parameter Trough Plasma Concentration (Ctrough) of Quizartinib and Active Metabolite (AC886) After a Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT02834390 (10) [back to overview]	Number of Participants Treatment-Emergent Adverse Events Reported During Induction Phase After a Daily Dose of 20 mg or 40 mg in Combination With Standard Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT02834390 (10) [back to overview]	Summary of Best Response Rates After the First Oral Dose of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia
NCT02834390 (10) [back to overview]	Summary of Best Responses After a Daily Dose of 20 mg or 40 mg in Combination With Standard Chemotherapy to Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT02834390 (10) [back to overview]	Number of Participants Treatment-Emergent Adverse Events Reported During Consolidation Phase After a Daily Dose of 20 mg or 40 mg in Combination With Standard Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT02873338 (10) [back to overview]	Time to Platelet Recovery
NCT02873338 (10) [back to overview]	Number of Subjects Who Died by Day 60.
NCT02873338 (10) [back to overview]	Number of Subjects Who Died by Day 30
NCT02873338 (10) [back to overview]	Number of Subjects Who Achieved Composite Complete Remission
NCT02873338 (10) [back to overview]	Duration of Morphologic Complete Remission
NCT02873338 (10) [back to overview]	Duration of Event-free Survival
NCT02873338 (10) [back to overview]	Number of Subjects Who Achieved Morphologic Complete Remission
NCT02873338 (10) [back to overview]	Time to Recovery of Neutrophils
NCT02873338 (10) [back to overview]	Time to Leukemia-free Survival
NCT02873338 (10) [back to overview]	Number of Subjects Who Died by Day 90
NCT03860844 (13) [back to overview]	Number of Participants With Infusion Reactions (IRs)
NCT03860844 (13) [back to overview]	Overall Response Rate (ORR)
NCT03860844 (13) [back to overview]	Percentage of Participants With Complete Response (CR) Rate
NCT03860844 (13) [back to overview]	AML: Ceoi of Isatuximab
NCT03860844 (13) [back to overview]	AML: Plasma Concentration Reached by Isatuximab Before Next Dose Administration (Ctrough)
NCT03860844 (13) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
NCT03860844 (13) [back to overview]	Cluster of Differentiation (CD)38 Receptor Density
NCT03860844 (13) [back to overview]	B-ALL and T-ALL: Plasma Concentration Reached by Isatuximab Before Next Dose Administration (Ctrough)
NCT03860844 (13) [back to overview]	CD38 Receptor Occupancy
NCT03860844 (13) [back to overview]	AML: AUC of Isatuximab
NCT03860844 (13) [back to overview]	B-ALL and T-ALL: Concentrations at the End of Infusion (Ceoi) of Isatuximab
NCT03860844 (13) [back to overview]	B-ALL and T-ALL: Area Under the Concentration Time Curve (AUC) of Isatuximab
NCT03860844 (13) [back to overview]	CD38 Receptor Occupancy

Overall Response Rate (ORR)

Percentage of participants with complete response following treatment out of all participants in that particular treatment group. Response assessed by blood test or bone marrow aspirate following day 21 of induction and then every 2 weeks thereafter until remission or non-response. Complete remission (CR): Disappearance all clinical and/or radiologic evidence of disease; Neutrophil count > 1.0 x10^9/L and platelet count >100x10^9/L, and normal bone marrow differential (< 5% blasts). Complete remission without platelet recovery (CRp): Peripheral blood and bone marrow results as for CR, but with platelet counts of > 20 x 10^9/L and < 100 x 10^9/L. Partial remission (PR): Peripheral blood count recovery as for CR, but with decrease in marrow blasts of > 50% and not more than 6-25% abnormal cells in the marrow. All other responses considered as failures. (NCT00067028)
Timeframe: Up to 6 years

Intervention	Percentage of Participants (Number)
Clofarabine + Ara-C	36
Clofarabine + Idarubicin	44
Clofarabine + Idarubicin + Ara-C	24

Intervention	Participants (Count of Participants)
ATRA + ATO: Low Risk (WBC<10,000)	55
ATRA+ATO+IDA: High Risk (WBC >10,000)	5
ATO+ATRA+GO	15

Intervention	participants (Number)
Group 1 (Lestaurtinib Dose 50 mg/m2	5
Group 2 (Lestaurtinib: Dose 62.5 mg/m2	5

Intervention	Proportion of pts alive in remission (Number)
Unfavorable Risk Cytogenetics	0.33
Intermediate Risk Cytogenetics	0.75
Favorable Risk Cytogenetics	0.75
Unknown Risk: Rejected Cytogenetics Study	0.73

Intervention	Participants (Number)
	Complete Response	No Complete Response
Sorafenib + Idarubicin + Ara-C	54	21

Intervention	Participants (Count of Participants)
	SAE	Drug-related TEAE
LY2181308	6	2
LY2181308 + Idarubicin + Cytarabine	13	11

Intervention	Participants (Count of Participants)
	Death due to progressive disease	Death due to unknown cause
LY2181308	1	1
LY2181308 + Idarubicin + Cytarabine	0	0

Intervention	participants (Number)
	Complete Response (CR)	Partial Response (PR)	Complete Response without platelet recovery (CRp)	Progressive Disease (PD)	No response
Idarubicin + Ara-C + Vorinostat	67	0	11	0	24

Intervention	ratio (Mean)
	Baseline β1	Baseline β5
Bortezomib 1.0mg/m2-assess Feasibility High Anthracycline Exp	0.7894	0.2576
Bortezomib 1.3 mg/m2-assess Efficacy High Anthracycline Exp	0.2895143	0.3721286
Bortezomib 1.3mg/m2-assess Efficacy-low Anthracycline Exposure	0.08115	0.121575

Intervention	participants (Number)
Bortezomib 1.3mg/m2-assess Efficacy-low Anthracycline Exposure	0
Bortezomib 1.0mg/m2-assess Feasibility High Anthracycline Exp	1
Bortezomib 1.3 mg/m2-assess Feasibility High Anthracycline Exp	0
Bortezomib 1.3 mg/m2-assess Efficacy High Anthracycline Exp	0

Intervention	percentage of LIC depletion (Mean)
	Prior to Treatment	Post Treatment
Bortezomib 1.3 mg/m2-assess Efficacy High Anthracycline Exp	1.6385	0.0435
Bortezomib 1.3 mg/m2-assess Feasibility High Anthracycline Exp	0.2	0.43
Bortezomib 1.3mg/m2-assess Efficacy-low Anthracycline Exposure	0.013667	0.021

Intervention	ng/Mg protein (Mean)
	Baseline	24 Hrs after treatment
Bortezomib 1.0mg/m2-assess Feasibility High Anthracycline Exp	655.4	345.46
Bortezomib 1.3 mg/m2-assess Efficacy High Anthracycline Exp	408.144	497.31
Bortezomib 1.3 mg/m2-assess Feasibility High Anthracycline Exp	974.66	855.96
Bortezomib 1.3mg/m2-assess Efficacy-low Anthracycline Exposure	718.218	774.1925

Intervention	Participants (Count of Participants)
	Leukocytes (total WBC) - low - Grade 1 or 2	Leukocytes (total WBC) - low - Grade 3 or 4	ANC/AGC - Grade 1 or 2	ANC/AGC - Grade 3 or 4	Platelets - low - Grade 1 or 2	Platelets - low - Grade 3 or 4	Fatigue - Grade 1 or 2	Fatigue - Grade 3 or 4	Dry skin - Grade 1 or 2	Dry skin - Grade 3 or 4	Pruritus/itching - Grade 1 or 2	Pruritus/itching - Grade 3 or 4	Rash/desquamation - Grade 1 or 2	Rash/desquamation - Grade 3 or 4	Constipation - Grade 1 or 2	Constipation - Grade 3 or 4	Diarrhea - Grade 1 or 2	Diarrhea - Grade 3 or 4	Nausea - Grade 1 or 2	Nausea - Grade 3 or 4	Ulcer, GI - Anus - Grade 1 or 2	Ulcer, GI - Anus - Grade 3 or 4	Hemorrhage, GI - Rectum - Grade 1 or 2	Hemorrhage, GI - Rectum - Grade 3 or 4	Infection - Skin (cellulitis) Grade 1 or 2	Infection - Skin (cellulitis) Grade 3 or 4	AST, SGOT - Grade 1 of 2	AST, SGOT - Grade 3 or 4	Pain - Head/headache - Grade 1 or 2	Pain - Head/headache - Grade 3 or 4
Maintenance Phase Participants	1	0	0	1	3	0	1	0	1	0	1	0	2	0	1	0	2	0	1	0	1	0	1	0	1	0	2	0	1	0

Intervention	months (Median)
Initial Cohort: Relapsed AML With Previous Remission ≥ 3 Month	10
Poor-risk Cohort: MDS Transformed to AML	10
Poor-risk Cohort: Refractory/Relapsed AML, < 6 Mths Remission	4

Intervention	months (Median)
Initial Cohort: Relapsed AML With Previous Remission ≥ 3 Month	9
Poor-risk Cohort: MDS Transformed to AML	19.4
Poor-risk Cohort: Refractory/Relapsed AML, < 6 Mths Remission	2.7

Intervention	Participants (Number)
	ALT, SGPT (serum glutamic pyruvic transaminase)	AST, SGOT	Acidosis (metabolic or respiratory)	Albumin, serum-low (hypoalbuminemia)	Alkaline phosphatase	Alkalosis (metabolic or respiratory)	Anorexia	Bilirubin (hyperbilirubinemia)	Blood/Bone Marrow-Other (Specify)	Bone marrow cellularity	Calcium, serum-low (hypocalcemia)	Carbon monoxide diffusion capacity (DL(co))	Cardiac General-Other (Specify)	Cardiac-ischemia/infarction	Colitis, infectious (e.g., Clostridium difficile)	Conduction abnormality - Asystole	Confusion	Constitutional Symptoms-Other (Specify)	Creatinine	Diarrhea	Distention/bloating, abdominal	Dry mouth/salivary gland (xerostomia)	Dyspnea (shortness of breath)	Edema: limb	Esophagitis	Fatigue (asthenia, lethargy, malaise)	Febrile neutropenia	Glucose, serum-high (hyperglycemia)	Hemoglobin	Hemorrhage, GI - Duodenum	Hemorrhage, GU - Vagina	Hemorrhage, pulmo/upper resp- Bronchopulmonary NOS	Hemorrhage, pulmonary/upper respiratory - Nose	Hemorrhage/Bleeding-Other (Specify)	Hypertension	Hypotension	Hypoxia	Ileus, GI (functional obstruction of bowel)	Inf (clin/microbio) w/Gr 3-4 neuts - Blood	Inf (clin/microbio) w/Gr 3-4 neuts - Bronchus	Inf (clin/microbio) w/Gr 3-4 neuts - Kidney	Inf (clin/microbio) w/Gr 3-4 neuts - Lung	Inf (clin/microbio) w/Gr 3-4 neuts - Meninges	Inf (clin/microbio) w/Gr 3-4 neuts - Sinus	Inf (clin/microbio) w/Gr 3-4 neuts - Skin	Inf (clin/microbio) w/Gr 3-4 neuts - Small bowel	Inf (clin/microbio) w/Gr 3-4 neuts - Stomach	Infection with unknown ANC - Blood	Infection with unknown ANC - Lung (pneumonia)	Infection with unknown ANC - Mucosa	Infection with unknown ANC - Sinus	Infection with unknown ANC - Small bowel NOS	Infection-Other (Specify)	Left ventricular diastolic dysfunction	Leukocytes (total WBC)	Lipase	Lymphopenia	Magnesium, serum-high (hypermagnesemia)	Mental status	Mucositis/stomatitis (clinical exam) - Oral cavity	Mucositis/stomatitis (clinical exam) - Pharynx	Mucositis/stomatitis (functional/symp) - Oral cav	Musculoskeletal/Soft Tissue-Other (Specify)	Nausea	Necrosis, GI - Small bowel NOS	Neutrophils/granulocytes (ANC/AGC)	Obstruction, GI - Small bowel NOS	Ocular/Visual-Other (Specify)	Opportunistic inf associated w/gt=Gr 2 lymphopenia	Pain - Abdomen NOS	Pain - Bone	Pain - Esophagus	Pain - Extremity-limb	Pain - Oral cavity	Pain - Peritoneum	Phosphate, serum-low (hypophosphatemia)	Platelets	Pleural effusion (non-malignant)	Potassium, serum-high (hyperkalemia)	Potassium, serum-low (hypokalemia)	Pulmonary hypertension	Pulmonary/Upper Respiratory-Other (Specify)	Rash/desquamation	Renal failure	Renal/Genitourinary-Other (Specify)	SVT and nodal arrhythmia - Atrial fibrillation	SVT and nodal arrhythmia - Atrial flutter	Sodium, serum-high (hypernatremia)	Sodium, serum-low (hyponatremia)	Syncope (fainting)	Typhlitis (cecal inflammation)	Ulcer, GI - Duodenum	Ulceration	Vomiting	Weight loss
Initial Cohort: Relapsed AML With Previous Remission ≥ 3 Month	0	0	0	1	0	0	1	2	2	1	2	1	1	0	0	1	1	0	0	3	0	0	2	0	1	3	20	1	11	0	1	0	0	1	1	1	1	1	4	1	0	5	0	1	0	1	0	1	0	0	1	0	1	2	16	1	6	0	1	0	0	1	0	2	0	14	0	1	0	1	0	0	0	0	0	2	17	0	0	6	1	0	0	0	0	1	1	1	1	1	0	0	0	2	0
Poor-risk Cohort: MDS Transformed to AML	2	3	1	3	0	1	1	2	1	0	5	4	0	1	1	0	0	2	3	4	2	1	1	2	0	2	18	2	14	1	0	0	0	0	0	2	2	2	4	0	0	2	0	0	1	0	0	2	1	0	0	1	1	0	11	0	5	1	0	0	0	0	1	1	1	15	1	0	0	3	0	0	0	0	1	4	16	1	2	3	0	1	0	0	1	1	0	0	0	0	0	1	0	2	0
Poor-risk Cohort: Refractory/Relapsed AML, < 6 Mths Remission	2	1	0	6	1	0	0	0	0	0	3	1	0	0	1	0	0	0	2	8	0	0	2	0	0	2	32	0	21	0	0	1	1	0	0	1	3	0	7	1	1	6	1	0	0	0	1	4	0	1	0	0	0	0	17	0	9	0	0	1	1	1	0	3	0	16	0	0	2	0	1	1	1	3	0	2	19	0	0	3	0	0	1	2	0	0	0	0	1	0	1	0	1	0	2

Intervention	Weeks (Median)
Arm A, Step 4	10
Arm B, Steps 1-6	4.9
Arm B, Step 7	3.7
Arm B, Step 9	3.9

Intervention	Weeks (Number)
Arm A, Step 2	26.3
Arm A, Step 3	20.6
Arm A, Step 4	28.1
Arm B, Step 7	30.3
Arm B, Step 9	6.1

Intervention	Weeks (Median)
Arm A, Step 1	5.1
Arm A, Step 2	3.1
Arm A, Step 3	8.0
Arm A, Step 4	6.5
Arm B, Steps 1-6	2.0
Arm B, Step 7	5.4
Arm B, Step 8	5.4
Arm B, Step 9	6.4

Intervention	Hours (Mean)
Arm A, Cycle 1 Day 4	12.7
Arm A, Cycle 1 Day 5	13.1
Arm B, Cycle 1 Day 1 and Day 2	4.21

Intervention	ng/mL (Mean)
Arm A, Cycle 1 Day 4	38744
Arm A, Cycle 1 Day 5	31952
Arm B, Cycle 1 Day 1 and Day 2	9657

idarubicin

Description

Cross-References

Synonyms (109)

Research Excerpts

Overview

Effects

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (3)

Protein Targets (62)

Potency Measurements

Activation Measurements

Biological Processes (125)

Molecular Functions (23)

Ceullar Components (47)

Bioassays (122)

Research

Studies (1,686)

Market Indicators

Research Demand Index: 50.53

Study Types

Clinical Trials (221)

Trial Overview

Trial Outcomes

Overall Response Rate (ORR)

Participants With a Response

Number of Participants With Complete Response

Complete Response (CR) Rate

Overall Survival (OS)

Event-Free Survival (EFS)

Number of Patients Reaching Complete Hematological Response After Induction Therapy

Percentage of Participants Reaching Disease Free Survival

Percentage of Participants Reaching Overall Survival

>80% Inhibition of FLT3 Phosphorylation in a Majority of Post-treatment Trough Time Points

Dose-limiting Toxicity

Molecular Remission Rate

Disease-Free Survival at 2-Year Post-Transplant

Disease-Free Survival at 2-Year Post-Transplant by Cytogenetic Risk

Maximum Tolerated Dose (MTD)

Number of Participants With Complete Response

Percentage of Participants With Response to LY2181308 Sodium in Combination With Idarubicin and Cytarabine (Remission Rates)

Change From Baseline in Survivin Index at Day 2

Area Under the Curve of LY2181308 Over the Dosing Interval

Number of Participants With Adverse Events (Safety Profile)

Number of Participants Who Died Due to Progressive Disease or Unknown Cause During the 21 Days Post Study Treatment Follow-Up

Pharmacodynamics: Number of Participants With Survivin Protein Expression

Progression Free Survival (PFS) at 7 Months

Participant Response

Proteasome Inhibition Activity

Dose Limiting Toxicity

Overall Response (Complete Remission [CR] and CR With Partial Recovery [CRp]) During Course 1

Feasibility of Stem Cell Quantitation: Percentage of Leukemia Initiation Cells (LIC) Depletion

NF-kB Activity by Enzyme-linked Immunosorbent Assay (ELISA)

Median Overall Survival (OS)

Rate of Lenalidomide Related Toxicity During Maintenance Therapy

Phase II: Complete Response Rate of Participants Treated at Maximum Tolerated Dose (MTD)

Median Progression-Free Survival (PFS)

Phase I: Recommended Phase II Dose

Overall Survival (OS)

Relapse-free Survival (RFS)

Frequency and Severity of Toxicity as Assessed by NCI CTCAE Version 3.0

Complete Remission (CR) Rate (Including CR With Incomplete Recovery)

Event-free Survival (EFS)

Hematologic Remission Rate

Overall Survival (OS)

Hematologic, Molecular, and Cytogenetic Remission Rate

Overall Survival

Relapse-Free Survival

Remission Duration

Time to Response (CR and PR)

Event-Free Survival

Elimination t½

Duration of Response (CR and PR)

Belinostat Cmax

Belinostat AUC (Area Under Curve)

Intervention	ng*hrs/mL (Mean)
Arm A, Cycle 1 Day 4	21850
Arm A, Cycle 1 Day 5	21322
Arm B, Cycle 1 Day 1 and Day 2	172823

Intervention	participants (Number)
	Complete Remission	Complete Remission without Platelet Recovery
Clofarabine, Cytarabine + Idarubicin	42	3

Intervention	Participants (Count of Participants)
Arm I (Decitabine Day -4 to Day 0), Idarubicin, Cytarabine)	3
Arm II (Decitabine (Day -9 to Day -5), Idarubicin, Cytarabine)	0

Intervention	participants (Number)
	CR	CRi-MRD (Minimal Residual Disease)	Refractory
Arm I (Decitabine Day -4 to Day 0), Idarubicin, Cytarabine)	2	1	1
Arm II (Decitabine (Day -9 to Day -5), Idarubicin, Cytarabine)	0	0	3

Intervention	Participants (Count of Participants)
	CYCLE 1 : Infection Grade 3	CYCLE 1 : Infection Grade 4	CYCLE 1 : Hepatobiliary Grade 3	CYCLE 1 : Blood and Lymphatic Grade 3	CYCLE 1 : Gastrointenstinal Grade 3	CYCLE 2 : Infection Grade 3	CYCLE 2 : Infection Grade 4	CYCLE 2 : Hepatobiliary Grade 3	CYCLE 2 : Blood and Lymphatic Grade 3	CYCLE 2 : Gastrointenstinal Grade 3
Arm I (Decitabine Day -4 to Day 0), Idarubicin, Cytarabine)	2	0	0	3	0	0	0	0	1	1
Arm II (Decitabine (Day -9 to Day -5), Idarubicin, Cytarabine)	0	1	1	1	0	0	0	0	0	0

Intervention	Proportion of participants (Number)
Arm I (Standard Dose Cytarabine, Daunorubicin Hydrochloride)	0.36
Arm II (High-dose Cytarabine, Idarubicin)	0.41

Intervention	percentage of participants (Number)
	High risk	Intermediate risk	Low risk
All Arms Combined	22.3	64.2	13.5

Intervention	Participants (Count of Participants)
	Abdominal distension	Abdominal infection	Abdominal pain	Acidosis	Acute kidney injury	Adult respiratory distress syndrome	Alanine aminotransferase increased	Alkaline phosphatase increased	Alkalosis	Allergic reaction	Anal hemorrhage	Anal pain	Anal ulcer	Anemia	Anorectal infection	Anorexia	Aspartate aminotransferase increased	Atelectasis	Atrial fibrillation	Atrial flutter	Atrioventricular block complete	Blood and lymphatic system disorders - Other	Blood bilirubin increased	Bone infection	Bone pain	Bronchopulmonary hemorrhage	Bullous dermatitis	CD4 lymphocytes decreased	Cardiac arrest	Cardiac disorders - Other, specify	Cardiac troponin I increased	Catheter related infection	Chills	Chronic kidney disease	Cognitive disturbance	Colitis	Colonic hemorrhage	Colonic perforation	Conduction disorder	Confusion	Conjunctivitis	Constipation	Constrictive pericarditis	Creatinine increased	Death NOS	Dehydration	Dental caries	Device related infection	Diarrhea	Disseminated intravascular coagulation	Dry mouth	Dry skin	Duodenal hemorrhage	Dyspepsia	Dysphagia	Dyspnea	Edema cerebral	Edema limbs	Ejection fraction decreased	Electrocardiogram QT corrected interval prolonged	Encephalopathy	Enterocolitis	Enterocolitis infectious	Epistaxis	Erythema multiforme	Erythroderma	Esophageal hemorrhage	Esophageal pain	Esophagitis	Eye infection	Fatigue	Febrile neutropenia	Fever	GGT increased	Gait disturbance	Gastric hemorrhage	Gastritis	Gastroesophageal reflux disease	Gastrointestinal disorders - Other, specify	General disorders and admin site conditions-Other	Generalized muscle weakness	Genital edema	Glucose intolerance	Gum infection	Headache	Heart failure	Hematoma	Hematuria	Hepatic failure	Hepatic infection	Hepatobiliary disorders - Other, specify	Hyperglycemia	Hyperhidrosis	Hyperkalemia	Hypermagnesemia	Hypernatremia	Hypertension	Hyperuricemia	Hypoalbuminemia	Hypocalcemia	Hypoglycemia	Hypokalemia	Hypomagnesemia	Hyponatremia	Hypophosphatemia	Hypotension	Hypoxia	Ileus	Infections and infestations - Other, specify	Infective myositis	Injury, poison and procedural complications-Other	Intracranial hemorrhage	Investigations - Other, specify	Irregular menstruation	Jejunal obstruction	Kidney infection	Laryngeal edema	Laryngeal mucositis	Left ventricular systolic dysfunction	Leukocytosis	Lipase increased	Lower gastrointestinal hemorrhage	Lung infection	Lymphocyte count decreased	Menorrhagia	Metabolism and nutrition disorders-Other, specify	Middle ear inflammation	Mucosal infection	Mucositis oral	Multi-organ failure	Musculoskeletal and connective tiss disorder-Other	Myalgia	Nausea	Neck edema	Nervous system disorders - Other, specify	Neutrophil count decreased	Non-cardiac chest pain	Oral pain	Pain	Pain in extremity	Palmar-plantar erythrodysesthesia syndrome	Papulopustular rash	Paresthesia	Pericardial effusion	Pericardial tamponade	Periorbital edema	Peripheral sensory neuropathy	Pharyngeal mucositis	Pharyngitis	Platelet count decreased	Pleural effusion	Pneumonitis	Pruritus	Pulmonary edema	Purpura	Rash acneiform	Rash maculo-papular	Rectal hemorrhage	Rectal pain	Renal and urinary disorders - Other, specify	Resp, thoracic and mediastinal disorders - Other	Respiratory failure	Restrictive cardiomyopathy	Salivary duct inflammation	Scrotal infection	Scrotal pain	Seizure	Sepsis	Sinus bradycardia	Sinus tachycardia	Sinusitis	Skin and subcutaneous tissue disorders - Other	Skin infection	Skin ulceration	Small intestinal obstruction	Soft tissue infection	Sore throat	Stomach pain	Stroke	Supraventricular tachycardia	Syncope	Testicular disorder	Thromboembolic event	Thrombotic thrombocytopenic purpura	Tooth infection	Tumor lysis syndrome	Typhlitis	Upper gastrointestinal hemorrhage	Upper respiratory infection	Urinary incontinence	Urinary tract infection	Urine output decreased	Vaginal hemorrhage	Vascular access complication	Vasovagal reaction	Ventricular tachycardia	Vomiting	Weight loss	White blood cell decreased	Wound infection
Arm I (Standard Dose Cytarabine, Daunorubicin Hydrochloride)	1	1	4	1	2	1	12	2	1	0	0	0	0	158	0	5	8	0	0	0	0	1	9	1	0	1	0	1	1	1	0	3	1	0	0	3	2	0	1	0	1	0	1	1	1	1	1	1	15	2	0	0	1	1	1	3	0	0	2	0	0	1	1	2	1	0	0	1	3	0	14	152	4	3	0	0	1	1	1	0	2	0	1	1	2	3	0	0	1	1	1	5	1	0	0	0	7	0	5	8	0	18	0	20	21	3	2	0	18	1	1	0	1	1	0	0	1	0	2	1	0	0	21	89	1	1	1	1	19	1	0	0	7	0	0	141	1	5	1	1	0	0	0	0	0	0	0	1	1	175	1	1	0	1	0	1	11	1	1	0	1	3	1	1	0	0	1	16	0	0	2	0	5	0	1	1	1	1	0	0	2	0	1	3	1	4	8	1	2	0	5	0	0	0	0	0	3	2	156	1
Arm II (High-dose Cytarabine, Idarubicin)	0	1	6	1	5	3	17	2	1	0	0	1	0	164	0	16	15	0	3	1	1	1	15	0	1	1	2	1	3	1	1	7	0	2	0	9	0	0	0	2	0	1	0	6	1	0	0	3	20	1	1	2	0	0	1	7	0	3	6	2	1	6	4	1	0	0	0	1	2	1	18	160	7	2	0	2	0	0	5	4	1	0	0	0	2	2	1	2	0	1	0	12	1	1	1	0	6	1	8	17	0	20	1	20	31	12	4	1	21	0	0	0	6	0	0	1	0	0	3	1	0	1	22	107	0	1	0	0	18	3	1	0	15	0	1	128	0	5	0	0	2	1	0	0	0	1	0	0	0	168	0	4	1	2	1	1	26	0	0	1	3	8	0	0	0	0	0	26	0	2	0	2	1	0	0	0	2	0	1	1	2	1	0	0	0	8	14	0	1	0	2	0	0	2	1	1	6	0	150	0
Arm III (Vorinostat, High-dose Cytarabine, Idarubicin)	1	1	9	2	4	4	20	1	2	2	1	0	1	106	4	12	12	1	1	1	0	0	22	0	0	3	0	0	2	1	0	4	0	0	1	5	1	1	0	0	0	0	0	4	0	3	0	0	38	1	0	0	0	0	0	8	1	2	4	2	0	5	4	2	0	1	1	0	1	0	13	114	6	4	1	3	0	0	1	1	2	1	0	0	4	3	0	0	0	0	1	16	0	1	0	2	6	1	8	25	1	24	2	9	31	9	9	2	14	0	0	1	3	0	1	0	0	1	0	1	2	3	14	77	0	0	0	1	11	5	1	1	5	1	0	104	1	0	0	1	1	0	1	1	1	0	1	0	0	128	1	2	1	5	0	0	10	0	1	0	2	14	0	0	1	1	1	34	1	2	0	1	4	1	0	0	2	0	1	1	3	0	0	1	0	9	23	1	2	1	6	1	2	1	1	0	4	2	112	0

Intervention	Proportion of participants (Number)
Arm I (Standard Dose Cytarabine, Daunorubicin Hydrochloride)	0.48
Arm II (High-dose Cytarabine, Idarubicin)	0.51
Arm III (Vorinostat, High-dose Cytarabine, Idarubicin)	0.46

Intervention	Participants (Count of Participants)
	CR	CRi	PR
Treatment (Pravastatin Sodium, Idarubicin, and Cytarabine)	15	2	0